{"0037085421443b808dff3d84e452c5e952df09b6": [["A National Strategy for Ventilator and ICU resource allocation during the COVID-19 PandemicClinicians across the country have watched the COVID-19 pandemic unfold with very different local experiences.", [["Ventilator", "TREATMENT", 24, 34]]], ["While some in \"hotspots\" like New York have found their resources rapidly depleted, others have found themselves managing largely empty ICUs waiting for an inevitable surge of critically ill, COVID-19 patients.", [["critically ill", "DISEASE", 176, 190], ["patients", "ORGANISM", 201, 209], ["patients", "SPECIES", 201, 209]]], ["Some of us are focused on aggressive preparations without significant current strain (North Carolina and Syracuse, NY), others are managing steadily rising cases and rapidly expanding staffing (Boston and Chicago), while others are battling an overwhelming and disastrous surge (New York).", [["aggressive preparations", "TREATMENT", 26, 49]]], ["We suggest that a coordinated nationwide response may be more effective and agile as the pandemic moves across the country.A National Strategy for Ventilator and ICU resource allocation during the COVID-19 PandemicAs the COVID-19 pandemic reaches its peak in the United States over the next several weeks, The Institute for Health Metrics and Evaluation (IHME) has projected that demand for critical care beds and ventilators will outstrip supply in numerous locations (1).", [["Ventilator", "TREATMENT", 147, 157], ["the COVID", "TEST", 193, 202], ["Evaluation", "TEST", 343, 353], ["critical care beds", "TREATMENT", 391, 409], ["ventilators", "TREATMENT", 414, 425]]], ["There are not enough ventilators in the Strategic National Stockpile (SNP) to meet demand, nor can we build enough ventilators quickly enough to meet the surging demand over the next month over widespread geographical locations.", [["SNP", "CHEMICAL", 70, 73], ["not", "UNCERTAINTY", 10, 13], ["enough", "OBSERVATION_MODIFIER", 14, 20], ["ventilators", "OBSERVATION", 21, 32]]], ["This has led to discussions in the medical community revolving around the triage of patients so that ventilators are allocated to patients in the most logical and ethical way possible.", [["patients", "ORGANISM", 84, 92], ["patients", "ORGANISM", 130, 138], ["patients", "SPECIES", 84, 92], ["patients", "SPECIES", 130, 138], ["ventilators", "TREATMENT", 101, 112]]], ["Most of these discussions assume that there is a national shortage of ventilators and other ICU resources.", [["ventilators", "TREATMENT", 70, 81]]], ["Viewed through this lens, the problem is not so much a ventilator shortage as it is a ventilator distribution problem.", [["a ventilator shortage", "TREATMENT", 53, 74], ["a ventilator distribution problem", "PROBLEM", 84, 117], ["ventilator distribution", "OBSERVATION", 86, 109]]], ["This presents a tangible opportunity for collaborative allocation; the best way to meet excess demand is by reallocating scarce supplies from areas with excess supply to areas with need.A National Strategy for Ventilator and ICU resource allocation during the COVID-19 PandemicThe best estimate of the number of ventilators in the United States puts their numbers at approximately 160,000 based on a 2010 survey of hospitals.", [["collaborative allocation", "TREATMENT", 41, 65], ["Ventilator", "TREATMENT", 210, 220], ["the COVID", "TEST", 256, 265]]], ["(2) The actual number of ventilators at the present time is not known.", [["ventilators", "TREATMENT", 25, 36]]], ["In order to properly allocate this life saving resource we need an immediate and accurate count of all ventilators in the country.", [["all ventilators", "TREATMENT", 99, 114]]], ["Upon defining this number, in conjunction with projected ICU utilization, we must move quickly to reallocate resources from areas where need is projected to be low, to those with an acute shortage.", [["projected ICU utilization", "TREATMENT", 47, 72], ["an acute shortage", "PROBLEM", 179, 196]]], ["In the other it rests upon states to act on their own behalf.A National Strategy for Ventilator and ICU resource allocation during the COVID-19 PandemicGiven the interstate scope of this disease, a federal model is the most ideal.", [["Ventilator", "TREATMENT", 85, 95], ["this disease", "PROBLEM", 182, 194], ["a federal model", "TREATMENT", 196, 211], ["disease", "OBSERVATION", 187, 194]]], ["The federal government's current focus remains on distribution of resources from the SNP.", [["SNP", "CHEMICAL", 85, 88], ["the SNP", "TREATMENT", 81, 88]]], ["Distribution of SNP resources generally parallels population estimates based on the most recent census data (3).", [["SNP", "CHEMICAL", 16, 19], ["SNP resources", "PROBLEM", 16, 29]]], ["This is inherently inefficient, as COVID-19 does not strike populations in a uniform manner.", [["COVID-19", "DNA", 35, 43], ["COVID", "TEST", 35, 40], ["inefficient", "OBSERVATION_MODIFIER", 19, 30]]], ["By deploying military assets, the federal government could quickly obtain an inventory of ICU resources including ventilators, determine need, and redistribute them faster than any other national organization or the state government machinery.", [["ICU resources", "TREATMENT", 90, 103], ["ventilators", "TREATMENT", 114, 125]]], ["Data for local disease activity from Centers for Disease Control and Prevention (CDC), and local health departments should be used to guide reallocation of resources.", [["local disease activity", "PROBLEM", 9, 31], ["Disease Control", "TREATMENT", 49, 64]]], ["For states with relatively small resource deficits, a reallocation of their own resources may be adequate to meet demand, while those with relatively large deficits will require resources from other states.", [["relatively small resource deficits", "PROBLEM", 16, 50], ["relatively large deficits", "PROBLEM", 139, 164], ["small", "OBSERVATION_MODIFIER", 27, 32], ["deficits", "OBSERVATION", 42, 50]]], ["In a federally led model, the federal government would have an inventory of ICU resources throughout the country, and thus be in the best position to objectively reallocate resources while minimizing risk of harm.A National Strategy for Ventilator and ICU resource allocation during the COVID-19 PandemicA state-led model would require that states take stock of their own ventilator inventory.", [["Ventilator", "TREATMENT", 237, 247], ["the COVID", "TEST", 283, 292]]], ["States that are expected to have a large deficit (> 50%) of ICU beds and ventilators, while also seeking unused supplies from within their borders, should also seek to partner with other states for help.", [["a large deficit", "PROBLEM", 33, 48], ["ventilators", "TREATMENT", 73, 84], ["large", "OBSERVATION_MODIFIER", 35, 40], ["deficit", "OBSERVATION", 41, 48]]], ["Under this agreement a state like Massachusetts, for example, whose ICU bed deficit is projected to be 2745 beds could request assistance from California and Texas who together are projected to have an excess capacity of 2769 ICU beds.", [["an excess capacity", "PROBLEM", 199, 217]]], ["It is vitally important in such cases that both the requesting and donor states carefully scrutinize available data to ensure that any potential surge does not coincide.A National Strategy for Ventilator and ICU resource allocation during the COVID-19 PandemicWhile this article's primary consideration is ventilator reallocation, the principles discussed could be applied to other aspects of the ICU supply chain.", [["Ventilator", "TREATMENT", 193, 203], ["the COVID", "TREATMENT", 239, 248], ["ventilator reallocation", "TREATMENT", 306, 329], ["ventilator reallocation", "OBSERVATION", 306, 329]]], ["Medications, protective equipment, and personnel would also fall under the purview of EMAC.", [["EMAC", "CANCER", 86, 90], ["Medications", "TREATMENT", 0, 11], ["protective equipment", "TREATMENT", 13, 33]]], ["Reciprocal states could request and agree to movement of healthcare supplies and workers between them without relicensing requirements, and assuring workers that they would not lose their job by volunteering in the reciprocal state.A National Strategy for Ventilator and ICU resource allocation during the COVID-19 PandemicThe looming question is whether reallocation of ventilators would be adequate to meet the expected tremendous shortage.", [["Ventilator", "TREATMENT", 256, 266], ["the COVID", "TEST", 302, 311], ["ventilators", "TREATMENT", 371, 382]]], ["There are several reasons why the deficit of ventilators may not be as large as initially projected.", [["the deficit of ventilators", "PROBLEM", 30, 56], ["may not be", "UNCERTAINTY", 57, 67], ["large", "OBSERVATION", 71, 76]]], ["First, the best estimate of ventilator supply is now 10 years old, and it is likely that hospitals will have increased their supplies since that time.", [["is likely", "UNCERTAINTY", 74, 83]]], ["Indeed, hospitals have been acquiring ventilators since the beginning of this crisis, and these numbers may not be reflected in current ventilator inventory estimates.", [["ventilators", "TREATMENT", 38, 49], ["this crisis", "PROBLEM", 73, 84], ["may not be", "UNCERTAINTY", 104, 114]]], ["Many physicians have been innovative in dealing with the shortage, by repurposing bilevel devices (4) and even splitting ventilators between multiple patients.", [["patients", "ORGANISM", 150, 158], ["patients", "SPECIES", 150, 158], ["repurposing bilevel devices", "TREATMENT", 70, 97], ["splitting ventilators", "TREATMENT", 111, 132]]], ["The federal government's deployment of military assets including field hospitals and military ships may help to ameliorate the shortage in some areas.", [["military ships", "TREATMENT", 85, 99]]], ["Additionally, significant progress appears to have been made on \"flattening the curve\"; as IHME's newest projections showed a decrease in projected hospital admissions and deaths.", [["deaths", "DISEASE", 172, 178], ["significant", "OBSERVATION_MODIFIER", 14, 25], ["decrease", "OBSERVATION_MODIFIER", 126, 134]]], ["It is also possible that treatments currently under trial will have some success in reducing the number of patients that may need ventilators.", [["patients", "ORGANISM", 107, 115], ["patients", "SPECIES", 107, 115], ["treatments", "TREATMENT", 25, 35], ["ventilators", "TREATMENT", 130, 141], ["also possible", "UNCERTAINTY", 6, 19]]], ["Finally, the pandemic may urge clinicians and families to have appropriate and timely in-depth conversations about end of life wishes and goals of care, which may also result in reduced ventilator demand.A National Strategy for Ventilator and ICU resource allocation during the COVID-19 PandemicLogistical challenges notwithstanding, there are tremendous ethical, political, economic and social implications to consider when taking lifesaving equipment from one group of people and giving it to another.", [["people", "ORGANISM", 471, 477], ["people", "SPECIES", 471, 477], ["reduced ventilator demand", "PROBLEM", 178, 203], ["Ventilator", "TREATMENT", 228, 238], ["the COVID-19 PandemicLogistical challenges", "TREATMENT", 274, 316], ["lifesaving equipment", "TREATMENT", 432, 452], ["ventilator demand", "OBSERVATION", 186, 203], ["tremendous", "OBSERVATION_MODIFIER", 344, 354]]], ["We strongly caution any group to consider these carefully before carrying out a redistribution of life saving resources.", [["a redistribution of life saving resources", "TREATMENT", 78, 119]]], ["Citizens who lend their supplies to another region must be shown data, either from testing or projections, that disease activity in their area is low and that they are not expected to have a shortage of ventilators in the near future.", [["ventilators", "TREATMENT", 203, 214]]], ["Officials must take into account the natural history of COVID-19 including the proportion of patients who may develop ARDS, and thus require a mechanical ventilator for a prolonged period.", [["ARDS", "DISEASE", 118, 122], ["patients", "ORGANISM", 93, 101], ["patients", "SPECIES", 93, 101], ["COVID", "TEST", 56, 61], ["ARDS", "PROBLEM", 118, 122], ["a mechanical ventilator", "TREATMENT", 141, 164], ["ARDS", "OBSERVATION", 118, 122]]], ["If Louisiana agrees to return ventilators to Oregon by a certain date, will they need to take patients off life support in order to accommodate them?", [["patients", "ORGANISM", 94, 102], ["patients", "SPECIES", 94, 102], ["ventilators", "TREATMENT", 30, 41], ["life support", "TREATMENT", 107, 119]]], ["Despite this, the net benefits will likely outweigh these individual losses.A National Strategy for Ventilator and ICU resource allocation during the COVID-19 PandemicWhile there are numerous challenges to the reallocation of ventilators, in times of crisis, Americans have always overcome such barriers by putting our nation's needs above our own.", [["these individual losses", "PROBLEM", 52, 75], ["Ventilator", "TREATMENT", 100, 110], ["the COVID", "TREATMENT", 146, 155], ["ventilators", "TREATMENT", 226, 237], ["crisis", "PROBLEM", 251, 257]]], ["Many will die from this disease.", [["this disease", "PROBLEM", 19, 31], ["disease", "OBSERVATION", 24, 31]]], ["However, people will also die from lack of supplies and lack of political will.", [["people", "ORGANISM", 9, 15], ["people", "SPECIES", 9, 15]]]], "c82709bc8ccdb60dbdd956981721c608a1d86fb0": [["Virology in the era of giant virusesThe ongoing COVID-19 pandemic [1] is a respiratory illness caused by the rapid global transmission of SARS-CoV-2 [2] , the seventh coronavirus known to infect humans.", [["giant viruses", "DISEASE", 23, 36], ["respiratory illness", "DISEASE", 75, 94], ["SARS", "DISEASE", 138, 142], ["giant viruses", "ORGANISM", 23, 36], ["SARS-CoV-2", "ORGANISM", 138, 148], ["coronavirus", "ORGANISM", 167, 178], ["humans", "ORGANISM", 195, 201], ["CoV-2", "SPECIES", 143, 148], ["humans", "SPECIES", 195, 201], ["SARS-CoV", "SPECIES", 138, 146], ["humans", "SPECIES", 195, 201], ["giant viruses", "PROBLEM", 23, 36], ["The ongoing COVID", "TEST", 36, 53], ["a respiratory illness", "PROBLEM", 73, 94], ["the rapid global transmission of SARS", "PROBLEM", 105, 142], ["CoV", "TEST", 143, 146], ["the seventh coronavirus", "PROBLEM", 155, 178], ["giant viruses", "OBSERVATION", 23, 36], ["respiratory illness", "OBSERVATION", 75, 94], ["seventh coronavirus", "ANATOMY", 159, 178], ["infect", "OBSERVATION", 188, 194]]], ["This ravaging disease illustrates the planetary consequences of recurrent episodes of zoonotic transmission from animals to human populations.", [["human", "ORGANISM", 124, 129], ["human", "SPECIES", 124, 129], ["human", "SPECIES", 124, 129], ["This ravaging disease", "PROBLEM", 0, 21], ["zoonotic transmission", "PROBLEM", 86, 107], ["planetary", "OBSERVATION_MODIFIER", 38, 47], ["recurrent", "OBSERVATION_MODIFIER", 64, 73], ["episodes", "OBSERVATION_MODIFIER", 74, 82], ["zoonotic", "OBSERVATION_MODIFIER", 86, 94]]], ["Viruses are seen as noxious agents of infection and death.", [["infection", "DISEASE", 38, 47], ["death", "DISEASE", 52, 57], ["Viruses", "PROBLEM", 0, 7], ["infection", "PROBLEM", 38, 47], ["death", "PROBLEM", 52, 57], ["infection", "OBSERVATION", 38, 47]]], ["Pandemics also poise philosophers and virologists to wonder about the origins of viruses and their ability to infect all cellular lineages on Earth [3] [4] [5] [6] [7] .", [["cellular", "ANATOMY", 121, 129], ["Earth [3] [4] [5] [6]", "CHEMICAL", 142, 163], ["cellular", "CELL", 121, 129], ["Earth [3] [4] [5] [6] [7]", "SIMPLE_CHEMICAL", 142, 167], ["virologists", "TREATMENT", 38, 49], ["viruses", "PROBLEM", 81, 88], ["viruses", "OBSERVATION", 81, 88]]], ["Disagreements on whether viruses are living or nonliving persist despite more than a hundred years of virological research and recent data-driven breakthroughs in the field of evolutionary genomics [8] [9] [10] [11] .", [["[8] [9] [10] [11]", "SIMPLE_CHEMICAL", 198, 215], ["viruses", "PROBLEM", 25, 32], ["virological research", "TREATMENT", 102, 122], ["recent data", "TEST", 127, 138]]], ["In 2003, the discovery of 'giant' viruses [12] revived the debate and challenged epistemological foundations [7, 13] .", [["'giant' viruses", "PROBLEM", 26, 41]]], ["The size of their genomes rivals that of several parasitic organisms from all three cellular domains (superkingdoms) of life [14] .", [["cellular", "ANATOMY", 84, 92], ["cellular", "CELL", 84, 92], ["several parasitic organisms", "PROBLEM", 41, 68], ["size", "OBSERVATION_MODIFIER", 4, 8], ["genomes rivals", "OBSERVATION", 18, 32], ["several", "OBSERVATION_MODIFIER", 41, 48], ["parasitic", "OBSERVATION_MODIFIER", 49, 58], ["organisms", "OBSERVATION", 59, 68], ["all", "OBSERVATION_MODIFIER", 74, 77], ["three", "OBSERVATION_MODIFIER", 78, 83], ["cellular domains", "OBSERVATION", 84, 100]]], ["Their virions, vehicles of transmission that embed the genetic material of the virus with a capsid (protein shell) and a lipid envelope, are cell-like and large enough to be visualized under a light microscope [14] .", [["virions", "ANATOMY", 6, 13], ["lipid envelope", "ANATOMY", 121, 135], ["cell", "ANATOMY", 141, 145], ["cell", "CELL", 141, 145], ["the virus", "PROBLEM", 75, 84], ["a capsid (protein shell", "TREATMENT", 90, 113], ["a lipid envelope", "PROBLEM", 119, 135], ["a light microscope", "TEST", 191, 209], ["lipid envelope", "OBSERVATION", 121, 135], ["large", "OBSERVATION_MODIFIER", 155, 160]]], ["These and other features (some cell-like) were previously never thought to be associated with viruses [4] .", [["cell", "ANATOMY", 31, 35], ["cell", "CELL", 31, 35], ["viruses", "PROBLEM", 94, 101], ["viruses", "OBSERVATION", 94, 101]]], ["Today, dozens of giant viruses have been discovered inhabiting a wide range of environments on Earth [16, 17] .", [["giant viruses", "ORGANISM", 17, 30], ["giant viruses", "PROBLEM", 17, 30], ["giant", "OBSERVATION_MODIFIER", 17, 22], ["viruses", "OBSERVATION", 23, 30]]], ["They were hiding in plain sight [18] .Virology in the era of giant virusesThe new findings were met with equal criticism and enthusiasm.", [["giant viruses", "DISEASE", 61, 74], ["giant viruses", "ORGANISM", 61, 74], ["giant viruses", "PROBLEM", 61, 74], ["giant viruses", "OBSERVATION", 61, 74], ["new", "OBSERVATION_MODIFIER", 78, 81]]], ["Some scientists, including us, proposed that giant viruses are 'living' parts of complex cellular cycles and together with other viruses make up an additional supergroup or a 'fourth' domain of life [8, 9, 11, [19] [20] [21] [22] , whereas others dismissed their living status altogether and attributed their size to massive genetic transfer from cellular genomes [23] [24] [25] .", [["cellular", "ANATOMY", 89, 97], ["cellular", "ANATOMY", 347, 355], ["giant viruses", "DISEASE", 45, 58], ["cellular", "CELL", 89, 97], ["cellular", "CELL", 347, 355], ["giant viruses", "PROBLEM", 45, 58]]], ["Despite controversy, giant viruses have redefined virology in several ways.", [["giant viruses", "PROBLEM", 21, 34], ["giant", "OBSERVATION_MODIFIER", 21, 26], ["viruses", "OBSERVATION", 27, 34]]], ["Building on previous ideas [26] , new intelligent definitions of viruses have been proposed (e.g., the virocell and virion-factory concepts discussed below) [4, 27] that highlight the distinction between viruses and virions [7, 28] .", [["virocell", "CANCER", 103, 111], ["new intelligent definitions of viruses", "PROBLEM", 34, 72], ["viruses", "OBSERVATION", 65, 72]]], ["In parallel, we and others have integrated the genomes of giant viruses into phylogenetic and phylogenomic studies to investigate their origin, evolution, and coevolution with their hosts [3, 9, 11, 14, [29] [30] [31] [32] [33] , some fueled by the appreciation of the importance of protein structure [34, 35] .Virology in the era of giant virusesHere, we summarize our phylogenomic effort, which spans over a decade of investigations [3, 8-10, 29, 36] .", [["giant viruses", "DISEASE", 334, 347], ["giant viruses", "ORGANISM", 334, 347], ["giant viruses", "PROBLEM", 58, 71], ["phylogenomic studies", "TEST", 94, 114], ["protein structure", "TEST", 283, 300], ["giant viruses", "PROBLEM", 334, 347], ["giant viruses", "OBSERVATION", 334, 347]]], ["Unlike traditional approaches, our strategy focuses on protein structural domains grouped by conserved threedimensional structural backbones [35] .", [["protein structural domains", "PROTEIN", 55, 81], ["traditional approaches", "TREATMENT", 7, 29], ["protein structural domains", "PROBLEM", 55, 81]]], ["Protein structures are more resistant to evolutionary change than gene and protein sequences [34] .", [["Protein structures", "TEST", 0, 18], ["gene and protein sequences", "TEST", 66, 92], ["more resistant", "OBSERVATION_MODIFIER", 23, 37]]], ["Their higher evolutionary conservation allows comparison of distantly related and fast-evolving genomes with a higher level of accuracy [35] .", [["fast-evolving genomes", "PROBLEM", 82, 103]]], ["In turn, sequence alignments of highly divergent datasets often fail to preserve a sufficient and reliable evolutionary signal for downstream analysis.", [["downstream analysis", "TEST", 131, 150]]], ["For example, a recent study showed that it was impossible to reliably align large blocks of RNAdependent RNA polymerase (RdRp) protein sequences from several families of RNA viruses [37] .", [["RNAdependent RNA polymerase (RdRp) protein sequences", "DNA", 92, 144], ["a recent study", "TEST", 13, 27], ["RNAdependent RNA polymerase (RdRp) protein sequences", "PROBLEM", 92, 144], ["RNA viruses", "PROBLEM", 170, 181]]], ["Here, we show how protein structures can outperform sequences in such cases by highlighting our past discoveries and updating an important study [9] by adding and analyzing newer genomes and structures.Hybrid models of virus origins and evolutionOne main question concerning viruses is the timing and mechanism of their origin.", [["how protein structures", "PROBLEM", 14, 36], ["an important study", "TEST", 126, 144], ["Hybrid models of virus origins", "PROBLEM", 202, 232], ["viruses", "PROBLEM", 275, 282], ["virus origins", "OBSERVATION", 219, 232], ["viruses", "OBSERVATION", 275, 282], ["origin", "ANATOMY_MODIFIER", 320, 326]]], ["The major roadblock is the unusually high genetic and morphological diversity seen in hundreds (possibly thousands) of extant viral lineages [38, 39] .", [["the unusually high genetic and morphological diversity", "PROBLEM", 23, 77], ["extant viral lineages", "PROBLEM", 119, 140], ["unusually", "OBSERVATION_MODIFIER", 27, 36], ["high", "OBSERVATION_MODIFIER", 37, 41], ["morphological diversity", "OBSERVATION", 54, 77], ["viral lineages", "OBSERVATION", 126, 140]]], ["No single feature appears conserved across the virosphere, the world of virus diversity.", [["virus diversity", "PROBLEM", 72, 87], ["virus diversity", "OBSERVATION", 72, 87]]], ["This likely suggests that viruses originated multiple times in evolution, and possibly via more than one mechanism.", [["viruses", "PROBLEM", 26, 33], ["likely suggests", "UNCERTAINTY", 5, 20], ["viruses", "OBSERVATION", 26, 33]]], ["The lack of unity also suggests that viruses are probably very ancient.", [["viruses", "PROBLEM", 37, 44], ["viruses", "OBSERVATION", 37, 44]]], ["Under these assumptions, three classical viewpoints have emerged in the scientific literature in various forms: (i) the virus-first hypothesis, which posits that viruses originated from precellular genetic elements, (ii) the reduction hypothesis, in which viruses originated from cells via reductive evolution, leading to extraordinary genomic and physical streamlining, and (iii) the escape hypothesis, in which cellular genes escaped from cells and transformed into (enveloped) viruses (Fig. 1A) .", [["cells", "ANATOMY", 280, 285], ["cellular", "ANATOMY", 413, 421], ["cells", "ANATOMY", 441, 446], ["cells", "CELL", 280, 285], ["cellular", "CELL", 413, 421], ["cells", "CELL", 441, 446], ["(enveloped) viruses", "ORGANISM", 468, 487], ["precellular genetic elements", "DNA", 186, 214], ["cellular genes", "DNA", 413, 427], ["the virus", "PROBLEM", 116, 125], ["first hypothesis", "PROBLEM", 126, 142], ["viruses", "PROBLEM", 162, 169], ["the reduction hypothesis", "PROBLEM", 221, 245], ["extraordinary genomic and physical streamlining", "PROBLEM", 322, 369], ["the escape hypothesis", "PROBLEM", 381, 402], ["reduction", "OBSERVATION_MODIFIER", 225, 234], ["hypothesis", "OBSERVATION", 235, 245], ["reductive", "OBSERVATION_MODIFIER", 290, 299], ["extraordinary", "OBSERVATION_MODIFIER", 322, 335]]], ["None of these models satisfactorily captures or explains the massive diversity of the virosphere.", [["the massive diversity of the virosphere", "PROBLEM", 57, 96], ["massive", "OBSERVATION_MODIFIER", 61, 68], ["diversity", "OBSERVATION", 69, 78]]], ["We will discuss two such models (Fig. 1B) .Hybrid models of virus origins and evolutionThe model of Krupovic et al. [40] combines elements from the virus-first and escape models, making it chimeric.", [["Hybrid models of virus origins", "PROBLEM", 43, 73], ["the virus", "PROBLEM", 144, 153], ["virus origins", "OBSERVATION", 60, 73]]], ["The authors divide virus genes into two genetic modules, one involved in replication and the other in virion structure and assembly.", [["virus genes", "DNA", 19, 30], ["virus genes", "OBSERVATION", 19, 30], ["genetic modules", "OBSERVATION", 40, 55]]], ["The replication module originated in an 'ancient world' inhabited by primordial genetic elements that existed prior to cells [40] .", [["cells", "ANATOMY", 119, 124], ["cells", "CELL", 119, 124], ["primordial genetic elements", "DNA", 69, 96], ["The replication module", "PROBLEM", 0, 22], ["primordial genetic elements", "OBSERVATION", 69, 96]]], ["This ancestrality explains the massive diversity seen in the replication strategies and genomes of modern-day viral lineages.", [["the massive diversity", "PROBLEM", 27, 48], ["the replication strategies", "TREATMENT", 57, 83], ["massive", "OBSERVATION_MODIFIER", 31, 38], ["diversity", "OBSERVATION", 39, 48]]], ["In turn, the structural genes responsible for virion formation and assembly were gradually captured from cells, once they appeared in evolution [40] .", [["virion", "ANATOMY", 46, 52], ["cells", "ANATOMY", 105, 110], ["virion", "CELLULAR_COMPONENT", 46, 52], ["cells", "CELL", 105, 110], ["structural genes", "DNA", 13, 29], ["virion formation", "PROBLEM", 46, 62]]], ["Indeed, the single jelly-roll fold, the most common capsid protein fold in RNA viruses, has structural homologies to several cellular proteins, mainly carbohydrate-binding proteins [30] .", [["cellular", "ANATOMY", 125, 133], ["carbohydrate", "CHEMICAL", 151, 163], ["cellular", "CELL", 125, 133], ["carbohydrate-binding proteins", "GENE_OR_GENE_PRODUCT", 151, 180], ["capsid protein", "PROTEIN", 52, 66], ["cellular proteins", "PROTEIN", 125, 142], ["carbohydrate-binding proteins", "PROTEIN", 151, 180], ["the single jelly-roll fold", "TREATMENT", 8, 34], ["the most common capsid protein fold in RNA viruses", "PROBLEM", 36, 86], ["several cellular proteins", "PROBLEM", 117, 142], ["protein fold", "OBSERVATION", 59, 71], ["RNA viruses", "OBSERVATION", 75, 86]]], ["While capsids hold a central place in any model of virion origins, capsid-like analogs are rare or absent in cells [9] , and some capsid protein folds are unique to viruses [39] .", [["cells", "ANATOMY", 109, 114], ["cells", "CELL", 109, 114], ["capsid protein folds", "PROTEIN", 130, 150], ["a central place", "TREATMENT", 19, 34], ["capsid", "TEST", 67, 73], ["absent in cells", "PROBLEM", 99, 114], ["some capsid protein folds", "PROBLEM", 125, 150], ["protein folds", "OBSERVATION", 137, 150]]], ["In addition, the rise of genetics prior to cells implies an ancient nucleic acid world (typically an \"RNA world\"), which brings all its difficulties and is incompatible with significant evidence [41] .Hybrid models of virus origins and evolutionIn contrast, the 'co-evolutionary' symbiogenic model of Nasir and Caetano-Anoll\u00e9s [3] proposes that viruses reduced from ancient cells with segmented RNA genomes as the world of communal cells was originating on the planet and was giving rise to the ancestors of Archaea, Bacteria, and Eukarya [9, 10] .", [["cells", "ANATOMY", 43, 48], ["cells", "ANATOMY", 374, 379], ["cells", "ANATOMY", 432, 437], ["nucleic acid", "CHEMICAL", 68, 80], ["cells", "CELL", 43, 48], ["cells", "CELL", 374, 379], ["communal cells", "CELL", 423, 437], ["segmented RNA genomes", "DNA", 385, 406], ["communal cells", "CELL_TYPE", 423, 437], ["Hybrid models of virus origins", "PROBLEM", 201, 231], ["Nasir", "TREATMENT", 301, 306], ["Caetano-Anoll\u00e9s", "TREATMENT", 311, 326], ["viruses", "PROBLEM", 345, 352], ["segmented RNA genomes", "PROBLEM", 385, 406], ["communal cells", "PROBLEM", 423, 437], ["Archaea", "PROBLEM", 508, 515], ["Bacteria", "PROBLEM", 517, 525], ["Eukarya", "TEST", 531, 538], ["virus origins", "OBSERVATION", 218, 231], ["RNA genomes", "OBSERVATION", 395, 406], ["communal cells", "OBSERVATION", 423, 437]]], ["Phylogenetically, the model thus invokes a fourth sister group arising with the three ancestors of cellular domains.", [["cellular", "ANATOMY", 99, 107], ["cellular", "CELL", 99, 107], ["cellular domains", "PROTEIN", 99, 115], ["cellular domains", "OBSERVATION", 99, 115]]], ["Unlike its other siblings, this primordial group devolved into viruses by selective loss while remaining linked to cellular hosts via cycles of cellular internalization.Hybrid models of virus origins and evolutionThe key difference with previous models therefore lies in the timing of genome origins and gradual unfolding of replication novelties in cells, not prior to them.", [["cellular", "ANATOMY", 115, 123], ["cellular", "ANATOMY", 144, 152], ["cells", "ANATOMY", 350, 355], ["cellular", "CELL", 115, 123], ["cellular", "CELL", 144, 152], ["cells", "CELL", 350, 355], ["selective loss", "PROBLEM", 74, 88], ["cellular internalization", "TREATMENT", 144, 168], ["Hybrid models of virus origins", "PROBLEM", 169, 199], ["gradual unfolding of replication novelties in cells", "PROBLEM", 304, 355], ["cellular internalization", "OBSERVATION", 144, 168], ["virus origins", "OBSERVATION", 186, 199], ["difference", "OBSERVATION_MODIFIER", 221, 231], ["gradual", "OBSERVATION_MODIFIER", 304, 311], ["unfolding", "OBSERVATION", 312, 321]]], ["In other words, instead of virus-like genetic elements evolving in a pre-cellular world, their genetics co-evolved alongside ancient cells.", [["cells", "ANATOMY", 133, 138], ["cells", "CELL", 133, 138], ["virus-like genetic elements", "DNA", 27, 54], ["ancient cells", "CELL_TYPE", 125, 138], ["virus", "PROBLEM", 27, 32]]], ["The symbiogenic model also proposes that RNA viruses originated first in evolution.", [["RNA viruses", "PROBLEM", 41, 52], ["RNA viruses", "OBSERVATION", 41, 52]]], ["Later, the retro-transcribing and DNA viruses either (co)evolved directly from the RNA viruses or evolved independently from the viral stem line of descent when RNA-based replication systems were gradually replaced by DNA-based replication counterparts.", [["stem line", "ANATOMY", 135, 144], ["DNA", "CELLULAR_COMPONENT", 34, 37], ["DNA", "CELLULAR_COMPONENT", 218, 221], ["the retro-transcribing and DNA viruses", "PROBLEM", 7, 45], ["the RNA viruses", "PROBLEM", 79, 94], ["RNA-based replication systems", "TREATMENT", 161, 190], ["RNA viruses", "OBSERVATION", 83, 94], ["viral stem line", "OBSERVATION", 129, 144]]], ["The model is compatible with one that links the cellular origin of giant viruses to the RNA-to-DNA evolutionary transition [27] , prior to the radiation of cellular lineages [7] .", [["cellular", "ANATOMY", 48, 56], ["cellular", "ANATOMY", 156, 164], ["cellular", "CELL", 48, 56], ["DNA", "CELLULAR_COMPONENT", 95, 98], ["cellular", "CELL", 156, 164], ["giant viruses", "PROBLEM", 67, 80], ["compatible with", "UNCERTAINTY", 13, 28], ["cellular", "OBSERVATION_MODIFIER", 48, 56], ["origin", "OBSERVATION_MODIFIER", 57, 63], ["giant", "OBSERVATION_MODIFIER", 67, 72], ["viruses", "OBSERVATION", 73, 80], ["cellular lineages", "OBSERVATION", 156, 173]]], ["The symbiogenic model also considers capsid proteins to have originated in the stem line at the onset of organismal lineage diversification or having been coopted from co-existing emerging cellular lineages.Hybrid models of virus origins and evolutionThe symbiogenic model draws inferences from the strong reductive tendencies that have become a hallmark feature of obligate parasitic and endosymbiotic organisms.", [["stem line", "ANATOMY", 79, 88], ["cellular", "ANATOMY", 189, 197], ["stem line", "CELL", 79, 88], ["cellular", "CELL", 189, 197], ["capsid proteins", "PROTEIN", 37, 52], ["capsid proteins", "PROBLEM", 37, 52], ["organismal lineage diversification", "PROBLEM", 105, 139], ["Hybrid models of virus origins", "PROBLEM", 207, 237], ["the strong reductive tendencies", "PROBLEM", 295, 326], ["obligate parasitic and endosymbiotic organisms", "PROBLEM", 366, 412], ["capsid proteins", "OBSERVATION", 37, 52], ["stem line", "OBSERVATION", 79, 88], ["organismal lineage diversification", "OBSERVATION", 105, 139], ["cellular lineages", "OBSERVATION", 189, 206], ["virus origins", "OBSERVATION", 224, 237], ["strong", "OBSERVATION_MODIFIER", 299, 305], ["reductive tendencies", "OBSERVATION", 306, 326], ["endosymbiotic organisms", "OBSERVATION", 389, 412]]], ["It would be difficult to imagine that viruses, which are the ultimate parasites, would prefer any another route [7] .", [["viruses", "PROBLEM", 38, 45], ["viruses", "OBSERVATION", 38, 45]]], ["Moreover, the model offers no constraint for ancient viruses to propagate via virion synthesis or other means.", [["virion", "CELLULAR_COMPONENT", 78, 84], ["ancient viruses", "PROBLEM", 45, 60], ["virion synthesis", "TREATMENT", 78, 94]]], ["The ancient cells simply produced vesicles that transported genetic cargo within the emergent cellular community (facilitating 'vesiduction' [42] ).", [["cells", "ANATOMY", 12, 17], ["vesicles", "ANATOMY", 34, 42], ["cellular community", "ANATOMY", 94, 112], ["cells", "CELL", 12, 17], ["vesicles", "CELLULAR_COMPONENT", 34, 42], ["cellular", "CELL", 94, 102], ["ancient cells", "OBSERVATION", 4, 17]]], ["The vesicle-mediated transport is routinely observed in multicellular organisms and, interestingly, shows remarkable resemblances to virus exit pathways [43] .", [["vesicle", "ANATOMY", 4, 11], ["multicellular organisms", "ANATOMY", 56, 79], ["vesicle", "CELLULAR_COMPONENT", 4, 11]]], ["Thus, ancient virions were likely free-floating vesicles that mimicked modern-day virus transmission via virions.", [["virions", "ANATOMY", 14, 21], ["vesicles", "ANATOMY", 48, 56], ["vesicles", "CELLULAR_COMPONENT", 48, 56], ["ancient virions", "TREATMENT", 6, 21], ["floating vesicles", "PROBLEM", 39, 56]]], ["More-sophisticated virion structures evolved much later at a time when diversified cellular lineages appeared.", [["virion structures", "ANATOMY", 19, 36], ["cellular", "ANATOMY", 83, 91], ["cellular", "CELL", 83, 91], ["More-sophisticated virion structures", "PROBLEM", 0, 36], ["diversified cellular lineages", "PROBLEM", 71, 100], ["cellular lineages", "OBSERVATION", 83, 100]]], ["The rise of virions is therefore explained as an enhancement of viral spread, very much as social media has enhanced the spread of news in human society.", [["virions", "ANATOMY", 12, 19], ["human", "ORGANISM", 139, 144], ["human", "SPECIES", 139, 144], ["human", "SPECIES", 139, 144], ["The rise of virions", "PROBLEM", 0, 19], ["viral spread", "PROBLEM", 64, 76], ["rise", "OBSERVATION_MODIFIER", 4, 8], ["virions", "OBSERVATION", 12, 19], ["viral spread", "OBSERVATION", 64, 76], ["spread", "OBSERVATION_MODIFIER", 121, 127]]], ["All aspects of this symbiogenic model of viral evolution are strongly supported by the data-driven comparative genomics and phylogenomic analyses we will now describe.Comparative genomics supports cellular history in virus evolutionThe cell-like existence of viruses in the distant past was strongly supported by our comparative genomic surveys, which compared the spread and distribution of fold superfamilies (FSFs) of protein structural domains in thousands of proteomes [9] .", [["cellular", "ANATOMY", 197, 205], ["cell", "ANATOMY", 236, 240], ["cellular", "CELL", 197, 205], ["cell", "CELL", 236, 240], ["fold superfamilies", "PROTEIN", 392, 410], ["FSFs", "PROTEIN", 412, 416], ["protein structural domains", "PROTEIN", 421, 447], ["the data", "TEST", 83, 91], ["phylogenomic analyses", "TEST", 124, 145], ["viruses", "PROBLEM", 259, 266], ["fold superfamilies", "PROBLEM", 392, 410], ["protein structural domains", "PROBLEM", 421, 447], ["viral", "OBSERVATION", 41, 46], ["viruses", "OBSERVATION", 259, 266], ["distant", "OBSERVATION_MODIFIER", 274, 281]]], ["FSFs, as defined by the Structural Classification of Proteins (SCOP) gold standard [44] , are groupings of one or several fold families (FFs).", [["FSFs", "PROTEIN", 0, 4], ["SCOP", "PROTEIN", 63, 67], ["FFs", "PROTEIN", 137, 140], ["FSFs", "TEST", 0, 4]]], ["FFs include domains that have sequence and structural evidence of common origin.", [["FFs", "GENE_OR_GENE_PRODUCT", 0, 3], ["FFs", "PROTEIN", 0, 3], ["common origin", "OBSERVATION", 66, 79]]], ["FFs are thus orthologous evolutionary units.", [["FFs", "GENE_OR_GENE_PRODUCT", 0, 3], ["FFs", "PROTEIN", 0, 3]]], ["In turn, FSFs group FFs with conserved structural cores and molecular functions.", [["FSFs", "GENE_OR_GENE_PRODUCT", 9, 13], ["FSFs", "PROTEIN", 9, 13], ["FSFs group FFs", "TEST", 9, 23], ["structural cores", "OBSERVATION", 39, 55], ["molecular functions", "OBSERVATION", 60, 79]]], ["Thus, domains grouped into an FSF may have little or no sequence identity but strong structural and functional similarities, which indicate evolutionary relatedness.", [["FSF", "GENE_OR_GENE_PRODUCT", 30, 33], ["FSF", "DNA", 30, 33], ["sequence identity", "PROBLEM", 56, 73], ["evolutionary relatedness", "OBSERVATION", 140, 164]]], ["FSFs are thus more conserved than FFs but provide less resolution in exploring relatively recent evolutionary relationships.", [["FSFs", "GENE_OR_GENE_PRODUCT", 0, 4], ["FSFs", "PROTEIN", 0, 4], ["FSFs", "TEST", 0, 4]]], ["The virus-first hypothesis postulates ancient origins of viruses that preceded cellular life.", [["cellular", "ANATOMY", 79, 87], ["cellular", "CELL", 79, 87], ["The virus", "PROBLEM", 0, 9], ["viruses", "PROBLEM", 57, 64], ["virus", "OBSERVATION", 4, 9], ["ancient origins", "OBSERVATION_MODIFIER", 38, 53], ["viruses", "OBSERVATION", 57, 64], ["cellular life", "OBSERVATION", 79, 92]]], ["The reduction hypothesis suggests that the origin of cells preceded that of viruses, with DNA viruses evolving via reduction in their genomes.", [["cells", "ANATOMY", 53, 58], ["cells", "CELL", 53, 58], ["DNA", "CELLULAR_COMPONENT", 90, 93], ["The reduction hypothesis", "PROBLEM", 0, 24], ["viruses", "PROBLEM", 76, 83], ["DNA viruses", "PROBLEM", 90, 101], ["reduction", "OBSERVATION_MODIFIER", 4, 13], ["viruses", "OBSERVATION", 76, 83], ["reduction", "OBSERVATION_MODIFIER", 115, 124]]], ["The escape hypothesis deems viruses as selfish genetic elements that escaped control of cellular machinery and 'pickpocketed' genes via HGT.", [["cellular", "ANATOMY", 88, 96], ["cellular", "CELL", 88, 96], ["pickpocketed'", "CELLULAR_COMPONENT", 112, 125], ["selfish genetic elements", "DNA", 39, 63], ["pickpocketed' genes", "DNA", 112, 131], ["HGT", "DNA", 136, 139], ["The escape hypothesis", "PROBLEM", 0, 21], ["cellular machinery", "TREATMENT", 88, 106]]], ["The hybrid 'chimeric' model put forth by Krupovic and coworkers [40] suggests an ancient origin of virus genomes and late recruitment of cellular proteins for capsid proteins to 'escape' from cells.", [["cellular", "ANATOMY", 137, 145], ["cells", "ANATOMY", 192, 197], ["cellular", "CELL", 137, 145], ["cells", "CELL", 192, 197], ["cellular proteins", "PROTEIN", 137, 154], ["capsid proteins", "PROTEIN", 159, 174], ["The hybrid 'chimeric' model", "TREATMENT", 0, 27], ["virus genomes", "PROBLEM", 99, 112], ["cellular proteins", "PROBLEM", 137, 154], ["capsid proteins", "PROBLEM", 159, 174], ["virus genomes", "OBSERVATION", 99, 112]]], ["The 'symbiogenic' model proposed by Nasir and Caetano-Anoll\u00e9s [3] hypothesizes that ancient cells coexisted with ancient virocells and that modern-day viruses evolved by genomic reductionComparative genomics supports cellular history in virus evolutionWe discovered that roughly one-fourth of total FSFs were shared between cells and viruses (the ABEV group) [9] .", [["cells", "ANATOMY", 92, 97], ["virocells", "ANATOMY", 121, 130], ["cellular", "ANATOMY", 217, 225], ["cells", "ANATOMY", 324, 329], ["cells", "CELL", 92, 97], ["virocells", "CANCER", 121, 130], ["cellular", "CELL", 217, 225], ["FSFs", "GENE_OR_GENE_PRODUCT", 299, 303], ["cells", "CELL", 324, 329], ["FSFs", "PROTEIN", 299, 303], ["The 'symbiogenic' model", "TREATMENT", 0, 23], ["ancient cells", "PROBLEM", 84, 97], ["ancient virocells", "PROBLEM", 113, 130], ["cellular history in virus evolutionWe", "PROBLEM", 217, 254], ["total FSFs", "PROBLEM", 293, 303]]], ["Several of these FSFs included ancient domains involved in metabolic functions and were components of cell membranes [9] .", [["cell membranes", "ANATOMY", 102, 116], ["FSFs", "GENE_OR_GENE_PRODUCT", 17, 21], ["cell membranes", "CELLULAR_COMPONENT", 102, 116], ["FSFs", "PROTEIN", 17, 21], ["these FSFs", "TEST", 11, 21], ["ancient domains", "PROBLEM", 31, 46], ["cell membranes", "PROBLEM", 102, 116], ["metabolic functions", "OBSERVATION", 59, 78], ["cell membranes", "OBSERVATION", 102, 116]]], ["These findings endorsed the idea of a shared cellular history of viruses.", [["cellular", "ANATOMY", 45, 53], ["cellular", "CELL", 45, 53], ["viruses", "PROBLEM", 65, 72], ["viruses", "OBSERVATION", 65, 72]]], ["Since the publication of this most recent study, an even greater sampling of proteomes and a focus on FFs rather than FSFs confirmed the overall comparative genomic patterns.", [["FFs", "GENE_OR_GENE_PRODUCT", 102, 105], ["this most recent study", "TEST", 25, 47], ["FSFs", "TEST", 118, 122], ["greater", "OBSERVATION_MODIFIER", 57, 64], ["genomic patterns", "OBSERVATION", 157, 173]]], ["Fig. 2 illustrates the distribution of 3,892 FF domains in 8,127 reference-quality proteomes.", [["3,892 FF domains", "DNA", 39, 55]]], ["Two FFs embedded in the RdRp and spike complex of SARS-CoV-2, the betacoronavirus responsible for the COVID-19 pandemic, exemplify the structural entities of the proteomic census.", [["FFs", "ANATOMY", 4, 7], ["SARS", "DISEASE", 50, 54], ["FFs", "CANCER", 4, 7], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 50, 60], ["betacoronavirus", "GENE_OR_GENE_PRODUCT", 66, 81], ["FFs", "PROTEIN", 4, 7], ["RdRp and spike complex", "PROTEIN", 24, 46], ["SARS-CoV", "SPECIES", 50, 58], ["the RdRp", "PROBLEM", 20, 28], ["SARS", "PROBLEM", 50, 54], ["CoV", "TEST", 55, 58], ["the betacoronavirus", "PROBLEM", 62, 81], ["the COVID", "TEST", 98, 107], ["pandemic", "PROBLEM", 111, 119], ["spike", "OBSERVATION_MODIFIER", 33, 38], ["proteomic census", "OBSERVATION", 162, 178]]], ["In these studies, 139 archaeal, 1,734 bacterial, 210 eukaryal, and 6,044 viral proteomes were selected from the RefSeq database [45] .", [["these studies", "TEST", 3, 16], ["archaeal", "TEST", 22, 30], ["bacterial", "TEST", 38, 47], ["eukaryal", "TEST", 53, 61], ["viral proteomes", "TEST", 73, 88], ["the RefSeq database", "TEST", 108, 127]]], ["Again, the ABEV group included a significant fraction of the FF domain repertoire (979 out of 3,892, 25%).", [["ABEV", "CANCER", 11, 15], ["FF domain repertoire", "PROTEIN", 61, 81], ["the FF domain repertoire", "TEST", 57, 81], ["significant", "OBSERVATION_MODIFIER", 33, 44], ["fraction", "OBSERVATION", 45, 53]]], ["The next-largest group was the ABE group (899 out of 3,892, 23%), which supports a stem line of descent embodying universal 'cellular' ancestors.", [["stem line", "ANATOMY", 83, 92], ["cellular", "ANATOMY", 125, 133], ["cellular", "CELL", 125, 133], ["a stem line", "TREATMENT", 81, 92], ["largest", "OBSERVATION_MODIFIER", 9, 16], ["stem line", "OBSERVATION", 83, 92]]], ["Note also how the Venn diagram is complete (there are no zeroes) and holds several supergroup-specific FFs in viruses, Archaea, Bacteria, and Eukarya.", [["FFs", "GENE_OR_GENE_PRODUCT", 103, 106], ["Venn diagram", "DNA", 18, 30], ["the Venn diagram", "TEST", 14, 30], ["viruses", "PROBLEM", 110, 117], ["Archaea", "PROBLEM", 119, 126], ["Bacteria", "PROBLEM", 128, 136], ["viruses", "OBSERVATION", 110, 117]]], ["Remarkably, the virus supergroup had Venn distributions comparable to those of the three cellular domains.Viruses complete the evolutionary pictureIn absence of retrodiction (the use of phylogenetic methods to travel back in time), the Venn group distributions of either FSFs or FFs can help infer how the cellular domains diversified from the last universal common ancestor (LUCA) of life.", [["cellular", "ANATOMY", 89, 97], ["cellular", "ANATOMY", 306, 314], ["cellular", "CELL", 89, 97], ["FSFs", "GENE_OR_GENE_PRODUCT", 271, 275], ["FFs", "GENE_OR_GENE_PRODUCT", 279, 282], ["cellular", "CELL", 306, 314], ["Venn", "DNA", 37, 41], ["FSFs", "PROTEIN", 271, 275], ["FFs", "PROTEIN", 279, 282], ["Venn distributions", "PROBLEM", 37, 55], ["Viruses", "PROBLEM", 106, 113], ["retrodiction", "PROBLEM", 161, 173], ["phylogenetic methods", "TREATMENT", 186, 206], ["virus", "OBSERVATION", 16, 21], ["Venn distributions", "OBSERVATION", 37, 55], ["cellular domains", "OBSERVATION", 89, 105]]], ["This is another highly charged and controversial problem that divides evolutionary biologists.", [["controversial problem", "PROBLEM", 35, 56]]], ["All kinds of phylogenetic trees have been published supporting distinct topologies of the 'tree of life'.", [["phylogenetic trees", "OBSERVATION", 13, 31]]], ["The canonical view of a threedomain (3D) cellular world endorsed by the school of Carl R. Woese and supported by rRNA sequence analysis roots the tree of life in the branch leading to Bacteria and produces a sister-group relationship between Archaea and Eukarya [46] .", [["cellular", "ANATOMY", 41, 49], ["cellular", "CELL", 41, 49], ["rRNA sequence", "DNA", 113, 126], ["rRNA sequence analysis", "TEST", 113, 135], ["Bacteria", "PROBLEM", 184, 192], ["tree", "OBSERVATION_MODIFIER", 146, 150], ["branch", "ANATOMY_MODIFIER", 166, 172], ["Bacteria", "OBSERVATION", 184, 192]]], ["The 3D view is backed by several ribosomal proteins that are conserved in Archaea and Eukarya but absent in Bacteria [47] , although this may be due in part to incomplete sampling of the bacterial superkingdom, especially the surveys of CPR proteomes (e.g. [48] ).", [["ribosomal", "ANATOMY", 33, 42], ["Archaea", "CELLULAR_COMPONENT", 74, 81], ["Eukarya", "CELLULAR_COMPONENT", 86, 93], ["ribosomal proteins", "PROTEIN", 33, 51], ["The 3D view", "TEST", 0, 11], ["several ribosomal proteins", "PROBLEM", 25, 51], ["absent in Bacteria", "PROBLEM", 98, 116], ["the bacterial superkingdom", "PROBLEM", 183, 209], ["CPR proteomes", "TEST", 237, 250], ["ribosomal proteins", "OBSERVATION", 33, 51], ["Bacteria", "OBSERVATION_MODIFIER", 108, 116], ["may be due in", "UNCERTAINTY", 138, 151], ["bacterial superkingdom", "OBSERVATION", 187, 209]]], ["The 3D tree was challenged by the discovery and subsequent phylogenetic analysis of the proteins encoded by the \u00c5sgard superphylum of Archaea [49] .", [["subsequent phylogenetic analysis", "TEST", 48, 80], ["the proteins", "PROBLEM", 84, 96], ["tree", "OBSERVATION_MODIFIER", 7, 11]]], ["The \u00c5sgard encode several eukaryotespecific proteins, including proteins involved in cytoskeleton formation and cell rearrangement, which brought to fame the old 'eocyte' tree hypothesis championed by James Lake and colleagues in the 1980s [50] .", [["cytoskeleton", "ANATOMY", 85, 97], ["cell", "ANATOMY", 112, 116], ["cytoskeleton", "CELLULAR_COMPONENT", 85, 97], ["cell", "CELL", 112, 116], ["\u00c5sgard", "PROTEIN", 4, 10], ["eukaryotespecific proteins", "PROTEIN", 26, 52], ["several eukaryotespecific proteins", "PROBLEM", 18, 52], ["cytoskeleton formation", "OBSERVATION", 85, 107], ["cell rearrangement", "OBSERVATION", 112, 130]]], ["The eocyte tree is effectively [63] , with a fold of very ancient origin.", [["eocyte tree", "ANATOMY", 4, 15], ["eocyte tree", "MULTI-TISSUE_STRUCTURE", 4, 15], ["tree", "ANATOMY_MODIFIER", 11, 15]]], ["On the right, a structural model illustrates the three subunits of the spike complex of SARS-CoV-2 (PDB entry 6VSB), which makes the outer surface 'corona' that is responsible for recognizing crucial molecules of the lung and causing the COVID-19 disease [64] .", [["outer surface", "ANATOMY", 133, 146], ["lung", "ANATOMY", 217, 221], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 88, 98], ["PDB entry 6VSB", "GENE_OR_GENE_PRODUCT", 100, 114], ["outer surface", "CELLULAR_COMPONENT", 133, 146], ["lung", "ORGAN", 217, 221], ["spike complex", "PROTEIN", 71, 84], ["SARS-CoV-2", "PROTEIN", 88, 98], ["PDB entry 6VSB", "PROTEIN", 100, 114], ["SARS", "TEST", 88, 92], ["CoV", "TEST", 93, 96], ["the COVID-19 disease", "PROBLEM", 234, 254], ["right", "ANATOMY_MODIFIER", 7, 12], ["spike", "OBSERVATION_MODIFIER", 71, 76], ["responsible for", "UNCERTAINTY", 164, 179], ["lung", "ANATOMY", 217, 221]]], ["Subunits are colored with different shades of blue and purple.", [["colored", "OBSERVATION", 13, 20], ["different shades", "OBSERVATION_MODIFIER", 26, 42], ["blue", "OBSERVATION_MODIFIER", 46, 50], ["purple", "OBSERVATION_MODIFIER", 55, 61]]], ["They are made of a virus-specific protein FF (d.318.1.1), the evolutionarily recent SARS receptor-binding domain-like fold a two-domain (2D) world scenario, which supports two primary domains, Archaea and Bacteria, with the merger of the two leading to the origin of Eukarya.", [["FF", "GENE_OR_GENE_PRODUCT", 42, 44], ["d.318.1.1", "PROTEIN", 46, 55], ["SARS receptor-binding domain", "PROTEIN", 84, 112], ["a virus", "PROBLEM", 17, 24], ["specific protein FF", "TEST", 25, 44], ["the evolutionarily recent SARS receptor-binding domain", "PROBLEM", 58, 112], ["two primary domains", "PROBLEM", 172, 191], ["Archaea and Bacteria", "PROBLEM", 193, 213], ["Bacteria", "OBSERVATION_MODIFIER", 205, 213], ["origin", "ANATOMY_MODIFIER", 257, 263], ["Eukarya", "OBSERVATION", 267, 274]]], ["The 2D tree is widely popular but has been challenged by a number of conceptual and methodological difficulties related to phylogenetic reconstruction [51] [52] [53] .", [["methodological difficulties", "PROBLEM", 84, 111], ["phylogenetic reconstruction", "TEST", 123, 150], ["tree", "ANATOMY_MODIFIER", 7, 11], ["widely", "OBSERVATION_MODIFIER", 15, 21], ["popular", "OBSERVATION", 22, 29]]], ["The 2D tree has multiple forms that vary with regard to the nature of the prokaryotic host cell and the timing of a putative primordial 'phagocytosis' event [54] .", [["cell", "ANATOMY", 91, 95], ["host cell", "CELL", 86, 95], ["multiple", "OBSERVATION_MODIFIER", 16, 24], ["prokaryotic host cell", "OBSERVATION", 74, 95]]], ["Similarly, the 3D tree has two significant variations.", [["tree", "ANATOMY_MODIFIER", 18, 22], ["two", "OBSERVATION_MODIFIER", 27, 30], ["significant", "OBSERVATION_MODIFIER", 31, 42], ["variations", "OBSERVATION_MODIFIER", 43, 53]]], ["In one model, the tree is rooted in the branch leading to Eukarya [55, 56] .", [["tree", "OBSERVATION_MODIFIER", 18, 22], ["branch", "ANATOMY_MODIFIER", 40, 46]]], ["In the other, the 'Archaea-first' model, the tree is rooted in branches leading to Archaea [57] [58] [59] .", [["tree", "ANATOMY_MODIFIER", 45, 49], ["branches", "ANATOMY_MODIFIER", 63, 71]]], ["Rooted trees built from structural domains in proteomes defined with different classifications and classification levels [59] [60] [61] and from Gene Ontology (GO) terms in genomes [62] , and inter-proteome and ribosomal protein similarities consistent with vertical transmission [63] , support the Archaea-first model.", [["ribosomal", "ANATOMY", 211, 220], ["ribosomal", "CELLULAR_COMPONENT", 211, 220], ["classification levels", "TEST", 99, 120], ["ribosomal protein similarities", "PROBLEM", 211, 241], ["vertical transmission", "PROBLEM", 258, 279], ["ribosomal protein", "OBSERVATION", 211, 228], ["consistent with", "UNCERTAINTY", 242, 257]]], ["In contrast, the 'Eukarya-first' 3D view was challenged on methodological and conceptual grounds related to phylogenetic rooting and the model of biological change [64, 65] .", [["phylogenetic rooting", "PROBLEM", 108, 128], ["phylogenetic rooting", "OBSERVATION", 108, 128]]], ["Despite the constant evolutionary presence of viruses across domains of life, all of these models and most studies exclude viruses.", [["viruses", "PROBLEM", 123, 130], ["viruses", "OBSERVATION", 46, 53]]], ["This yields an incomplete picture that fosters controversy.Viruses complete the evolutionary pictureWithout any formal phylogenetic analysis, the Venn group distributions already help us rule out some of the above-mentioned scenarios.", [["Viruses", "PROBLEM", 59, 66]]], ["For example, a 2D tree implies a very strong genetic affiliation between Archaea and Eukarya or a lesser affiliation between Archaea and Bacteria.", [["Archaea and Bacteria", "PROBLEM", 125, 145], ["very", "OBSERVATION_MODIFIER", 33, 37], ["strong", "OBSERVATION_MODIFIER", 38, 44], ["lesser", "OBSERVATION_MODIFIER", 98, 104], ["Archaea", "OBSERVATION_MODIFIER", 125, 132], ["Bacteria", "OBSERVATION_MODIFIER", 137, 145]]], ["Archaea and Eukarya share only 49 unique FFs (the AE group), while Archaea and Bacteria share 168 FFs (the AB group).Viruses complete the evolutionary pictureIn contrast, Bacteria and Eukarya share 485 FFs (the BE group).", [["BE", "CHEMICAL", 211, 213], ["FFs", "PATHOLOGICAL_FORMATION", 41, 44], ["Bacteria", "TEST", 79, 87], ["Viruses", "PROBLEM", 117, 124], ["Bacteria", "PROBLEM", 171, 179], ["FFs", "TEST", 202, 205]]], ["In absence of horizontal genetic exchange, their stronger genetic affiliation falsifies the expectation of a 2D scenario.", [["horizontal genetic exchange", "PROBLEM", 14, 41]]], ["Venn diagrams group viral FFs according to the cellular domain of the virus hosts.", [["cellular", "ANATOMY", 47, 55], ["cellular", "CELL", 47, 55], ["Venn diagrams group viral FFs", "TREATMENT", 0, 29], ["virus hosts", "OBSERVATION", 70, 81]]], ["For example, abe indicates FFs conserved in archaeoviruses, bacterioviruses, and eukaryoviruses.", [["archaeoviruses", "ANATOMY", 44, 58], ["bacterioviruses", "ANATOMY", 60, 75], ["FFs", "GENE_OR_GENE_PRODUCT", 27, 30], ["archaeoviruses", "GENE_OR_GENE_PRODUCT", 44, 58], ["FFs", "PROTEIN", 27, 30], ["FFs", "TEST", 27, 30], ["archaeoviruses", "PROBLEM", 44, 58], ["bacterioviruses", "PROBLEM", 60, 75], ["eukaryoviruses", "PROBLEM", 81, 95]]], ["Quite remarkably, the abe group shares a biologically and numerically significant core of 112 FFs.", [["FFs", "CANCER", 94, 97]]], ["This is additional evidence that the virus mode of life likely evolved prior to the diversification of modern cells.", [["cells", "ANATOMY", 110, 115], ["cells", "CELL", 110, 115], ["modern cells", "CELL_TYPE", 103, 115], ["modern cells", "PROBLEM", 103, 115], ["virus", "OBSERVATION", 37, 42], ["modern cells", "OBSERVATION", 103, 115]]], ["Again, there is very little or no overlap between the prokaryotic viruses (Venn group ab, 56 FFs) or between the archaeoviruses and eukaryoviruses (ae, 6) , when compared to FFs shared by bacterioviruses and eukaryoviruses (be, 352).", [["archaeoviruses", "ANATOMY", 113, 127], ["Venn group ab", "GENE_OR_GENE_PRODUCT", 75, 88], ["FFs", "GENE_OR_GENE_PRODUCT", 174, 177], ["the prokaryotic viruses", "PROBLEM", 50, 73], ["Venn group ab", "TEST", 75, 88], ["the archaeoviruses and eukaryoviruses", "PROBLEM", 109, 146], ["FFs", "TEST", 174, 177], ["eukaryoviruses", "TEST", 208, 222], ["very", "OBSERVATION_MODIFIER", 16, 20], ["little", "OBSERVATION_MODIFIER", 21, 27], ["prokaryotic", "OBSERVATION_MODIFIER", 54, 65], ["viruses", "OBSERVATION", 66, 73]]], ["If eukaryotes either descended from or are sister to Archaea, we should expect to see higher genetic similarity in either the two domains or their viruses.", [["eukaryotes", "PROBLEM", 3, 13], ["viruses", "OBSERVATION", 147, 154]]], ["However, FF evidence is not consistent with such a view.", [["not consistent with", "UNCERTAINTY", 24, 43]]], ["The strongest similarities are observed between Bacteria and Eukarya and their viruses, which supports the Archaea-first 3D tree.", [["Bacteria", "CELLULAR_COMPONENT", 48, 56], ["Eukarya", "CELLULAR_COMPONENT", 61, 68], ["3D tree", "MULTI-TISSUE_STRUCTURE", 121, 128], ["Bacteria", "PROBLEM", 48, 56], ["Eukarya and their viruses", "PROBLEM", 61, 86], ["viruses", "OBSERVATION", 79, 86]]], ["We would, however, like to clarify that Venn group numbers can be affected by microbial proteomes that have not been sequenced [52, 66] .", [["microbial proteomes", "TEST", 78, 97]]], ["So far, however, the patterns of distribution we report here have remained robust over a decade of investigations.", [["investigations", "TEST", 99, 113]]], ["(C) The abundance of each viral replicon type by host superkingdom and major taxonomic groups in Eukarya.", [["viral replicon", "OBSERVATION", 26, 40]]], ["Hosts were grouped into Archaea, Bacteria, Protista (animal-like protists), Fungi, plants (all plants, blue-green algae, and diatoms), invertebrates and plants (IP), and Metazoa (vertebrates, invertebrates, and humans).", [["humans", "ORGANISM", 211, 217], ["humans", "SPECIES", 211, 217], ["humans", "SPECIES", 211, 217], ["Bacteria", "PROBLEM", 33, 41], ["Protista", "TEST", 43, 51], ["Fungi", "PROBLEM", 76, 81], ["blue-green algae", "TREATMENT", 103, 119], ["plants (IP)", "TREATMENT", 153, 164], ["Metazoa (vertebrates", "TREATMENT", 170, 190]]], ["Numbers on bars represent the total virus count in each host groupProtein fold families recapitulate evolutionary historyThe Venn diagrams are merely descriptive and can only help approximate the most parsimonious evolutionary scenario.", [["Venn diagrams", "DNA", 125, 138], ["the total virus count", "TEST", 26, 47], ["The Venn diagrams", "TEST", 121, 138], ["virus count", "OBSERVATION", 36, 47]]], ["While the molecular census can be biased by unequal samplings and/or uneven performance of bioinformatics programs on different genomic datasets [19, 51] , comparative genomic approaches are necessarily limited by the effect of horizontal genetic exchange, which complicates any evolutionary inference derived from extant data that considers only vertical descent.", [["unequal samplings", "PROBLEM", 44, 61], ["bioinformatics programs", "TREATMENT", 91, 114], ["horizontal genetic exchange", "TREATMENT", 228, 255], ["extant data", "TEST", 315, 326], ["vertical descent", "PROBLEM", 347, 363], ["vertical descent", "OBSERVATION", 347, 363]]], ["These limitations prompt the use of data-driven phylogenomic methods that are capable of reconstructing the past from a census of structural domains in proteomes [9] .", [["structural domains", "PROTEIN", 130, 148], ["phylogenomic methods", "TREATMENT", 48, 68]]], ["Using the extended genomic dataset described above, we now dissect different evolutionary phases in the history of cells and viruses by a method that traces the origin of the FFs or FSFs of each Venn group [60, 67] .", [["cells", "ANATOMY", 115, 120], ["FFs", "ANATOMY", 175, 178], ["cells", "CELL", 115, 120], ["FFs", "CANCER", 175, 178], ["FFs", "DNA", 175, 178], ["cells", "PROBLEM", 115, 120], ["viruses", "PROBLEM", 125, 132], ["a method", "TREATMENT", 136, 144]]], ["In these experiments, phylogenomic trees are reconstructed that describe the evolution of structural domains.", [["structural domains", "PROTEIN", 90, 108], ["structural domains", "PROBLEM", 90, 108], ["phylogenomic trees", "OBSERVATION", 22, 40], ["structural domains", "OBSERVATION", 90, 108]]], ["These trees differ from the more traditional trees that describe the evolution of the proteomes of cellular organisms and/or viruses.", [["cellular organisms", "ANATOMY", 99, 117], ["cellular", "CELL", 99, 107], ["cellular organisms", "PROBLEM", 99, 117], ["viruses", "PROBLEM", 125, 132], ["cellular organisms", "OBSERVATION", 99, 117]]], ["The leaves (taxa) of the trees are domains instead of proteomes.", [["leaves", "ANATOMY", 4, 10], ["leaves", "ORGANISM_SUBDIVISION", 4, 10], ["The leaves (taxa", "TREATMENT", 0, 16]]], ["To calculate the relative age of each domain in a Venn group, a 'node distance' (nd) from the base of the tree to each leaf allows us to build evolutionary timelines of appearance of structural domains in proteomes, with nd = 0 representing the origin of protein domains and nd = 1 representing the present [9, 59, 68] .", [["node", "ANATOMY", 65, 69], ["leaf", "ANATOMY", 119, 123], ["leaf", "ORGAN", 119, 123], ["structural domains", "PROTEIN", 183, 201], ["protein domains", "PROTEIN", 255, 270], ["a 'node distance'", "TREATMENT", 62, 79], ["structural domains in proteomes", "PROBLEM", 183, 214], ["node", "OBSERVATION", 65, 69], ["base", "ANATOMY_MODIFIER", 94, 98], ["tree", "ANATOMY_MODIFIER", 106, 110], ["origin", "ANATOMY_MODIFIER", 245, 251]]], ["Ages can be calibrated with a molecular clock of folds that coverts the relative timeline into geological timescales by correlating domain ancestry with domain structures linked to markers of the geological record [69] .", [["a molecular clock of folds", "PROBLEM", 28, 54]]], ["Six major evolutionary phases are evident in the timelines of FFs (Fig. 4A and B) .", [["B", "GENE_OR_GENE_PRODUCT", 79, 80], ["evolutionary phases", "OBSERVATION", 10, 29]]], ["(Table S7) , these wrapping structures may represent cellular ancestors of viral capsids.", [["cellular", "ANATOMY", 53, 61], ["cellular", "CELL", 53, 61], ["these wrapping structures", "TREATMENT", 13, 38], ["viral capsids", "PROBLEM", 75, 88], ["may represent", "UNCERTAINTY", 39, 52], ["cellular ancestors", "OBSERVATION", 53, 71], ["viral capsids", "OBSERVATION", 75, 88]]], ["They are probably almost absent in viruses because they have been superseded through reductive evolution by the late appearance of viral capsids. v. Diversification of Archaea, Eukarya, and Viruses (nd = 0.464-0.77).", [["viral capsids", "PROBLEM", 131, 144], ["Archaea", "PROBLEM", 168, 175], ["Viruses", "TEST", 190, 197], ["probably", "UNCERTAINTY", 9, 17], ["almost", "OBSERVATION_MODIFIER", 18, 24], ["absent", "OBSERVATION", 25, 31], ["viruses", "OBSERVATION", 35, 42], ["viral capsids", "OBSERVATION", 131, 144], ["Archaea", "OBSERVATION", 168, 175], ["Viruses", "OBSERVATION_MODIFIER", 190, 197]]], ["The lineages leading to viruses, Archaea, and Eukarya also diversified with the innovation of group-specific FFs.", [["FFs", "PATHOLOGICAL_FORMATION", 109, 112], ["The lineages", "PROBLEM", 0, 12], ["viruses", "PROBLEM", 24, 31], ["Archaea", "PROBLEM", 33, 40], ["lineages", "OBSERVATION_MODIFIER", 4, 12], ["viruses", "OBSERVATION", 24, 31]]], ["Remarkably, the gains by the viral supergroup included FFs that confer capsids and virulence to viral proteomes and were part of the virus-specific V group, which appeared early during this phase.", [["FFs", "GENE_OR_GENE_PRODUCT", 55, 58], ["FFs", "PROTEIN", 55, 58], ["FFs", "TREATMENT", 55, 58], ["capsids", "TREATMENT", 71, 78], ["virulence to viral proteomes", "PROBLEM", 83, 111], ["the virus", "PROBLEM", 129, 138]]], ["Interestingly, the AV, BV, and EV groups soon followed the appearances of A, B, and E groups.", [["BV", "ANATOMY", 23, 25], ["BV", "ORGANISM_SUBSTANCE", 23, 25], ["B", "CELL", 77, 78], ["AV", "ANATOMY", 19, 21]]], ["These observations therefore suggest that viral pathogenesis started soon after the diversification of the host.", [["viral pathogenesis", "PROBLEM", 42, 60]]], ["A GO [71] enrichment analysis of FFs in AV, BV, and EV confirms that these protein domains enable viruses to infect hosts and ensure their survival (Table S8 ).", [["BV", "ANATOMY", 44, 46], ["FFs", "GENE_OR_GENE_PRODUCT", 33, 36], ["AV", "MULTI-TISSUE_STRUCTURE", 40, 42], ["BV", "ORGANISM_SUBSTANCE", 44, 46], ["FFs", "PROTEIN", 33, 36], ["protein domains", "PROTEIN", 75, 90], ["enrichment analysis", "TEST", 10, 29], ["FFs", "TEST", 33, 36], ["AV", "TEST", 40, 42], ["these protein domains enable viruses", "PROBLEM", 69, 105], ["AV", "ANATOMY", 40, 42]]], ["The findings were expected; pathogenicity implies the ability to recognize and distinguish between different hosts, which is only possible if the hosts represent diversified lineages. vi.", [["pathogenicity", "PROBLEM", 28, 41], ["different", "OBSERVATION_MODIFIER", 99, 108], ["hosts", "OBSERVATION", 109, 114], ["diversified", "OBSERVATION_MODIFIER", 162, 173], ["lineages", "OBSERVATION", 174, 182]]], ["A large number of FFs appearing in the final phase were specific to eukaryotic lineages, contributing to the late development of eukaryal proteomes as well as acquisition of advanced functionalities such as those involved in regulation, signaling and intracellular processes [60] .Protein fold families recapitulate evolutionary historyThe FF timeline is consistent with our previous results [3] .", [["FFs", "ANATOMY", 18, 21], ["eukaryal proteomes", "ANATOMY", 129, 147], ["intracellular", "ANATOMY", 251, 264], ["FFs", "CANCER", 18, 21], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 251, 264], ["FFs", "PROTEIN", 18, 21], ["eukaryotic lineages", "CELL_TYPE", 68, 87], ["A large number of FFs", "PROBLEM", 0, 21], ["eukaryotic lineages", "PROBLEM", 68, 87], ["eukaryal proteomes", "PROBLEM", 129, 147], ["advanced functionalities", "PROBLEM", 174, 198], ["signaling and intracellular processes", "PROBLEM", 237, 274], ["large", "OBSERVATION_MODIFIER", 2, 7], ["number", "OBSERVATION_MODIFIER", 8, 14], ["eukaryotic lineages", "OBSERVATION", 68, 87], ["consistent with", "UNCERTAINTY", 355, 370]]], ["It indicates that the viral supergroup had cellular origins and diversified from a stem line of descent very early in evolution.", [["cellular", "ANATOMY", 43, 51], ["stem line", "ANATOMY", 83, 92], ["cellular", "CELL", 43, 51], ["a stem line", "TREATMENT", 81, 92], ["viral", "OBSERVATION_MODIFIER", 22, 27], ["cellular origins", "OBSERVATION", 43, 59], ["diversified", "OBSERVATION_MODIFIER", 64, 75], ["stem line", "OBSERVATION", 83, 92], ["very", "OBSERVATION_MODIFIER", 104, 108], ["early", "OBSERVATION_MODIFIER", 109, 114]]], ["This primordial viral stem line then continued to evolve via reductive evolution.", [["stem line", "ANATOMY", 22, 31], ["stem line", "CELL", 22, 31], ["primordial viral stem line", "CELL_LINE", 5, 31], ["This primordial viral stem line", "TREATMENT", 0, 31], ["viral stem line", "OBSERVATION", 16, 31], ["reductive evolution", "OBSERVATION", 61, 80]]], ["We have termed these celllike entities 'proto-virocells' because they combined the modern autonomous replication of modern virus genomes inside a host (virocell) [28] with the ability to spread genetic (and cellular) wealth to other cells through ancient vesiclelike structures.", [["virocell", "ANATOMY", 152, 160], ["cellular", "ANATOMY", 207, 215], ["cells", "ANATOMY", 233, 238], ["vesiclelike structures", "ANATOMY", 255, 277], ["proto-virocells", "CELL", 40, 55], ["virocell", "CELL", 152, 160], ["cellular", "CELL", 207, 215], ["cells", "CELL", 233, 238], ["vesiclelike structures", "MULTI-TISSUE_STRUCTURE", 255, 277], ["proto-virocells", "TREATMENT", 40, 55], ["modern virus genomes", "TREATMENT", 116, 136], ["a host (virocell)", "TREATMENT", 144, 161]]], ["Remarkably, the reductive tendencies were later also observed in the archaeal lineage and are common in modern day endosymbionts and obligate parasites [72] .", [["archaeal lineage", "CELL_TYPE", 69, 85], ["the reductive tendencies", "PROBLEM", 12, 36], ["obligate parasites", "PROBLEM", 133, 151], ["reductive", "OBSERVATION_MODIFIER", 16, 25], ["tendencies", "OBSERVATION", 26, 36], ["archaeal lineage", "OBSERVATION", 69, 85]]], ["To illustrate, Fig. 5 reveals an overlap of FF use and reuse values between bacterial parasites and giant viruses.", [["bacterial parasites", "PROBLEM", 76, 95], ["giant viruses", "PROBLEM", 100, 113], ["bacterial parasites", "OBSERVATION", 76, 95], ["giant viruses", "OBSERVATION", 100, 113]]], ["The reduction model of virus evolution is also supported by the distribution of FFs in different virus replicon types of the Baltimore virus classification (Fig. 6 ).", [["FFs", "GENE_OR_GENE_PRODUCT", 80, 83], ["FFs", "PROTEIN", 80, 83], ["Baltimore virus", "SPECIES", 125, 140], ["virus evolution", "PROBLEM", 23, 38], ["different virus replicon", "TREATMENT", 87, 111], ["reduction", "OBSERVATION_MODIFIER", 4, 13], ["virus", "OBSERVATION", 23, 28], ["distribution", "OBSERVATION_MODIFIER", 64, 76], ["different virus replicon", "OBSERVATION", 87, 111]]], ["Very few, if any, FFs are conserved between the different virus subgroups.", [["FFs", "GENE_OR_GENE_PRODUCT", 18, 21], ["any, FFs", "PROBLEM", 13, 21], ["few", "OBSERVATION_MODIFIER", 5, 8]]], ["The dsDNA viruses harbor the maximum number of FFs.", [["FFs", "GENE_OR_GENE_PRODUCT", 47, 50], ["FFs", "PROTEIN", 47, 50], ["The dsDNA viruses", "TREATMENT", 0, 17], ["maximum", "OBSERVATION_MODIFIER", 29, 36], ["number", "OBSERVATION_MODIFIER", 37, 43]]], ["Out of the 1,526 FFs, ~92% (1,409) were unique to each viral subgroup, while only 8% (117) were shared by more than one subgroup.", [["FFs", "CANCER", 17, 20]]], ["There were no FFs common to all subgroups.", [["FFs", "PROBLEM", 14, 17], ["no", "UNCERTAINTY", 11, 13]]], ["However, the \"Reverse transcriptase\" (e.8.1.2) FF was the most shared domain, present in five of the seven viral subgroups (Table S4 ).", [["Reverse transcriptase", "PROTEIN", 14, 35], ["viral subgroups", "OBSERVATION", 107, 122]]], ["The data therefore show a very patchy distribution of FFs within the virosphere, which falsifies a monophyletic origin but can be reconciled with reductive evolution of viruses.Protein fold families recapitulate evolutionary historyInterestingly, the patterns of emergence and loss of FF domains are also remarkably similar to the host preferences of viral lineages.", [["virosphere", "ANATOMY", 69, 79], ["FFs", "GENE_OR_GENE_PRODUCT", 54, 57], ["FF", "GENE_OR_GENE_PRODUCT", 285, 287], ["FF domains", "PROTEIN", 285, 295], ["viral lineages", "CELL_TYPE", 351, 365], ["The data", "TEST", 0, 8], ["a very patchy distribution of FFs", "PROBLEM", 24, 57], ["viruses", "PROBLEM", 169, 176], ["loss of FF domains", "PROBLEM", 277, 295], ["viral lineages", "PROBLEM", 351, 365], ["very", "OBSERVATION_MODIFIER", 26, 30], ["patchy", "OBSERVATION_MODIFIER", 31, 37], ["distribution", "OBSERVATION_MODIFIER", 38, 50], ["monophyletic origin", "OBSERVATION", 99, 118], ["viruses", "OBSERVATION", 169, 176], ["loss", "OBSERVATION_MODIFIER", 277, 281], ["viral lineages", "OBSERVATION", 351, 365]]], ["Archaea and Bacteria encode smaller FF repertoires and also exhibit lower diversity in the number [73] .", [["FF", "GENE_OR_GENE_PRODUCT", 36, 38], ["FF repertoires", "PROTEIN", 36, 50], ["Archaea and Bacteria encode smaller FF repertoires", "PROBLEM", 0, 50], ["Bacteria", "OBSERVATION", 12, 20], ["smaller", "OBSERVATION_MODIFIER", 28, 35], ["lower", "OBSERVATION_MODIFIER", 68, 73], ["diversity", "OBSERVATION_MODIFIER", 74, 83]]], ["Eukaryotes encode the richest FF repertoires and also the maximum diversity in the number and types of virus interactions.", [["FF", "GENE_OR_GENE_PRODUCT", 30, 32], ["virus interactions", "PROBLEM", 103, 121], ["maximum", "OBSERVATION_MODIFIER", 58, 65], ["diversity", "OBSERVATION_MODIFIER", 66, 75], ["virus", "OBSERVATION", 103, 108]]], ["For example, eukaryotes, especially animals, are infected by a wide range of RNA and retro-transcribing viruses that are completely absent in Archaea, or are rarely detected or absent in Bacteria, respectively [73, 74] .", [["a wide range of RNA and retro-transcribing viruses", "PROBLEM", 61, 111], ["infected", "OBSERVATION_MODIFIER", 49, 57], ["wide", "OBSERVATION_MODIFIER", 63, 67], ["viruses", "OBSERVATION", 104, 111], ["Archaea", "OBSERVATION_MODIFIER", 142, 149], ["Bacteria", "OBSERVATION_MODIFIER", 187, 195]]], ["If the earliest cells contained segmented RNA genomes, as we propose [3, 9] , the absence of RNA viruses in Archaea can be explained by the loss of ancient RNA viruses.", [["cells", "ANATOMY", 16, 21], ["cells", "CELL", 16, 21], ["segmented RNA genomes", "DNA", 32, 53], ["the earliest cells", "PROBLEM", 3, 21], ["segmented RNA genomes", "PROBLEM", 32, 53], ["RNA viruses", "PROBLEM", 93, 104], ["the loss of ancient RNA viruses", "PROBLEM", 136, 167], ["segmented", "OBSERVATION_MODIFIER", 32, 41], ["RNA genomes", "OBSERVATION", 42, 53], ["RNA viruses", "OBSERVATION", 93, 104], ["RNA viruses", "OBSERVATION", 156, 167]]], ["Perhaps, RNA viruses triggered the early 'archaeal split' [73, 75] .", [["RNA viruses", "PROBLEM", 9, 20], ["RNA viruses", "OBSERVATION", 9, 20]]], ["These insights align with interpretations from the Venn group data (Fig. 2) .Virus-specific genes and virus-to-cell gene transferThe number of virus particles in the universe probably exceeds the number of progeny of cellular organisms [76] .", [["cell", "ANATOMY", 111, 115], ["cellular", "ANATOMY", 217, 225], ["Virus", "ORGANISM", 77, 82], ["cell", "CELL", 111, 115], ["cellular", "CELL", 217, 225], ["Virus-specific genes", "DNA", 77, 97], ["Virus", "PROBLEM", 77, 82], ["virus", "PROBLEM", 102, 107], ["virus particles", "PROBLEM", 143, 158], ["virus particles", "OBSERVATION", 143, 158], ["cellular organisms", "OBSERVATION", 217, 235]]], ["Despite their small genome sizes, collectively, the virus genetic pool likely exceeds that of cells by several-fold.", [["cells", "ANATOMY", 94, 99], ["cells", "CELL", 94, 99], ["their small genome sizes", "PROBLEM", 8, 32], ["the virus genetic pool", "PROBLEM", 48, 70], ["small", "OBSERVATION_MODIFIER", 14, 19], ["genome", "OBSERVATION_MODIFIER", 20, 26], ["sizes", "OBSERVATION_MODIFIER", 27, 32]]], ["The genes of this genetic pool could make their way to cellular genomes via virus-to-cell gene transfer through virus infection, outnumbering transfers of cellular genes into viral genomes.", [["cellular", "ANATOMY", 55, 63], ["cell", "ANATOMY", 85, 89], ["cellular", "ANATOMY", 155, 163], ["infection", "DISEASE", 118, 127], ["cellular", "CELL", 55, 63], ["cell", "CELL", 85, 89], ["cellular", "CELL", 155, 163], ["cellular genomes", "DNA", 55, 71], ["cellular genes", "DNA", 155, 169], ["viral genomes", "DNA", 175, 188], ["this genetic pool", "PROBLEM", 13, 30], ["cellular genomes via virus", "PROBLEM", 55, 81], ["virus infection", "PROBLEM", 112, 127], ["viral genomes", "OBSERVATION", 175, 188]]], ["Such lateral transfers could occur at rates matching Avogadro's number, ~ 10 24 viral infections per second in the oceans [77] .", [["infections", "DISEASE", 86, 96], ["viral infections", "PROBLEM", 80, 96]]], ["These concepts have been nicely illustrated before.", [["nicely", "OBSERVATION_MODIFIER", 25, 31], ["illustrated", "OBSERVATION", 32, 43]]], ["Virus genes without any detectable cellular homolog or ORFans, virus-specific genes, constitute >90% of the genes in the proposed family \"Pandoraviridae\" [78] , whose members possess the largest virus genomes ever discovered [14] .", [["cellular", "ANATOMY", 35, 43], ["Virus", "ORGANISM", 0, 5], ["cellular homolog", "GENE_OR_GENE_PRODUCT", 35, 51], ["ORFans", "GENE_OR_GENE_PRODUCT", 55, 61], ["Pandoraviridae", "GENE_OR_GENE_PRODUCT", 138, 152], ["Virus genes", "DNA", 0, 11], ["cellular homolog", "DNA", 35, 51], ["ORFans", "DNA", 55, 61], ["virus-specific genes", "DNA", 63, 83], ["Virus genes", "PROBLEM", 0, 11], ["any detectable cellular homolog or ORFans", "PROBLEM", 20, 61], ["virus", "PROBLEM", 63, 68], ["without", "UNCERTAINTY", 12, 19]]], ["A very recent study identified an amoeba virus (Yaravirus) with a nearly complete 'ORFan genome' [79] .", [["Yaravirus", "CANCER", 48, 57], ["ORFan genome", "DNA", 83, 95], ["A very recent study", "TEST", 0, 19], ["an amoeba virus (Yaravirus)", "PROBLEM", 31, 58], ["amoeba virus", "OBSERVATION", 34, 46]]], ["These virus-specific genes are starkly different even among members of the same virus family [14, 32] .", [["virus-specific genes", "DNA", 6, 26]]], ["These observations suggest these genes partake in highly dynamic processes of change and likely originate continuously in the virus genomes.", [["virus genomes", "DNA", 126, 139], ["virus genomes", "OBSERVATION", 126, 139]]], ["Our global analyses also revealed similar patterns.", [["Our global analyses", "TEST", 0, 19], ["similar patterns", "OBSERVATION", 34, 50]]], ["On average, ~80% of proteins of prokaryotic viruses and ~60% of eukaryoviral proteins lacked domain assignments (Fig. 7A) .", [["eukaryoviral proteins", "PROTEIN", 64, 85], ["prokaryotic viruses", "PROBLEM", 32, 51], ["eukaryoviral proteins", "TEST", 64, 85], ["prokaryotic viruses", "OBSERVATION", 32, 51]]], ["These results indicate that ORFans are a feature of viruses infecting all three domains of cellular life.", [["cellular", "ANATOMY", 91, 99], ["ORFans", "GENE_OR_GENE_PRODUCT", 28, 34], ["cellular", "CELL", 91, 99], ["ORFans", "PROTEIN", 28, 34], ["viruses", "PROBLEM", 52, 59], ["viruses", "OBSERVATION", 52, 59], ["cellular life", "OBSERVATION", 91, 104]]], ["Thus, virus genomes are better characterized by the presence of ORFan genes rather than the relatively smaller subgroup of proteins shared between viruses and their host proteomes (Fig. 3A) .", [["ORFan", "GENE_OR_GENE_PRODUCT", 64, 69], ["ORFan genes", "DNA", 64, 75], ["virus genomes", "PROBLEM", 6, 19], ["ORFan genes", "PROBLEM", 64, 75], ["virus genomes", "OBSERVATION", 6, 19], ["smaller", "OBSERVATION_MODIFIER", 103, 110], ["proteins", "OBSERVATION", 123, 131]]], ["Members of this second class of proteins, which accounts for 18-38%, do match structural domains detected in host proteomes.", [["structural domains", "PROTEIN", 78, 96]]], ["Their origin could be due to shared history, virus-to-cell gene transfer, or cell-to-virus gene transfer.", [["cell", "ANATOMY", 54, 58], ["cell", "ANATOMY", 77, 81], ["cell", "CELL", 54, 58], ["cell", "CELL", 77, 81], ["virus", "PROBLEM", 45, 50]]], ["A third class of proteins are the virus-specific proteins (VSFs) that match domains defined in the structure databases, but those domains have not been detected hitherto in any cellular proteome.", [["cellular proteome", "ANATOMY", 177, 194], ["VSFs", "GENE_OR_GENE_PRODUCT", 59, 63], ["cellular", "CELL", 177, 185], ["virus-specific proteins", "PROTEIN", 34, 57], ["VSFs", "PROTEIN", 59, 63], ["the virus", "PROBLEM", 30, 39]]], ["Together, the ORFans and virus-specific proteins overwhelmingly characterize viruses as gene creators rather than 'robbers' or hosts of genetic escapees from cells [78] .Virus-specific genes and virus-to-cell gene transferThe mechanistic details of virus gene creation abilities are nicely illustrated by the virocell concept [28] .", [["cells", "ANATOMY", 158, 163], ["cell", "ANATOMY", 204, 208], ["ORFans", "GENE_OR_GENE_PRODUCT", 14, 20], ["cells", "CELL", 158, 163], ["Virus", "ORGANISM", 170, 175], ["cell", "CELL", 204, 208], ["ORFans", "PROTEIN", 14, 20], ["virus-specific proteins", "PROTEIN", 25, 48], ["Virus-specific genes", "DNA", 170, 190], ["genetic escapees from cells", "PROBLEM", 136, 163], ["Virus", "PROBLEM", 170, 175], ["virus", "PROBLEM", 195, 200]]], ["In brief, a virus, upon infection, transforms the 'ribocells' of a ribosome-encoding cellular organism into a virocell that produces virions rather than dividing by binary fission.", [["ribosome", "ANATOMY", 67, 75], ["cellular organism", "ANATOMY", 85, 102], ["virocell", "ANATOMY", 110, 118], ["virions", "ANATOMY", 133, 140], ["infection", "DISEASE", 24, 33], ["ribosome", "CELLULAR_COMPONENT", 67, 75], ["cellular", "CELL", 85, 93], ["virocell", "CANCER", 110, 118], ["a virus", "PROBLEM", 10, 17], ["infection", "PROBLEM", 24, 33], ["a ribosome-encoding cellular organism", "PROBLEM", 65, 102], ["virus", "OBSERVATION", 12, 17], ["infection", "OBSERVATION", 24, 33], ["cellular organism", "OBSERVATION", 85, 102], ["virions", "OBSERVATION", 133, 140]]], ["The virocell is metabolically active and has lost its identity.", [["virocell", "ANATOMY", 4, 12], ["virocell", "CANCER", 4, 12], ["metabolically", "OBSERVATION_MODIFIER", 16, 29], ["active", "OBSERVATION_MODIFIER", 30, 36]]], ["During this stage, the virus can produce a virus-factory-like system that controls the cellular machinery and can create and replicate genes using the same mechanisms used previously by ribocells [27] .", [["cellular", "ANATOMY", 87, 95], ["cellular", "CELL", 87, 95], ["the virus", "PROBLEM", 19, 28]]], ["Interestingly, the modern virocell may be the closest visualization of the ancient cellular ancestors of viruses, which we have termed 'proto-virocells'.Virus-specific genes and virus-to-cell gene transferThe sheer number of VSFs would create ample opportunities for several virus genes to be endogenized and domesticated by their cellular hosts.", [["virocell", "ANATOMY", 26, 34], ["cellular", "ANATOMY", 83, 91], ["cell", "ANATOMY", 187, 191], ["cellular", "ANATOMY", 331, 339], ["virocell", "CANCER", 26, 34], ["cellular", "CELL", 83, 91], ["Virus", "ORGANISM", 153, 158], ["cell", "CELL", 187, 191], ["VSFs", "GENE_OR_GENE_PRODUCT", 225, 229], ["cellular", "CELL", 331, 339], ["Virus-specific genes", "DNA", 153, 173], ["virus genes", "DNA", 275, 286], ["viruses", "PROBLEM", 105, 112], ["'proto-virocells'", "TREATMENT", 135, 152], ["Virus", "PROBLEM", 153, 158], ["virus", "PROBLEM", 178, 183], ["several virus genes", "PROBLEM", 267, 286], ["cellular ancestors", "OBSERVATION", 83, 101], ["viruses", "OBSERVATION", 105, 112]]], ["There are several such examples, such as the abundance of endogenized virus-like elements in mammalian genomes and other proteins that perform useful functions.", [["endogenized virus-like elements", "DNA", 58, 89], ["mammalian genomes", "DNA", 93, 110], ["endogenized virus", "PROBLEM", 58, 75], ["virus", "OBSERVATION", 70, 75], ["mammalian genomes", "OBSERVATION", 93, 110]]], ["Endogenous viral elements, specifically mammalian endogenous retroviruses, appear to boost antiviral immunity in their hosts [80] .", [["retroviruses", "ORGANISM", 61, 73], ["Endogenous viral elements", "DNA", 0, 25], ["Endogenous viral elements", "PROBLEM", 0, 25], ["mammalian endogenous retroviruses", "PROBLEM", 40, 73], ["viral elements", "OBSERVATION", 11, 25], ["endogenous retroviruses", "OBSERVATION", 50, 73]]], ["Syncytins and Gag proteins derived from ancient retrotransposons are involved in placentation in mammals [80] .", [["Syncytins", "GENE_OR_GENE_PRODUCT", 0, 9], ["Gag", "GENE_OR_GENE_PRODUCT", 14, 17], ["Syncytins", "PROTEIN", 0, 9], ["Gag proteins", "PROTEIN", 14, 26], ["ancient retrotransposons", "DNA", 40, 64], ["Syncytins", "TREATMENT", 0, 9], ["Gag proteins", "PROBLEM", 14, 26], ["ancient retrotransposons", "PROBLEM", 40, 64], ["Gag proteins", "OBSERVATION", 14, 26]]], ["Gag proteins have also been found to participate in the evolution of the mammalian brain [80] .", [["brain", "ANATOMY", 83, 88], ["Gag", "GENE_OR_GENE_PRODUCT", 0, 3], ["brain", "ORGAN", 83, 88], ["Gag proteins", "PROTEIN", 0, 12], ["brain", "ANATOMY", 83, 88]]], ["To formally test this idea, we identified FFs that were shared by XV Venn groups but with sparse occurrence in X proteomes, X being a proteome of Archaea, Bacteria, or Eukarya.", [["FFs", "GENE_OR_GENE_PRODUCT", 42, 45], ["FFs", "PROTEIN", 42, 45], ["Archaea", "PROBLEM", 146, 153], ["Bacteria", "PROBLEM", 155, 163], ["Eukarya", "PROBLEM", 168, 175]]], ["We found an additional 64 putative VSFs using this approach.", [["VSFs", "CANCER", 35, 39], ["this approach", "TREATMENT", 46, 59]]], ["With the exception of five VSFs and three putative VSFs (Table S1 ), most VSFs were associated with a single viral subgroup.", [["VSFs", "ANATOMY", 74, 78], ["VSFs", "CANCER", 27, 31], ["VSFs", "GENE_OR_GENE_PRODUCT", 51, 55], ["Table S1", "GENE_OR_GENE_PRODUCT", 57, 65], ["VSFs", "GENE_OR_GENE_PRODUCT", 74, 78], ["VSFs", "PROTEIN", 27, 31], ["VSFs", "PROTEIN", 51, 55], ["most VSFs", "PROBLEM", 69, 78], ["a single viral subgroup", "PROBLEM", 100, 123]]], ["This matches the analysis of FSF domains and the proposal that each viral replicon type has evolved different VSFs for its survival, function and reproduction [9] .", [["FSF", "GENE_OR_GENE_PRODUCT", 29, 32], ["VSFs", "GENE_OR_GENE_PRODUCT", 110, 114], ["FSF domains", "DNA", 29, 40], ["FSF domains", "PROBLEM", 29, 40], ["viral replicon type", "TREATMENT", 68, 87]]], ["The list of new putative VSFs included several proteins responsible for viral core and structural components as well as cellular and nucleic acid binding (Table S5 ).", [["cellular", "ANATOMY", 120, 128], ["VSFs", "GENE_OR_GENE_PRODUCT", 25, 29], ["cellular", "CELL", 120, 128], ["nucleic acid", "SIMPLE_CHEMICAL", 133, 145], ["VSFs", "PROTEIN", 25, 29], ["new putative VSFs", "PROBLEM", 12, 29], ["several proteins", "PROBLEM", 39, 55], ["viral core and structural components", "PROBLEM", 72, 108], ["cellular and nucleic acid binding", "PROBLEM", 120, 153], ["structural components", "OBSERVATION", 87, 108], ["nucleic acid", "OBSERVATION", 133, 145]]], ["All four EV FFs from this list (Table S1 ) represent viral structural proteins with low spread in eukaryotes (Table S5) , indicating that these domains may have been acquired by eukaryotes via horizontal gene transfer or (less likely) could be a result of inaccurate hidden Markov model (HMM) assignment.", [["viral structural proteins", "PROTEIN", 53, 78], ["viral structural proteins", "PROBLEM", 53, 78], ["low spread in eukaryotes", "PROBLEM", 84, 108], ["viral", "OBSERVATION", 53, 58], ["low", "OBSERVATION_MODIFIER", 84, 87]]], ["Similarly, several of the BV domains identified as putative VSFs constitute viral proteins and encompass 65.63% of the putative VSFs (42 out of 64), indicating that most BV domains are derived from viruses.", [["BV", "GENE_OR_GENE_PRODUCT", 26, 28], ["VSFs", "GENE_OR_GENE_PRODUCT", 60, 64], ["VSFs", "GENE_OR_GENE_PRODUCT", 128, 132], ["BV domains", "PROTEIN", 26, 36], ["VSFs", "PROTEIN", 60, 64], ["viral proteins", "PROTEIN", 76, 90], ["VSFs", "PROTEIN", 128, 132], ["BV domains", "PROTEIN", 170, 180], ["the BV domains", "PROBLEM", 22, 36], ["putative VSFs", "TEST", 51, 64], ["viral proteins", "PROBLEM", 76, 90], ["the putative VSFs", "TEST", 115, 132], ["most BV domains", "PROBLEM", 165, 180], ["viruses", "PROBLEM", 198, 205], ["several", "OBSERVATION_MODIFIER", 11, 18], ["viral proteins", "OBSERVATION", 76, 90], ["viruses", "OBSERVATION", 198, 205]]], ["This observation is consistent with previous findings [9, 10] , given that bacterioviruses are known to facilitate genetic transfers among organisms and thus drive evolution in bacteria.Virus-specific genes and virus-to-cell gene transferThe virus-to-cell direction of gene transfer is further supported by the comparison of two different FF distributions: (i) FFs that are only shared among cells and (ii) FFs that are shared between cells and viruses.", [["cell", "ANATOMY", 220, 224], ["cell", "ANATOMY", 251, 255], ["cells", "ANATOMY", 392, 397], ["FFs", "ANATOMY", 407, 410], ["cells", "ANATOMY", 435, 440], ["bacterioviruses", "GENE_OR_GENE_PRODUCT", 75, 90], ["Virus", "ORGANISM", 186, 191], ["cell", "CELL", 220, 224], ["cell", "CELL", 251, 255], ["FFs", "GENE_OR_GENE_PRODUCT", 361, 364], ["cells", "CELL", 392, 397], ["FFs", "GENE_OR_GENE_PRODUCT", 407, 410], ["cells", "CELL", 435, 440], ["Virus-specific genes", "DNA", 186, 206], ["FFs", "PROTEIN", 407, 410], ["This observation", "TEST", 0, 16], ["bacterioviruses", "PROBLEM", 75, 90], ["genetic transfers among organisms", "PROBLEM", 115, 148], ["bacteria", "PROBLEM", 177, 185], ["Virus", "PROBLEM", 186, 191], ["virus", "PROBLEM", 211, 216], ["The virus", "TEST", 238, 247], ["consistent with", "UNCERTAINTY", 20, 35], ["virus", "OBSERVATION", 242, 247], ["viruses", "OBSERVATION", 445, 452]]], ["We find that the latter group was more widely distributed in proteomes when spread was measured with an f index (Fig. 8) , a finding that Irrespective of the magnitude of the median increase among superkingdoms, FFs shared with viruses were always significantly more widespread than those only shared with cells.", [["cells", "ANATOMY", 306, 311], ["cells", "CELL", 306, 311], ["an f index", "TEST", 101, 111], ["the median increase among superkingdoms", "PROBLEM", 171, 210], ["viruses", "PROBLEM", 228, 235], ["widely", "OBSERVATION_MODIFIER", 39, 45], ["distributed", "OBSERVATION_MODIFIER", 46, 57], ["median", "OBSERVATION_MODIFIER", 175, 181], ["increase", "OBSERVATION_MODIFIER", 182, 190], ["viruses", "OBSERVATION", 228, 235]]], ["The presence of these viral FFs in an assortment of cellular proteomes, from microorganisms to large eukaryotes, suggests that viruses are very ancient and already transferred genes to the last common ancestor of each superkingdom [9] .", [["cellular proteomes", "ANATOMY", 52, 70], ["cellular", "CELL", 52, 60], ["viral FFs", "DNA", 22, 31], ["these viral FFs", "PROBLEM", 16, 31], ["cellular proteomes", "PROBLEM", 52, 70], ["microorganisms", "PROBLEM", 77, 91], ["viruses", "PROBLEM", 127, 134], ["viral FFs", "OBSERVATION", 22, 31], ["cellular proteomes", "OBSERVATION", 52, 70], ["viruses", "OBSERVATION", 127, 134]]], ["Inspection of archaeal FFs shared with viral replicons showed an enrichment of all viral subgroups, including the presence of RNA viruses.", [["FFs", "GENE_OR_GENE_PRODUCT", 23, 26], ["archaeal FFs", "PROTEIN", 14, 26], ["Inspection of archaeal FFs", "TEST", 0, 26], ["viral replicons", "TREATMENT", 39, 54], ["all viral subgroups", "PROBLEM", 79, 98], ["RNA viruses", "PROBLEM", 126, 137], ["viral subgroups", "OBSERVATION", 83, 98], ["RNA viruses", "OBSERVATION", 126, 137]]], ["RNA viruses are unable to successfully infect Archaea.", [["RNA viruses", "PROBLEM", 0, 11], ["viruses", "OBSERVATION", 4, 11]]], ["It is therefore likely that RNA viruses infecting members of different superkingdoms exchanged FFs that were conserved in evolution from ancient cells [9] .", [["cells", "ANATOMY", 145, 150], ["FFs", "GENE_OR_GENE_PRODUCT", 95, 98], ["cells", "CELL", 145, 150], ["FFs", "PROTEIN", 95, 98], ["RNA viruses", "PROBLEM", 28, 39], ["different superkingdoms exchanged FFs", "PROBLEM", 61, 98], ["therefore likely", "UNCERTAINTY", 6, 22], ["RNA viruses", "OBSERVATION", 28, 39]]], ["Similarly, FFs shared with eukaryotes by each viral subgroup were greatly widespread, as revealed by high median f values (Fig. 8B) , which is consistent with eukaryotic proteomes hosting a large number of viruses from each subgroup (Fig. 3C) .Virus-specific genes and virus-to-cell gene transferThe negligible presence of capsid/coat proteins in cells uncovered by our analysis supports the role of virus-tocell horizontal gene transfer events that mediate molecular innovation.", [["cell", "ANATOMY", 278, 282], ["cells", "ANATOMY", 347, 352], ["FFs", "GENE_OR_GENE_PRODUCT", 11, 14], ["Virus", "ORGANISM", 244, 249], ["cell", "CELL", 278, 282], ["capsid/coat proteins", "GENE_OR_GENE_PRODUCT", 323, 343], ["cells", "CELL", 347, 352], ["FFs", "PROTEIN", 11, 14], ["Virus-specific genes", "DNA", 244, 264], ["capsid/coat proteins", "PROTEIN", 323, 343], ["each viral subgroup", "TEST", 41, 60], ["eukaryotic proteomes", "PROBLEM", 159, 179], ["Virus", "PROBLEM", 244, 249], ["virus", "PROBLEM", 269, 274], ["capsid/coat proteins in cells", "PROBLEM", 323, 352], ["our analysis", "TEST", 366, 378], ["virus", "TREATMENT", 400, 405], ["consistent with", "UNCERTAINTY", 143, 158], ["eukaryotic proteomes", "OBSERVATION", 159, 179], ["large", "OBSERVATION_MODIFIER", 190, 195], ["number", "OBSERVATION_MODIFIER", 196, 202], ["viruses", "OBSERVATION", 206, 213], ["capsid", "OBSERVATION", 323, 329], ["coat proteins", "OBSERVATION", 330, 343]]], ["Capsid/coat-related proteins are hallmark virus proteins that point to genetic innovation in viruses [29] .", [["Capsid", "GENE_OR_GENE_PRODUCT", 0, 6], ["Capsid/coat-related proteins", "PROTEIN", 0, 28], ["hallmark virus proteins", "PROTEIN", 33, 56], ["Capsid/coat", "TEST", 0, 11], ["related proteins", "PROBLEM", 12, 28], ["hallmark virus proteins", "PROBLEM", 33, 56], ["genetic innovation in viruses", "PROBLEM", 71, 100], ["virus proteins", "OBSERVATION", 42, 56]]], ["The cellular distribution of 37 FFs related to capsid/coat FSFs (identified using data from Nasir and Caetano-Anoll\u00e9s [9] ) attests to this innovation.", [["cellular", "ANATOMY", 4, 12], ["cellular", "CELL", 4, 12], ["FFs", "GENE_OR_GENE_PRODUCT", 32, 35], ["FFs", "PROTEIN", 32, 35], ["capsid/coat FSFs", "PROTEIN", 47, 63], ["capsid/coat FSFs", "PROBLEM", 47, 63], ["Nasir", "TEST", 92, 97], ["cellular", "OBSERVATION_MODIFIER", 4, 12], ["distribution", "OBSERVATION_MODIFIER", 13, 25], ["coat FSFs", "OBSERVATION", 54, 63]]], ["Only the \"Major capsid protein gp5\" FF (d.183.1.1) was present in roughly 29% of cellular proteomes (Table S3 ).", [["cellular proteomes", "ANATOMY", 81, 99], ["gp5", "GENE_OR_GENE_PRODUCT", 31, 34], ["cellular", "CELL", 81, 89], ["Major capsid protein", "PROTEIN", 10, 30], ["gp5", "PROTEIN", 31, 34], ["FF", "PROTEIN", 36, 38], ["d.183.1.1", "PROTEIN", 40, 49]]], ["Most of the capsid/coat FFs (27 out of 37) were completely absent or had a negligible presence in cellular proteomes.", [["cellular proteomes", "ANATOMY", 98, 116], ["cellular", "CELL", 98, 106], ["capsid/coat FFs", "PROTEIN", 12, 27], ["the capsid/coat FFs", "TEST", 8, 27], ["a negligible presence in cellular proteomes", "PROBLEM", 73, 116], ["cellular proteomes", "OBSERVATION", 98, 116]]], ["Their functions and design were developed in viruses and are still in the process of being recruited by cellular makeup [39] .Early origins of RNA virusesRNA viruses are thought to have been the first to evolve among viruses, with origins rooted in ancient cells [7, 27, 81] .", [["cellular", "ANATOMY", 104, 112], ["cells", "ANATOMY", 257, 262], ["cellular", "CELL", 104, 112], ["cells", "CELL", 257, 262], ["viruses", "PROBLEM", 45, 52], ["RNA virusesRNA viruses", "PROBLEM", 143, 165], ["viruses", "OBSERVATION", 45, 52], ["RNA virusesRNA viruses", "OBSERVATION", 143, 165], ["viruses", "OBSERVATION", 217, 224], ["ancient cells", "OBSERVATION", 249, 262]]], ["Our phylogenomic reconstructions using FSFs [9] and FFs, which we report here, support this hypothesis.", [["Our phylogenomic reconstructions", "TEST", 0, 32], ["FSFs", "TEST", 39, 43], ["FFs", "TEST", 52, 55]]], ["Two different approaches give further credence to the ancient origin of viruses.", [["viruses", "PROBLEM", 72, 79], ["viruses", "OBSERVATION", 72, 79]]], ["First, surveying the age distribution of FFs in the ancient ABEV group allowed us to establish the relative age of each viral subgroup (Fig. S2A) .", [["FFs", "CANCER", 41, 44], ["ABEV", "CANCER", 60, 64], ["S2A", "GENE_OR_GENE_PRODUCT", 141, 144], ["S2A", "PROTEIN", 141, 144]]], ["With the exception of dsDNA-RT viruses, the nd medians were fairly low and distributions had long right, which that are expected when the effects of horizontal gene transfer are recent.", [["dsDNA", "GENE_OR_GENE_PRODUCT", 22, 27], ["dsDNA", "PROBLEM", 22, 27], ["RT viruses", "PROBLEM", 28, 38], ["horizontal gene transfer", "TREATMENT", 149, 173], ["dsDNA", "OBSERVATION", 22, 27], ["RT", "ANATOMY", 28, 30], ["viruses", "OBSERVATION", 31, 38], ["fairly", "OBSERVATION_MODIFIER", 60, 66], ["low", "OBSERVATION", 67, 70], ["right", "ANATOMY_MODIFIER", 98, 103]]], ["The most ancient ABEV FFs belonged to plus-ssRNA and ssDNA, suggesting that they emerged prior to the very common dsDNA viruses.", [["ABEV", "GENE_OR_GENE_PRODUCT", 17, 21], ["-ssRNA", "GENE_OR_GENE_PRODUCT", 42, 48], ["ssDNA", "CELLULAR_COMPONENT", 53, 58], ["ABEV FFs", "DNA", 17, 25], ["-ssRNA", "PROTEIN", 42, 48], ["-ssRNA and ssDNA", "TREATMENT", 42, 58], ["the very common dsDNA viruses", "PROBLEM", 98, 127]]], ["Second, evolutionary principal coordinate (evoPCO) analysis, an multidimensional scaling strategy that determines the relative evolutionary ancestry of proteomes [9] , revealed the ancient origins of RNA viruses.", [["evoPCO", "DNA", 43, 49], ["an multidimensional scaling strategy", "TREATMENT", 61, 97], ["RNA viruses", "PROBLEM", 200, 211], ["ancient origins", "OBSERVATION_MODIFIER", 181, 196], ["RNA viruses", "OBSERVATION", 200, 211]]], ["Domains become part of each proteome at different evolutionary timepoints.", [["evolutionary timepoints", "OBSERVATION", 50, 73]]], ["This view can become more powerful than the standard 'tree of life' visualization because it minimizes problems of independence of phylogenetic characters known to plague sequence analysis [19, 64] .", [["life' visualization", "TREATMENT", 62, 81], ["plague sequence analysis", "TEST", 164, 188]]], ["Fig. 9 shows an evoPCO plot of FF data reflecting the 8,127 reference-quality proteomes of cellular organisms and viruses that we recently analyzed.", [["cellular organisms", "ANATOMY", 91, 109], ["cellular organisms", "CELL", 91, 109], ["an evoPCO plot", "TEST", 13, 27], ["FF data", "TEST", 31, 38], ["cellular organisms", "PROBLEM", 91, 109], ["viruses", "PROBLEM", 114, 121], ["cellular organisms", "OBSERVATION", 91, 109]]], ["The first three coordinates, which account for ~72% of total variance, revealed four distinct temporal clouds of proteomes dissecting viruses and each of the three superkingdoms (Fig. 9 ).", [["total variance", "TEST", 55, 69], ["four distinct temporal clouds of proteomes dissecting viruses", "PROBLEM", 80, 141], ["distinct", "OBSERVATION_MODIFIER", 85, 93], ["temporal", "OBSERVATION_MODIFIER", 94, 102], ["clouds", "OBSERVATION", 103, 109], ["viruses", "OBSERVATION", 134, 141]]], ["The evolutionary direction of the clouds of data points uncovered a temporal flow from viruses to cellular organisms that unfolded along the PCO1 axis.", [["cellular organisms", "ANATOMY", 98, 116], ["cellular", "CELL", 98, 106], ["PCO1", "GENE_OR_GENE_PRODUCT", 141, 145], ["a temporal flow", "PROBLEM", 66, 81], ["cellular organisms", "TEST", 98, 116], ["direction", "OBSERVATION_MODIFIER", 17, 26], ["temporal", "OBSERVATION_MODIFIER", 68, 76], ["flow", "OBSERVATION", 77, 81], ["cellular organisms", "OBSERVATION", 98, 116], ["unfolded", "OBSERVATION_MODIFIER", 122, 130], ["PCO1 axis", "ANATOMY", 141, 150]]], ["The cloud of RNA viral proteomes at the back of the evoPCO plot was temporally the most basal.", [["evoPCO", "GENE_OR_GENE_PRODUCT", 52, 58], ["The cloud of RNA viral proteomes", "TEST", 0, 32], ["the evoPCO plot", "TEST", 48, 63], ["cloud", "OBSERVATION_MODIFIER", 4, 9], ["RNA viral proteomes", "OBSERVATION", 13, 32]]], ["Two RNA (plus-ssRNA) viruses, Lasius neglectus virus 1 and Lygus lineolaris virus 1, belonging to the order Picornavirales, occupied the most basal position in the plot.", [["Lasius neglectus virus 1", "ORGANISM", 30, 54], ["Lygus lineolaris virus 1", "ORGANISM", 59, 83], ["Lasius neglectus virus 1", "SPECIES", 30, 54], ["Lygus lineolaris virus", "SPECIES", 59, 81], ["Lasius neglectus virus 1", "SPECIES", 30, 54], ["Lygus lineolaris virus 1", "SPECIES", 59, 83], ["Two RNA", "TEST", 0, 7], ["viruses", "PROBLEM", 21, 28], ["Lasius neglectus virus", "TREATMENT", 30, 52], ["Lygus lineolaris virus", "TREATMENT", 59, 81], ["most basal", "OBSERVATION_MODIFIER", 137, 147], ["position", "OBSERVATION_MODIFIER", 148, 156]]], ["The group of giant viruses was clearly dissected from the main viral cloud and was temporally closer to cellular proteomes, confirming results that suggest their late appearance in viral evolution [13, 31] and supporting the coexistence of ancient viruses with cells [8, 27] .", [["cellular proteomes", "ANATOMY", 104, 122], ["cells", "ANATOMY", 261, 266], ["cellular", "CELL", 104, 112], ["cells", "CELL", 261, 266], ["giant viruses", "PROBLEM", 13, 26], ["ancient viruses with cells", "PROBLEM", 240, 266], ["giant", "OBSERVATION_MODIFIER", 13, 18], ["viruses", "OBSERVATION", 19, 26], ["main", "OBSERVATION_MODIFIER", 58, 62], ["viral cloud", "OBSERVATION", 63, 74], ["late", "OBSERVATION_MODIFIER", 162, 166], ["viral", "OBSERVATION_MODIFIER", 181, 186], ["ancient viruses", "OBSERVATION", 240, 255]]], ["All results reinforce the notion of an ancient origin of RNA viruses.ConclusionsThe 21st century is the century of data science.", [["RNA viruses", "PROBLEM", 57, 68], ["RNA viruses", "OBSERVATION", 57, 68]]], ["The continuous flood of data and information that flows from multiple data streams can vastly improve life on our planet, from predictions that impact weather and climate change to understanding the structure and behavior of artificial and natural biological systems that generate, process, store, use and communicate information.", [["multiple data streams", "PROBLEM", 61, 82]]], ["These datasets provide unique opportunities to address age-old and puzzling mysteries.", [["old and puzzling mysteries", "PROBLEM", 59, 85]]], ["Here, we review our data-mining efforts to uncover the origins and evolution of viruses.", [["our data", "TEST", 16, 24], ["viruses", "PROBLEM", 80, 87], ["viruses", "OBSERVATION", 80, 87]]], ["Comparative genomic and phylogenomic approaches that take advantage of the three-dimensional atomic structure of proteins support the origin of viruses from cells predating the ancestors of cellular domains.", [["cells", "ANATOMY", 157, 162], ["cellular", "ANATOMY", 190, 198], ["cells", "CELL", 157, 162], ["cellular", "CELL", 190, 198], ["cellular domains", "PROTEIN", 190, 206], ["Comparative genomic and phylogenomic approaches", "PROBLEM", 0, 47], ["viruses", "PROBLEM", 144, 151], ["viruses", "OBSERVATION", 144, 151], ["cellular domains", "OBSERVATION", 190, 206]]], ["These ancient cells gradually devolved into modern-day viruses via reductive evolution, matching well-known processes that operate in Archaea and endosymbiotic organisms.", [["cells", "ANATOMY", 14, 19], ["cells", "CELL", 14, 19], ["These ancient cells", "PROBLEM", 0, 19], ["matching well-known processes", "PROBLEM", 88, 117], ["Archaea and endosymbiotic organisms", "PROBLEM", 134, 169], ["endosymbiotic organisms", "OBSERVATION", 146, 169]]], ["Contrary to popular belief, the genomes of viruses harbor an abundance of well-characterized virusspecific genes and encode numerous protein structures that carry significantly deep evolutionary information about a pervasive virus-to-cell genetic transfer of cellular innovations.", [["cell", "ANATOMY", 234, 238], ["cellular", "ANATOMY", 259, 267], ["cell", "CELL", 234, 238], ["cellular", "CELL", 259, 267], ["virusspecific genes", "DNA", 93, 112], ["virusspecific genes", "PROBLEM", 93, 112], ["encode numerous protein structures", "PROBLEM", 117, 151], ["a pervasive virus", "PROBLEM", 213, 230], ["cellular innovations", "PROBLEM", 259, 279], ["cellular innovations", "OBSERVATION", 259, 279]]], ["Thus, viruses should be considered drivers of cellular evolution rather than minimalistic genetic parasites.", [["cellular", "ANATOMY", 46, 54], ["cellular", "CELL", 46, 54], ["viruses", "PROBLEM", 6, 13], ["cellular evolution", "PROBLEM", 46, 64], ["minimalistic genetic parasites", "PROBLEM", 77, 107], ["viruses", "OBSERVATION", 6, 13]]], ["Following the breakthrough discovery of giant viruses, we should expect that the discovery of other Fig. 9 Evolutionary principal coordinate (evoPCO) analysis describing the evolution of the proteomes of cellular organisms and viruses.", [["cellular organisms", "ANATOMY", 204, 222], ["cellular", "CELL", 204, 212], ["giant viruses", "PROBLEM", 40, 53], ["other Fig", "PROBLEM", 94, 103], ["cellular organisms", "PROBLEM", 204, 222], ["viruses", "PROBLEM", 227, 234], ["giant viruses", "OBSERVATION", 40, 53], ["cellular organisms", "OBSERVATION", 204, 222]]], ["The 3-dimensional scatter plot describes the temporal relationships of 139 archaeal, 1,740 bacterial, 210 eukaryal and 6,044 viral proteomes, making up a total of 8,127 reference-quality proteomes and involving the ages of 3,892 FFs.", [["bacterial", "TEST", 91, 100], ["viral proteomes", "TEST", 125, 140], ["temporal", "ANATOMY_MODIFIER", 45, 53]]], ["The multidimensional scaling analysis highlights in its first three most significant axes a temporal flow from viruses to cellular organisms viruses inhabiting diverse hosts and habitats will help revise the way we think about viruses and the roles they play on our planet.", [["cellular", "ANATOMY", 122, 130], ["cellular", "CELL", 122, 130], ["The multidimensional scaling analysis", "TEST", 0, 37], ["a temporal flow from viruses", "PROBLEM", 90, 118], ["cellular organisms viruses", "PROBLEM", 122, 148], ["viruses", "PROBLEM", 227, 234], ["temporal", "OBSERVATION_MODIFIER", 92, 100], ["flow", "OBSERVATION", 101, 105], ["viruses", "OBSERVATION", 111, 118]]]], "fa38066e56bb3c558c91c8027c1e8b51719b825f": [["in as high as 54% of the affected children [12] .", [["children", "ORGANISM", 34, 42], ["children", "SPECIES", 34, 42]]], ["The high incidence of neurological complications in children with MIS-C Kawasaki-like disease remains unclear; nevertheless, the mechanism might be different from the thromboembolic mechanism of the cerebrovascular system observed frequently in adult COVID-19 patients.", [["neurological", "ANATOMY", 22, 34], ["cerebrovascular system", "ANATOMY", 199, 221], ["neurological complications", "DISEASE", 22, 48], ["Kawasaki-like disease", "DISEASE", 72, 93], ["thromboembolic", "DISEASE", 167, 181], ["children", "ORGANISM", 52, 60], ["cerebrovascular", "ANATOMICAL_SYSTEM", 199, 214], ["system", "ANATOMICAL_SYSTEM", 215, 221], ["patients", "ORGANISM", 260, 268], ["children", "SPECIES", 52, 60], ["patients", "SPECIES", 260, 268], ["neurological complications", "PROBLEM", 22, 48], ["MIS", "PROBLEM", 66, 69], ["C Kawasaki-like disease", "PROBLEM", 70, 93], ["the cerebrovascular system", "PROBLEM", 195, 221], ["high", "OBSERVATION_MODIFIER", 4, 8], ["neurological", "OBSERVATION_MODIFIER", 22, 34], ["complications", "OBSERVATION", 35, 48], ["thromboembolic", "OBSERVATION", 167, 181], ["cerebrovascular system", "ANATOMY", 199, 221]]]], "PMC7312368": [["IntroductionThis epidemiological investigation aims to determine and compare the HH knowledge level and behaviour of the Nepali people and the native Chinese population of Hong Kong.", [["people", "ORGANISM", 128, 134], ["people", "SPECIES", 128, 134], ["This epidemiological investigation", "TEST", 12, 46]]], ["Handwashing and hand drying behaviours were investigated.", [["hand", "ANATOMY", 16, 20], ["hand", "ORGANISM_SUBDIVISION", 16, 20]]], ["The findings of this cross-sectional study substantially contribute to the understanding of the knowledge gap and the HH behaviour of the two populations.", [["this cross-sectional study", "TEST", 16, 42]]], ["Subsequently, the findings provide information to deliver culturally sensitive health promotion activities and campaigns for the improvement of HH compliance.2.1.", [["HH compliance", "TREATMENT", 144, 157]]], ["SurveyMonkey allows participants to access the questionnaire, guides respondents to complete all the items, conducts analyses and exports results [17].", [["participants", "SPECIES", 20, 32]]], ["As most elders may not be smartphone users, questionnaires with a paper-and-pen format were distributed to a small number of participants, such as elders, to ensure good coverage of respondents and increase the generalisability of the findings.2.1.", [["participants", "SPECIES", 125, 137], ["small", "OBSERVATION_MODIFIER", 109, 114]]], ["Materials and MethodsThe protocol of this study was approved by the Ethics Committee of the participated university (HSEARS20180409006).", [["Methods", "TREATMENT", 14, 21], ["this study", "TEST", 37, 47]]], ["Participation to this survey was voluntary, and the confidentiality of the data was strictly observed.", [["the data", "TEST", 71, 79]]], ["Participants were fully aware of the purpose of the study before proceeding with the online-based survey.", [["Participants", "SPECIES", 0, 12], ["the study", "TEST", 48, 57]]], ["Materials and MethodsThe handwashing and drying questionnaire was constructed according to the literature related to handwashing and drying [18,19,20,21,22,23,24].", [["Methods", "TREATMENT", 14, 21]]], ["The items were related to common myths and fallacies of HH reported in the literature.", [["HH", "DISEASE", 56, 58], ["common myths and fallacies of HH", "PROBLEM", 26, 58], ["fallacies", "OBSERVATION", 43, 52]]], ["The score ranged from 0 to 12, and a high score indicated a high knowledge level on HH.", [["The score", "TEST", 0, 9], ["a high score", "PROBLEM", 35, 47]]], ["Part 3 comprised items related to self-reported handwashing and hand-drying practices, including but not limited to the most common handwashing methods under 14 specific conditions, usual duration for lathering the hands with soap before rinsing and hand drying methods commonly used in public washrooms and at home.", [["hand", "ANATOMY", 64, 68], ["hand", "ANATOMY", 250, 254], ["soap", "TREATMENT", 226, 230], ["rinsing", "TREATMENT", 238, 245], ["hand drying methods", "TREATMENT", 250, 269], ["hands", "ANATOMY", 215, 220]]], ["Data Analysis ::: 2.", [["Data Analysis", "TEST", 0, 13]]], ["Independent t-test or one-way ANOVA was used to determine the group differences in the knowledge score on HH.", [["Independent t-test", "TEST", 0, 18]]], ["SPSS version 25.0 (IBM Corporation, Armonk, NY, USA) was used for all statistical analyses.", [["SPSS version", "TEST", 0, 12], ["all statistical analyses", "TEST", 66, 90]]], ["All statistical tests were two-sided, with significance level set as p < 0.05.3.1.", [["All statistical tests", "TEST", 0, 21], ["significance level", "TEST", 43, 61]]], ["By contrast, statistically significant differences were observed in certain sociodemographic characteristics of respondents between groups.", [["significant", "OBSERVATION_MODIFIER", 27, 38]]], ["These differences were reflected by the high percentages of Nepali respondents who were males (56.2%), married/partnered (71.6%), with primary or below educational level (20.3%), without influenza vaccination over the past 12 months (91.9%) and with a habit of wearing rings (35.5%), artificial/acrylic nails (35.5%) and bracelets (51.7%).", [["influenza vaccination", "PROBLEM", 187, 208], ["artificial/acrylic nails", "TREATMENT", 284, 308], ["bracelets", "TREATMENT", 321, 330], ["high", "OBSERVATION_MODIFIER", 40, 44], ["acrylic nails", "ANATOMY", 295, 308]]], ["The habit of the local population to wear watches (58.6%) was higher.", [["habit", "OBSERVATION_MODIFIER", 4, 9]]], ["A considerable number of Nepali respondents could not differentiate the diseases that can or cannot be transmitted with poor HH, especially the item related to the human immunodeficiency virus infection (Nepalese vs. local: 47.7% vs. 2.7%), and upper respiratory tract infection/influenza-like illness (Nepalese vs. local: 56.6% vs. 85.9%).", [["upper respiratory tract", "ANATOMY", 245, 268], ["human immunodeficiency virus infection", "DISEASE", 164, 202], ["respiratory tract infection", "DISEASE", 251, 278], ["influenza-like illness", "DISEASE", 279, 301], ["human immunodeficiency virus", "ORGANISM", 164, 192], ["upper respiratory tract", "ORGANISM_SUBDIVISION", 245, 268], ["human", "SPECIES", 164, 169], ["immunodeficiency virus", "SPECIES", 170, 192], ["human immunodeficiency virus", "SPECIES", 164, 192], ["the diseases", "PROBLEM", 68, 80], ["poor HH", "PROBLEM", 120, 127], ["the human immunodeficiency virus infection", "PROBLEM", 160, 202], ["upper respiratory tract infection", "PROBLEM", 245, 278], ["influenza", "PROBLEM", 279, 288], ["considerable", "OBSERVATION_MODIFIER", 2, 14], ["diseases", "OBSERVATION", 72, 80], ["upper", "ANATOMY_MODIFIER", 245, 250], ["respiratory tract", "ANATOMY", 251, 268], ["infection", "OBSERVATION", 269, 278], ["influenza", "OBSERVATION", 279, 288]]], ["Almost half of the respondents carried the misconceptions that always keeping the hands clean may decrease the body\u2019s defence mechanism (49.4%, n = 238), hands must be held under water while lathering (48.1%, n = 232), an alcohol-based hand sanitiser containing 40% alcohol was sufficient for disinfection (41.4%, n = 199) and that lathering the hands for 10 s before rinsing was enough for disinfection (58.0, n = 279).", [["body", "ANATOMY", 111, 115], ["hand", "ANATOMY", 236, 240], ["alcohol", "CHEMICAL", 222, 229], ["alcohol", "CHEMICAL", 266, 273], ["alcohol", "CHEMICAL", 222, 229], ["alcohol", "CHEMICAL", 266, 273], ["body", "ORGANISM_SUBDIVISION", 111, 115], ["alcohol", "SIMPLE_CHEMICAL", 222, 229], ["hand", "ORGANISM_SUBDIVISION", 236, 240], ["alcohol", "SIMPLE_CHEMICAL", 266, 273], ["disinfection", "PROBLEM", 293, 305], ["rinsing", "TREATMENT", 368, 375], ["disinfection", "PROBLEM", 391, 403], ["hands", "ANATOMY", 346, 351]]], ["Over 30% of the respondents believed that water temperature caused a difference in the hand cleaning effect (37.8%, n = 133) (Table 2).3.2.", [["hand", "ANATOMY", 87, 91], ["hand", "ORGANISM_SUBDIVISION", 87, 91], ["water temperature", "PROBLEM", 42, 59]]], ["ResultsThere are significant age-related differences, with lower levels of knowledge in young and elder people.", [["people", "ORGANISM", 104, 110], ["people", "SPECIES", 104, 110], ["significant", "OBSERVATION_MODIFIER", 17, 28]]], ["Reduced HH knowledge was also observed in people with low educational level (primary or below) or with comorbid illness(es).", [["comorbid illness", "DISEASE", 103, 119], ["people", "ORGANISM", 42, 48], ["people", "SPECIES", 42, 48], ["comorbid illness", "PROBLEM", 103, 119]]], ["Respondents with better HH knowledge generally performed HH more often during infectious disease outbreaks and took longer time to lather the hands with soap before rinsing.", [["infectious disease outbreaks", "DISEASE", 78, 106], ["hands", "ORGANISM_SUBDIVISION", 142, 147], ["infectious disease outbreaks", "PROBLEM", 78, 106], ["hands", "ANATOMY", 142, 147]]], ["ResultsSignificant differences in the self-reported hand washing behaviours were seen between groups.", [["hand", "ANATOMY", 52, 56], ["hand", "ORGANISM_SUBDIVISION", 52, 56]]], ["For example, more Nepalese than the Chinese respondents indicated that they did not perform hand washing after handling food, cooking, urinating, defalcating, caring for a sick person, showing visibly dirty hands, touching livestock or animal waste, gardening or disposing garbage bag.", [["hand", "ANATOMY", 92, 96], ["person", "SPECIES", 177, 183], ["garbage bag", "TREATMENT", 273, 284], ["garbage bag", "OBSERVATION", 273, 284]]], ["Over 40% of the Nepalese indicated that they only hand wash for \u2264 5 s.", [["hand", "ANATOMY", 50, 54]]], ["An increased number of local respondents would hand wash more often during infectious disease outbreaks than the Nepalese (77.0% vs. 45.9%), with the latter group inclined to ignore hand washing if they are in a hurry (p < 0.001), nobody is in the washroom (p < 0.001) or they only urinated (p < 0.001).3.3.", [["hand", "ANATOMY", 47, 51], ["hand", "ANATOMY", 182, 186], ["infectious disease outbreaks", "DISEASE", 75, 103], ["increased", "OBSERVATION_MODIFIER", 3, 12], ["number", "OBSERVATION_MODIFIER", 13, 19], ["local", "OBSERVATION_MODIFIER", 23, 28]]], ["ResultsRegarding hand drying, more Nepalese always/sometimes dried their hands on their clothing (92.7% vs. 42.6%, p < 0.001) or used personal towel or handkerchief (83.0 vs. 35.8%, p < 0.001) than the Chinese respondents.", [["hand", "ANATOMY", 17, 21], ["hand", "ORGANISM_SUBDIVISION", 17, 21], ["hand drying", "PROBLEM", 17, 28], ["handkerchief", "TEST", 152, 164]]], ["The Chinese respondents generally preferred using paper towels supplied by the washrooms than the Nepalese (96.7% vs. 65.8%).", [["paper towels", "TREATMENT", 50, 62]]], ["Respondents might shake their hands to remove excess water before drying and limit the use of paper towels to two pieces.", [["paper towels", "TREATMENT", 94, 106]]], ["The average time for using either warm or jet hand dryers in the two groups were generally less than 20 s.", [["hand", "ANATOMY", 46, 50], ["warm or jet hand dryers", "TREATMENT", 34, 57]]], ["For the usual hand drying practice at home, the Nepalese preferred to rub their hands on their clothes or by air evaporation, whereas the Chinese population preferred using a towel shared with family members (Table 4).Limitations and Recommendations ::: 4.", [["hand", "ANATOMY", 14, 18], ["hand", "ORGANISM_SUBDIVISION", 14, 18]]], ["DiscussionThis study exhibits a few limitations.", [["This study", "TEST", 10, 20], ["few", "OBSERVATION_MODIFIER", 32, 35]]], ["The non-obtrusive monitoring of HH behaviour may be considered in future studies to provide an unbiased evaluation of the actual behaviour.", [["an unbiased evaluation", "TEST", 92, 114]]], ["Variables, such as duration of residency in the host country and place of birth, must be collected in the future survey to understand how these factors can influence one\u2019s acculturation level and behavioural patterns.", [["acculturation level", "TEST", 172, 191]]], ["Future studies must compare the knowledge and HH behaviours between the Nepalese in their home country and those immigrants to other countries.", [["Future studies", "TEST", 0, 14]]], ["Furthermore, studies must investigate the change in the behavioural patterns before and after substantial improvement in the sanitation facilities at Nepal in recent years.", [["studies", "TEST", 13, 20], ["the change", "PROBLEM", 38, 48], ["substantial", "OBSERVATION_MODIFIER", 94, 105], ["improvement", "OBSERVATION_MODIFIER", 106, 117]]], ["Inclusion of other common ethnic group, such as Filipinos or Indonesians, in future studies can provide valuable information for the development of culturally sensitive interventions related to HH in Hong Kong.5.", [["HH", "DISEASE", 194, 196], ["culturally sensitive interventions", "TREATMENT", 148, 182]]], ["Misconceptions related to the concepts associated with HH were prevalent in the two populations, indicating the need for educational enhancement.", [["HH", "PROBLEM", 55, 57], ["educational enhancement", "PROBLEM", 121, 144]]], ["The findings of this comparative study offer valuable information for the development of culturally sensitive health educational programs to enhance HH practices for the ethnic minorities and the general population of Hong Kong.", [["this comparative study", "TEST", 16, 38], ["HH practices", "TREATMENT", 149, 161]]]], "cbadebb1ecad9afab4ec48a717e56c9881031fb1": [["Bei synchronen Tools kollaborieren die Beteiligten zur gleichen Zeit und profitieren von der zeitnahen Diskussion aktueller Probleme oder Aufgaben.", [["Bei synchronen", "CHEMICAL", 0, 14], ["Bei synchronen", "SPECIES", 0, 14], ["Beteiligten zur gleichen Zeit und profitieren von der zeitnahen Diskussion aktueller Probleme oder Aufgaben", "SPECIES", 39, 146]]], ["B. von Skype.", [["von", "OBSERVATION", 3, 6]]], ["Die klassischen Telefonkonferenzen verlagern sich auch bei gro\u00dfen Unternehmen ins Internet, unsichtbar f\u00fcr die Nutzer, die mit normalen, internetf\u00e4higen Telefonapparaten telefonieren statt mit PC-Software und Headset.", [["Die klassischen Telefonkonferenzen verlagern sich auch bei gro\u00dfen Unternehmen ins Internet, unsichtbar f\u00fcr die Nutzer, die mit normalen, internetf\u00e4higen Telefonapparaten telefonieren statt mit PC-Software und Headset", "SPECIES", 0, 216]]]], "PMC7328546": [["The Ethics Committee of Saveh University of Medical Sciences approved this study.", [["this study", "TEST", 70, 80]]], ["Informed consent was obtained from all participants prior to the study.", [["participants", "SPECIES", 39, 51], ["the study", "TEST", 61, 70]]]], "806d9710eeb1687a5412794fe9443a0787795113": [["2 ED visits would currently place AD patients at high risk of contracting COVID-19, especially for 68 those on immunosuppressants.", [["AD", "DISEASE", 34, 36], ["patients", "ORGANISM", 37, 45], ["patients", "SPECIES", 37, 45], ["contracting COVID", "TEST", 62, 79], ["immunosuppressants", "TREATMENT", 111, 129]]], ["Continued outpatient care through telehealth platforms is vital to help 69 prevent and treat AD flares and to allow for early recognition and treatment of secondary bacterial 70 infections.", [["AD", "DISEASE", 93, 95], ["bacterial 70 infections", "DISEASE", 165, 188], ["AD flares", "PROBLEM", 93, 102], ["treatment", "TREATMENT", 142, 151], ["secondary bacterial 70 infections", "PROBLEM", 155, 188], ["infections", "OBSERVATION", 178, 188]]], ["Providers may examine patients' areas of concern via asynchronous or synchronous virtual 71 visits and reinforce eczema action plans that empower patients to self-treat mild flares, and to recognize 72 appropriate criteria to contact their provider.Strategy Practical RecommendationsReinforce proper skin care regimenStrategy Practical Recommendations\u2022 Advise patients to follow proper hand-washing techniques (preferred over hand sanitizers if accessible) as described by the CDC; use warm water and soap and wash hands for at least 20 seconds then gently pat skin until mostly dry \u2022 Instruct patients to apply moisturizer to hands immediately after washing hands each time \u2022 Counsel that hand sanitizer may be used if no access to water and soap, for example, when patient is outdoors or if patient without access to running water \u2022 Gentle cleansers and hand sanitizers that do not contain high-risk sensitizing ingredients (such as fragrance or unnecessary antiseptic ingredients) should be recommended to minimize risk of allergic contact dermatitis \u2022 Recommend applying a thick layer of a non-fragranced moisturizing cream or ointment like petroleum jelly to hands every night \u2022 Gloves should be worn when washing dishes or when cleaning with products such as disinfectant sprays \u2022 Counsel patients to wear cloth face coverings (surgical masks should be reserved for healthcare workers) in public settings as per CDC guidelines, and the masks should be made from cotton (instead of irritating fabrics such as wool) and free from synthetic dyes \u2022 The cloth masks should be laundered regularly along with other clothing items using fragrance-free detergent* that does not cause skin reactions in patients Provide access to telehealth encountersStrategy Practical Recommendations\u2022 Instruct patients to take photos of areas of concern for asynchronous store-andforward visit, or examine areas during synchronous video visit \u2022 Prioritize patients with complaint of AD flare to potentially diagnose and treat secondary infections (such as impetigo or eczema herpeticum) early \u2022 Reinforce eczema action plans to empower patients to self-manage mild AD flares at homeStrategy Practical RecommendationsOptimize AD treatment regimen*; consider discontinuation if upper respiratory tract viral infection symptoms present \u2022 For patients with moderate to severe AD whose disease requires a new systemic agent during this time, starting dupilumab may be preferable to starting a traditional immunosuppressant, though more data is needed. \u2022 Discontinuation of Janus kinase inhibitors (JAKi) during the time of initial infection may be beneficial, though the potential role of JAKi treatment for the cytokine release syndrome is being investigated.", [["skin", "ANATOMY", 300, 304], ["hand", "ANATOMY", 386, 390], ["hand", "ANATOMY", 426, 430], ["skin", "ANATOMY", 561, 565], ["hand", "ANATOMY", 690, 694], ["hand", "ANATOMY", 856, 860], ["skin", "ANATOMY", 1681, 1685], ["eczema", "DISEASE", 113, 119], ["allergic contact dermatitis", "DISEASE", 1026, 1053], ["AD", "DISEASE", 1965, 1967], ["infections", "DISEASE", 2018, 2028], ["impetigo", "DISEASE", 2038, 2046], ["eczema herpeticum", "DISEASE", 2050, 2067], ["eczema", "DISEASE", 2087, 2093], ["AD", "DISEASE", 2147, 2149], ["AD", "DISEASE", 2207, 2209], ["respiratory tract viral infection", "DISEASE", 2264, 2297], ["AD", "DISEASE", 2354, 2356], ["dupilumab", "CHEMICAL", 2428, 2437], ["infection", "DISEASE", 2608, 2617], ["JAKi", "CHEMICAL", 2666, 2670], ["dupilumab", "CHEMICAL", 2428, 2437], ["patients", "ORGANISM", 22, 30], ["patients", "ORGANISM", 146, 154], ["skin", "ORGAN", 300, 304], ["patients", "ORGANISM", 360, 368], ["hand", "ORGANISM_SUBDIVISION", 426, 430], ["skin", "ORGAN", 561, 565], ["patients", "ORGANISM", 594, 602], ["patient", "ORGANISM", 767, 774], ["patient", "ORGANISM", 793, 800], ["patients", "ORGANISM", 1295, 1303], ["skin", "ORGAN", 1681, 1685], ["patients", "ORGANISM", 1699, 1707], ["patients", "ORGANISM", 1792, 1800], ["patients", "ORGANISM", 1938, 1946], ["patients", "ORGANISM", 2118, 2126], ["upper respiratory tract", "ORGANISM_SUBDIVISION", 2258, 2281], ["patients", "ORGANISM", 2321, 2329], ["dupilumab", "SIMPLE_CHEMICAL", 2428, 2437], ["Janus kinase inhibitors", "SIMPLE_CHEMICAL", 2550, 2573], ["JAKi", "GENE_OR_GENE_PRODUCT", 2575, 2579], ["JAKi", "GENE_OR_GENE_PRODUCT", 2666, 2670], ["Janus kinase", "PROTEIN", 2550, 2562], ["cytokine", "PROTEIN", 2689, 2697], ["patients", "SPECIES", 22, 30], ["patients", "SPECIES", 146, 154], ["patients", "SPECIES", 360, 368], ["patients", "SPECIES", 594, 602], ["patient", "SPECIES", 767, 774], ["patient", "SPECIES", 793, 800], ["patients", "SPECIES", 1295, 1303], ["patients", "SPECIES", 1699, 1707], ["patients", "SPECIES", 1792, 1800], ["patients", "SPECIES", 1938, 1946], ["patients", "SPECIES", 2118, 2126], ["patients", "SPECIES", 2321, 2329], ["eczema action", "TREATMENT", 113, 126], ["mild flares", "PROBLEM", 169, 180], ["proper hand-washing techniques", "TREATMENT", 379, 409], ["hand sanitizers", "TREATMENT", 426, 441], ["warm water", "TREATMENT", 486, 496], ["soap and wash hands", "TREATMENT", 501, 520], ["moisturizer", "TREATMENT", 612, 623], ["hand sanitizer", "TREATMENT", 690, 704], ["running water", "TREATMENT", 819, 832], ["Gentle cleansers and hand sanitizers", "TREATMENT", 835, 871], ["high-risk sensitizing ingredients", "TREATMENT", 892, 925], ["unnecessary antiseptic ingredients", "TREATMENT", 948, 982], ["allergic contact dermatitis", "PROBLEM", 1026, 1053], ["a thick layer", "TREATMENT", 1075, 1088], ["a non-fragranced moisturizing cream", "TREATMENT", 1092, 1127], ["ointment", "TREATMENT", 1131, 1139], ["petroleum jelly", "TREATMENT", 1145, 1160], ["Gloves", "TREATMENT", 1184, 1190], ["disinfectant sprays", "TREATMENT", 1265, 1284], ["cloth face coverings", "TREATMENT", 1312, 1332], ["surgical masks", "TREATMENT", 1334, 1348], ["the masks", "TREATMENT", 1438, 1447], ["cotton", "TREATMENT", 1468, 1474], ["irritating fabrics", "TREATMENT", 1487, 1505], ["The cloth masks", "TREATMENT", 1551, 1566], ["fragrance-free detergent", "TREATMENT", 1635, 1659], ["skin reactions", "PROBLEM", 1681, 1695], ["AD flare", "PROBLEM", 1965, 1973], ["secondary infections", "PROBLEM", 2008, 2028], ["impetigo", "PROBLEM", 2038, 2046], ["eczema", "PROBLEM", 2050, 2056], ["eczema action", "TREATMENT", 2087, 2100], ["mild AD flares", "PROBLEM", 2142, 2156], ["AD treatment regimen*", "TREATMENT", 2207, 2228], ["discontinuation", "TREATMENT", 2239, 2254], ["upper respiratory tract viral infection symptoms", "PROBLEM", 2258, 2306], ["moderate to severe AD whose disease", "PROBLEM", 2335, 2370], ["a new systemic agent", "TREATMENT", 2380, 2400], ["a traditional immunosuppressant", "TREATMENT", 2468, 2499], ["Janus kinase inhibitors", "TREATMENT", 2550, 2573], ["initial infection", "PROBLEM", 2600, 2617], ["JAKi treatment", "TREATMENT", 2666, 2680], ["the cytokine release syndrome", "PROBLEM", 2685, 2714], ["skin", "ANATOMY", 300, 304], ["skin", "ANATOMY", 561, 565], ["allergic", "OBSERVATION", 1026, 1034], ["skin", "ANATOMY", 1681, 1685], ["reactions", "OBSERVATION", 1686, 1695], ["respiratory tract", "ANATOMY", 2264, 2281], ["infection", "OBSERVATION", 2608, 2617]]], ["5 \u2022 Maximize pillars of AD treatment including bleach baths, moisturizers, and topical therapeutics135Abbreviations: AD, atopic dermatitis; CDC, Centers for Disease Control and Prevention 136", [["AD", "DISEASE", 24, 26], ["AD", "DISEASE", 117, 119], ["atopic dermatitis", "DISEASE", 121, 138], ["AD treatment", "TREATMENT", 24, 36], ["bleach baths", "TREATMENT", 47, 59], ["moisturizers", "TREATMENT", 61, 73], ["topical therapeutics", "TREATMENT", 79, 99], ["AD", "PROBLEM", 117, 119], ["atopic dermatitis", "PROBLEM", 121, 138], ["Disease Control", "TREATMENT", 157, 172], ["atopic dermatitis", "OBSERVATION", 121, 138]]]], "19bee00eeb37e92f9b770999c6263263bcd1d280": [["IntroductionCharaterization of a variety of genomic defects in malignant cells (1) has led to attempts to treat cancer by gene therapy.", [["malignant cells", "ANATOMY", 63, 78], ["cancer", "ANATOMY", 112, 118], ["cancer", "DISEASE", 112, 118], ["malignant cells", "CELL", 63, 78], ["cancer", "CANCER", 112, 118], ["malignant cells", "CELL_TYPE", 63, 78], ["genomic defects in malignant cells", "PROBLEM", 44, 78], ["cancer", "PROBLEM", 112, 118], ["gene therapy", "TREATMENT", 122, 134], ["variety", "OBSERVATION_MODIFIER", 33, 40], ["genomic defects", "OBSERVATION", 44, 59], ["malignant cells", "OBSERVATION", 63, 78], ["cancer", "OBSERVATION", 112, 118]]], ["Gene therapy is a therapeutic approach in which therapeutic nucleic acids are transferred into the affected organs.", [["organs", "ANATOMY", 108, 114], ["nucleic acids", "CHEMICAL", 60, 73], ["nucleic acids", "SIMPLE_CHEMICAL", 60, 73], ["organs", "ORGAN", 108, 114], ["Gene therapy", "TREATMENT", 0, 12], ["a therapeutic approach", "TREATMENT", 16, 38], ["therapeutic nucleic acids", "TREATMENT", 48, 73], ["organs", "ANATOMY", 108, 114]]], ["Although the ideal concept would be the replacement of the abnormal gene by a copy of the functional gene, currently there have not been reliable and safe techniques to allow the site-specific integration of DNA into the human genome (2).", [["DNA", "CELLULAR_COMPONENT", 208, 211], ["human", "ORGANISM", 221, 226], ["abnormal gene", "DNA", 59, 72], ["human genome", "DNA", 221, 233], ["human", "SPECIES", 221, 226], ["human", "SPECIES", 221, 226], ["the replacement", "TREATMENT", 36, 51], ["the abnormal gene", "PROBLEM", 55, 72], ["safe techniques", "TREATMENT", 150, 165], ["the site", "PROBLEM", 175, 183], ["human genome", "ANATOMY", 221, 233]]], ["Thus, almost all gene therapies are developed by simply transferring the therapeutic gene into somatic cells without replacing the abnormal gene.", [["somatic cells", "ANATOMY", 95, 108], ["somatic cells", "CELL", 95, 108], ["therapeutic gene", "DNA", 73, 89], ["somatic cells", "CELL_TYPE", 95, 108], ["abnormal gene", "DNA", 131, 144], ["all gene therapies", "TREATMENT", 13, 31], ["the abnormal gene", "PROBLEM", 127, 144]]], ["The goal is to identify and correct genetic abnormalities interfering with the cell cycle and to correct them in all cells.", [["cell", "ANATOMY", 79, 83], ["cells", "ANATOMY", 117, 122], ["cell", "CELL", 79, 83], ["cells", "CELL", 117, 122], ["genetic abnormalities", "PROBLEM", 36, 57], ["the cell cycle", "TREATMENT", 75, 89], ["all cells", "OBSERVATION", 113, 122]]], ["Technically, there are two methods amenable for gene transfer: reintroduction of in vitro transferred gene into the body and direct transfer of gene into the target cells in vivo.IntroductionCancer is a genetic disease characterized by failure to maintain the fidelity of DNA because of germ-line and/or somatic gene changes (3).", [["body", "ANATOMY", 116, 120], ["cells", "ANATOMY", 165, 170], ["germ-line", "ANATOMY", 287, 296], ["IntroductionCancer", "DISEASE", 179, 197], ["body", "ORGANISM_SUBDIVISION", 116, 120], ["cells", "CELL", 165, 170], ["DNA", "CELLULAR_COMPONENT", 272, 275], ["germ-line", "CELL", 287, 296], ["in vitro transferred gene", "DNA", 81, 106], ["target cells", "CELL_TYPE", 158, 170], ["a genetic disease", "PROBLEM", 201, 218], ["failure", "PROBLEM", 236, 243], ["germ-line", "TREATMENT", 287, 296], ["somatic gene changes", "PROBLEM", 304, 324], ["failure", "OBSERVATION", 236, 243]]], ["Genes involved in carcinogenesis are often usefully categorized as either oncogenes contributing to the development of cancer or tumor suppressor genes suppressing the development and maintenance of the cancer phenotype.", [["cancer", "ANATOMY", 119, 125], ["tumor", "ANATOMY", 129, 134], ["cancer", "ANATOMY", 203, 209], ["carcinogenesis", "DISEASE", 18, 32], ["cancer", "DISEASE", 119, 125], ["tumor", "DISEASE", 129, 134], ["cancer", "DISEASE", 203, 209], ["cancer", "CANCER", 119, 125], ["tumor", "CANCER", 129, 134], ["cancer", "CANCER", 203, 209], ["oncogenes", "DNA", 74, 83], ["tumor suppressor genes", "DNA", 129, 151], ["cancer", "PROBLEM", 119, 125], ["tumor suppressor genes", "PROBLEM", 129, 151], ["the cancer phenotype", "PROBLEM", 199, 219], ["cancer", "OBSERVATION", 119, 125], ["tumor", "OBSERVATION", 129, 134], ["cancer", "OBSERVATION", 203, 209]]], ["Therefore, gene therapy is developed by targeting these two genes.", [["gene therapy", "TREATMENT", 11, 23]]], ["Current strategies undergoing development for gene therapy involve in restoring tumor suppressor gene function, downregulating oncogeneic expression, stimulating immune response, introducing genes that either increase drug sensitivity or confer multidrug resistance, and modulating tumor angiogenesis genetically (4-13).", [["tumor", "ANATOMY", 80, 85], ["tumor", "ANATOMY", 282, 287], ["tumor", "DISEASE", 80, 85], ["tumor", "DISEASE", 282, 287], ["tumor", "CANCER", 80, 85], ["tumor", "CANCER", 282, 287], ["gene therapy", "TREATMENT", 46, 58], ["restoring tumor suppressor gene function", "TREATMENT", 70, 110], ["downregulating oncogeneic expression", "TREATMENT", 112, 148], ["drug sensitivity", "PROBLEM", 218, 234], ["multidrug resistance", "PROBLEM", 245, 265], ["modulating tumor angiogenesis", "PROBLEM", 271, 300], ["tumor", "OBSERVATION", 80, 85], ["multidrug resistance", "OBSERVATION", 245, 265], ["tumor", "OBSERVATION", 282, 287]]], ["In this chapter, principles and methods of suicide gene therapy are reviewed together with the results of its clinical trials.", [["suicide gene therapy", "TREATMENT", 43, 63]]], ["Protocols required for application of human study are discussed in details by using Ad-TK gene therapy for liver tumors as an example.PrinciplesSuicide gene therapy consists of the intracellular delivery of a gene encoded for an enzyme that can transform a nontoxic prodrug into a toxic substance (14) .", [["liver tumors", "ANATOMY", 107, 119], ["intracellular", "ANATOMY", 181, 194], ["liver tumors", "DISEASE", 107, 119], ["human", "ORGANISM", 38, 43], ["Ad", "ORGANISM", 84, 86], ["liver tumors", "CANCER", 107, 119], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 181, 194], ["human", "SPECIES", 38, 43], ["human", "SPECIES", 38, 43], ["human study", "TEST", 38, 49], ["Ad-TK gene therapy", "TREATMENT", 84, 102], ["liver tumors", "PROBLEM", 107, 119], ["PrinciplesSuicide gene therapy", "TREATMENT", 134, 164], ["the intracellular delivery", "TREATMENT", 177, 203], ["an enzyme", "TEST", 226, 235], ["liver", "ANATOMY", 107, 112], ["tumors", "OBSERVATION", 113, 119]]], ["These suicide genes are not present in human cells, so an elective delivery of these genes into cancer cells followed by the administration of a prodrug can lead to a conversion of the drug into cytotoxic substances in the transduced cells.", [["cells", "ANATOMY", 45, 50], ["cancer cells", "ANATOMY", 96, 108], ["cells", "ANATOMY", 234, 239], ["cancer", "DISEASE", 96, 102], ["human", "ORGANISM", 39, 44], ["cells", "CELL", 45, 50], ["cancer cells", "CELL", 96, 108], ["cells", "CELL", 234, 239], ["suicide genes", "DNA", 6, 19], ["human cells", "CELL_TYPE", 39, 50], ["cancer cells", "CELL_TYPE", 96, 108], ["transduced cells", "CELL_LINE", 223, 239], ["human", "SPECIES", 39, 44], ["human", "SPECIES", 39, 44], ["an elective delivery", "TREATMENT", 55, 75], ["cancer cells", "PROBLEM", 96, 108], ["a prodrug", "TREATMENT", 143, 152], ["cytotoxic substances", "TREATMENT", 195, 215], ["the transduced cells", "TREATMENT", 219, 239], ["transduced cells", "OBSERVATION", 223, 239]]], ["The delivery and transcription of a tumor-specific suicide gene in vivo are crucial for suicide gene therapy to be effective.", [["tumor", "ANATOMY", 36, 41], ["tumor", "DISEASE", 36, 41], ["tumor", "CANCER", 36, 41], ["tumor-specific suicide gene", "DNA", 36, 63], ["The delivery", "TREATMENT", 0, 12], ["a tumor", "PROBLEM", 34, 41], ["suicide gene therapy", "TREATMENT", 88, 108], ["tumor", "OBSERVATION", 36, 41]]], ["Currently, two strategies are being investigated to selectively transduce tumor cells: tumor-specific vectors and control of suicide gene transcription in tissues or tumors with a tumor-specific promoter.", [["tumor cells", "ANATOMY", 74, 85], ["tumor", "ANATOMY", 87, 92], ["tissues", "ANATOMY", 155, 162], ["tumors", "ANATOMY", 166, 172], ["tumor", "ANATOMY", 180, 185], ["tumor", "DISEASE", 74, 79], ["tumor", "DISEASE", 87, 92], ["tumors", "DISEASE", 166, 172], ["tumor", "DISEASE", 180, 185], ["tumor cells", "CELL", 74, 85], ["tumor", "CANCER", 87, 92], ["tissues", "TISSUE", 155, 162], ["tumors", "CANCER", 166, 172], ["tumor", "CANCER", 180, 185], ["tumor cells", "CELL_TYPE", 74, 85], ["tumor-specific promoter", "DNA", 180, 203], ["tumor", "PROBLEM", 87, 92], ["suicide gene transcription in tissues", "PROBLEM", 125, 162], ["tumors", "PROBLEM", 166, 172], ["a tumor", "PROBLEM", 178, 185], ["tumor", "OBSERVATION", 74, 79], ["tumor", "OBSERVATION", 87, 92], ["tumors", "OBSERVATION", 166, 172], ["tumor", "OBSERVATION", 180, 185]]], ["Promoters such as carcinoembryonic antigen (CEA), or \u03b1-fetoprotein (AFP) for liver tumors, limit gene expression to CEA-or AFP-positive cells only.", [["liver tumors", "ANATOMY", 77, 89], ["AFP-positive cells", "ANATOMY", 123, 141], ["liver tumors", "DISEASE", 77, 89], ["carcinoembryonic antigen", "GENE_OR_GENE_PRODUCT", 18, 42], ["CEA", "GENE_OR_GENE_PRODUCT", 44, 47], ["\u03b1-fetoprotein", "GENE_OR_GENE_PRODUCT", 53, 66], ["AFP", "GENE_OR_GENE_PRODUCT", 68, 71], ["liver tumors", "CANCER", 77, 89], ["CEA", "GENE_OR_GENE_PRODUCT", 116, 119], ["AFP", "GENE_OR_GENE_PRODUCT", 123, 126], ["carcinoembryonic antigen", "PROTEIN", 18, 42], ["CEA", "PROTEIN", 44, 47], ["\u03b1-fetoprotein", "PROTEIN", 53, 66], ["AFP", "PROTEIN", 68, 71], ["CEA", "PROTEIN", 116, 119], ["AFP", "PROTEIN", 123, 126], ["carcinoembryonic antigen", "TEST", 18, 42], ["CEA", "TEST", 44, 47], ["\u03b1-fetoprotein (AFP", "PROBLEM", 53, 71], ["liver tumors", "PROBLEM", 77, 89], ["CEA", "TEST", 116, 119], ["AFP", "TEST", 123, 126], ["positive cells", "PROBLEM", 127, 141], ["liver", "ANATOMY", 77, 82], ["tumors", "OBSERVATION", 83, 89], ["positive cells", "OBSERVATION", 127, 141]]], ["The most commonly used suicide genes are cytosine deaminase (CD) and the herpes simplex virus-thymidine kinase (HSV-TK).Thymidine Kinase GeneAcyclovir and ganciclovir are used for the treatment of herpes simplex virus (HSV) infections.", [["cytosine", "CHEMICAL", 41, 49], ["herpes simplex virus-thymidine", "CHEMICAL", 73, 103], ["Thymidine", "CHEMICAL", 120, 129], ["GeneAcyclovir", "CHEMICAL", 137, 150], ["ganciclovir", "CHEMICAL", 155, 166], ["herpes simplex virus (HSV) infections", "DISEASE", 197, 234], ["cytosine", "CHEMICAL", 41, 49], ["thymidine", "CHEMICAL", 94, 103], ["Thymidine", "CHEMICAL", 120, 129], ["GeneAcyclovir", "CHEMICAL", 137, 150], ["ganciclovir", "CHEMICAL", 155, 166], ["cytosine deaminase", "GENE_OR_GENE_PRODUCT", 41, 59], ["CD", "GENE_OR_GENE_PRODUCT", 61, 63], ["herpes simplex virus", "ORGANISM", 73, 93], ["thymidine kinase", "GENE_OR_GENE_PRODUCT", 94, 110], ["HSV-TK", "ORGANISM", 112, 118], ["Thymidine Kinase GeneAcyclovir", "SIMPLE_CHEMICAL", 120, 150], ["ganciclovir", "SIMPLE_CHEMICAL", 155, 166], ["herpes simplex virus", "ORGANISM", 197, 217], ["HSV", "ORGANISM", 219, 222], ["suicide genes", "DNA", 23, 36], ["cytosine deaminase", "PROTEIN", 41, 59], ["thymidine kinase", "PROTEIN", 94, 110], ["TK", "PROTEIN", 116, 118], ["herpes simplex virus", "SPECIES", 73, 93], ["herpes simplex virus", "SPECIES", 197, 217], ["herpes simplex virus", "SPECIES", 73, 93], ["herpes simplex virus", "SPECIES", 197, 217], ["HSV", "SPECIES", 219, 222], ["cytosine deaminase (CD", "PROBLEM", 41, 63], ["the herpes simplex virus", "TEST", 69, 93], ["thymidine kinase", "TEST", 94, 110], ["Thymidine Kinase GeneAcyclovir", "TREATMENT", 120, 150], ["ganciclovir", "TREATMENT", 155, 166], ["herpes simplex virus (HSV) infections", "PROBLEM", 197, 234]]], ["These drugs are phosphorylated to the active form by the enzyme thymidine kinase (TK) encoded for part of the HSV genome.", [["thymidine", "CHEMICAL", 64, 73], ["thymidine", "CHEMICAL", 64, 73], ["thymidine kinase", "GENE_OR_GENE_PRODUCT", 64, 80], ["HSV", "ORGANISM", 110, 113], ["enzyme thymidine kinase", "PROTEIN", 57, 80], ["TK", "PROTEIN", 82, 84], ["HSV genome", "DNA", 110, 120], ["HSV", "SPECIES", 110, 113], ["These drugs", "TREATMENT", 0, 11], ["phosphorylated", "TREATMENT", 16, 30], ["the enzyme thymidine kinase", "TEST", 53, 80], ["the HSV genome", "PROBLEM", 106, 120], ["HSV genome", "OBSERVATION", 110, 120]]], ["The HSV-TK gene is expressed after herpetic viral TK transcription, leading to activation of the drug and cell death.", [["cell", "ANATOMY", 106, 110], ["death", "DISEASE", 111, 116], ["HSV-TK", "ORGANISM", 4, 10], ["cell", "CELL", 106, 110], ["HSV-TK gene", "DNA", 4, 15], ["HSV-TK", "SPECIES", 4, 10], ["The HSV", "TEST", 0, 7], ["herpetic viral TK transcription", "PROBLEM", 35, 66], ["cell death", "PROBLEM", 106, 116], ["TK", "ANATOMY", 8, 10], ["cell death", "OBSERVATION", 106, 116]]], ["To achieve expression of HSV-TK, which is specific only to hepatocellular carcinoma (HCC) cells, an AFP promoter has been constructed.", [["hepatocellular carcinoma (HCC) cells", "ANATOMY", 59, 95], ["hepatocellular carcinoma", "DISEASE", 59, 83], ["HCC", "DISEASE", 85, 88], ["HSV-TK", "ORGANISM", 25, 31], ["hepatocellular carcinoma (HCC) cells", "CELL", 59, 95], ["AFP", "GENE_OR_GENE_PRODUCT", 100, 103], ["HSV-TK", "DNA", 25, 31], ["hepatocellular carcinoma (HCC) cells", "CELL_TYPE", 59, 95], ["AFP promoter", "DNA", 100, 112], ["HSV-TK", "SPECIES", 25, 31], ["HSV-TK", "PROBLEM", 25, 31], ["hepatocellular carcinoma (HCC) cells", "PROBLEM", 59, 95], ["an AFP promoter", "TEST", 97, 112], ["hepatocellular", "ANATOMY", 59, 73], ["carcinoma", "OBSERVATION", 74, 83]]], ["The promoter ensures that only cells expressing AFP are able to transcribe and express the HSV-TK gene.Thymidine Kinase GeneThe first HSV-TK suicide gene system was introduced by Moolten (15,16) .", [["cells", "ANATOMY", 31, 36], ["Thymidine", "CHEMICAL", 103, 112], ["Thymidine", "CHEMICAL", 103, 112], ["cells", "CELL", 31, 36], ["AFP", "GENE_OR_GENE_PRODUCT", 48, 51], ["HSV-TK", "GENE_OR_GENE_PRODUCT", 91, 97], ["Thymidine Kinase Gene", "GENE_OR_GENE_PRODUCT", 103, 124], ["HSV", "ORGANISM", 134, 137], ["AFP", "PROTEIN", 48, 51], ["HSV-TK gene", "DNA", 91, 102], ["Thymidine Kinase Gene", "DNA", 103, 124], ["HSV-TK suicide gene system", "DNA", 134, 160], ["cells expressing AFP", "PROBLEM", 31, 51], ["the HSV", "TEST", 87, 94], ["Thymidine Kinase Gene", "TREATMENT", 103, 124], ["The first HSV-TK suicide gene system", "TREATMENT", 124, 160]]], ["Under the control of an AFP promoter, an adenoviral vector was used to bring the HSV-TK gene into various HCC cell lines (5).", [["HCC cell lines", "ANATOMY", 106, 120], ["HCC", "DISEASE", 106, 109], ["AFP", "GENE_OR_GENE_PRODUCT", 24, 27], ["adenoviral", "ORGANISM", 41, 51], ["HSV", "ORGANISM", 81, 84], ["HCC cell lines", "CELL", 106, 120], ["AFP promoter", "DNA", 24, 36], ["HSV-TK gene", "DNA", 81, 92], ["HCC cell lines", "CELL_LINE", 106, 120], ["an AFP promoter", "TREATMENT", 21, 36], ["an adenoviral vector", "TREATMENT", 38, 58], ["the HSV-TK gene into various HCC cell lines", "TREATMENT", 77, 120], ["HCC cell lines", "OBSERVATION", 106, 120]]], ["Following ganciclovir (GCV) administration, cell death occurred in hepatoma cells producing AFP, leaving non-AFP-producing cell lines unaffected.", [["cell", "ANATOMY", 44, 48], ["hepatoma cells", "ANATOMY", 67, 81], ["cell lines", "ANATOMY", 123, 133], ["ganciclovir", "CHEMICAL", 10, 21], ["GCV", "CHEMICAL", 23, 26], ["death", "DISEASE", 49, 54], ["ganciclovir", "CHEMICAL", 10, 21], ["GCV", "CHEMICAL", 23, 26], ["ganciclovir", "SIMPLE_CHEMICAL", 10, 21], ["GCV", "SIMPLE_CHEMICAL", 23, 26], ["cell", "CELL", 44, 48], ["hepatoma cells", "CELL", 67, 81], ["AFP", "GENE_OR_GENE_PRODUCT", 92, 95], ["non-AFP", "GENE_OR_GENE_PRODUCT", 105, 112], ["cell lines", "CELL", 123, 133], ["hepatoma cells", "CELL_TYPE", 67, 81], ["AFP", "PROTEIN", 92, 95], ["non-AFP-producing cell lines", "CELL_LINE", 105, 133], ["ganciclovir (GCV) administration", "TREATMENT", 10, 42], ["cell death", "PROBLEM", 44, 54], ["hepatoma cells", "PROBLEM", 67, 81], ["AFP", "TEST", 92, 95], ["non-AFP", "TEST", 105, 112], ["hepatoma cells", "OBSERVATION", 67, 81], ["cell lines", "OBSERVATION", 123, 133]]], ["Phosphorylated GCV is thought to cause cell death by the inhibition of DNA polymerase and by causing chain termination during DNA synthesis in dividing cells, which then leads to apoptosis (16).", [["cell", "ANATOMY", 39, 43], ["cells", "ANATOMY", 152, 157], ["GCV", "CHEMICAL", 15, 18], ["death", "DISEASE", 44, 49], ["GCV", "SIMPLE_CHEMICAL", 15, 18], ["cell", "CELL", 39, 43], ["DNA", "CELLULAR_COMPONENT", 71, 74], ["DNA", "CELLULAR_COMPONENT", 126, 129], ["cells", "CELL", 152, 157], ["DNA polymerase", "PROTEIN", 71, 85], ["dividing cells", "CELL_TYPE", 143, 157], ["Phosphorylated GCV", "TREATMENT", 0, 18], ["cell death", "PROBLEM", 39, 49], ["DNA polymerase", "PROBLEM", 71, 85], ["chain termination", "PROBLEM", 101, 118], ["DNA synthesis in dividing cells", "PROBLEM", 126, 157], ["apoptosis", "TEST", 179, 188], ["thought to cause", "UNCERTAINTY", 22, 38], ["cell death", "OBSERVATION", 39, 49]]], ["A bystander effect has been described, both in vitro and in vivo, where neighboring HSV-TK-negative cells have died when in contact with HSV-TK-positive cells after GCV treatment (17).", [["cells", "ANATOMY", 100, 105], ["cells", "ANATOMY", 153, 158], ["GCV", "CHEMICAL", 165, 168], ["GCV", "CHEMICAL", 165, 168], ["HSV-TK", "ORGANISM", 84, 90], ["cells", "CELL", 100, 105], ["HSV-TK", "ORGANISM", 137, 143], ["cells", "CELL", 153, 158], ["GCV", "SIMPLE_CHEMICAL", 165, 168], ["HSV-TK-negative cells", "CELL_LINE", 84, 105], ["HSV-TK-positive cells", "CELL_LINE", 137, 158], ["HSV", "SPECIES", 137, 140], ["neighboring HSV", "TEST", 72, 87], ["HSV", "TEST", 137, 140], ["GCV treatment", "TREATMENT", 165, 178], ["positive cells", "OBSERVATION_MODIFIER", 144, 158]]], ["This increases the effectiveness of suicide gene therapy, and only a part of a tumor mass needs to be transfected by a suicide gene for tumor destruction.", [["tumor mass", "ANATOMY", 79, 89], ["tumor", "ANATOMY", 136, 141], ["tumor", "DISEASE", 79, 84], ["tumor", "DISEASE", 136, 141], ["tumor", "CANCER", 79, 84], ["tumor", "CANCER", 136, 141], ["suicide gene therapy", "TREATMENT", 36, 56], ["a tumor mass", "PROBLEM", 77, 89], ["tumor destruction", "PROBLEM", 136, 153], ["tumor", "OBSERVATION", 79, 84], ["mass", "OBSERVATION", 85, 89], ["tumor", "OBSERVATION", 136, 141]]], ["A glucocorticoidresponsive element exists upstream of the AFP gene in hepatoma cells, which explains the increase in AFP observed after the addition of dexamethasone into the culture medium of such cells (18).", [["hepatoma cells", "ANATOMY", 70, 84], ["cells", "ANATOMY", 198, 203], ["dexamethasone", "CHEMICAL", 152, 165], ["dexamethasone", "CHEMICAL", 152, 165], ["AFP", "GENE_OR_GENE_PRODUCT", 58, 61], ["hepatoma cells", "CELL", 70, 84], ["AFP", "GENE_OR_GENE_PRODUCT", 117, 120], ["dexamethasone", "SIMPLE_CHEMICAL", 152, 165], ["cells", "CELL", 198, 203], ["glucocorticoidresponsive element", "DNA", 2, 34], ["AFP gene", "DNA", 58, 66], ["hepatoma cells", "CELL_TYPE", 70, 84], ["AFP", "PROTEIN", 117, 120], ["A glucocorticoidresponsive element", "TREATMENT", 0, 34], ["the AFP gene in hepatoma cells", "PROBLEM", 54, 84], ["the increase in AFP", "PROBLEM", 101, 120], ["dexamethasone", "TREATMENT", 152, 165], ["the culture", "TEST", 171, 182], ["such cells", "PROBLEM", 193, 203], ["hepatoma cells", "OBSERVATION", 70, 84], ["increase", "OBSERVATION_MODIFIER", 105, 113]]], ["It is possible that the potency of the TK/GCV suicide system could be enhanced by the addition of dexamethasone to a HepG2 cell line (19) .Thymidine Kinase GeneA retrovirus vector (LNAF0.3TK) carrying the HSV-TK gene regulated only by a human AFP promoter has also been reported to provide GCV-mediated cytotoxicity in high-AFP-producing human hepatoma cells, but not in low-AFP-producing cells.", [["HepG2 cell line", "ANATOMY", 117, 132], ["hepatoma cells", "ANATOMY", 344, 358], ["cells", "ANATOMY", 389, 394], ["GCV", "CHEMICAL", 42, 45], ["dexamethasone", "CHEMICAL", 98, 111], ["Thymidine", "CHEMICAL", 139, 148], ["GCV", "CHEMICAL", 290, 293], ["GCV", "CHEMICAL", 42, 45], ["dexamethasone", "CHEMICAL", 98, 111], ["Thymidine", "CHEMICAL", 139, 148], ["GCV", "CHEMICAL", 290, 293], ["dexamethasone", "SIMPLE_CHEMICAL", 98, 111], ["HepG2 cell line", "CELL", 117, 132], ["Thymidine Kinase", "GENE_OR_GENE_PRODUCT", 139, 155], ["LNAF0.3TK", "GENE_OR_GENE_PRODUCT", 181, 190], ["HSV-TK", "ORGANISM", 205, 211], ["human", "ORGANISM", 237, 242], ["AFP", "GENE_OR_GENE_PRODUCT", 243, 246], ["GCV", "SIMPLE_CHEMICAL", 290, 293], ["AFP", "GENE_OR_GENE_PRODUCT", 324, 327], ["human", "ORGANISM", 338, 343], ["hepatoma cells", "CELL", 344, 358], ["AFP", "GENE_OR_GENE_PRODUCT", 375, 378], ["cells", "CELL", 389, 394], ["HepG2 cell line", "CELL_LINE", 117, 132], ["Thymidine Kinase GeneA retrovirus vector", "DNA", 139, 179], ["LNAF0.3TK", "DNA", 181, 190], ["HSV-TK gene", "DNA", 205, 216], ["human AFP promoter", "DNA", 237, 255], ["high-AFP-producing human hepatoma cells", "CELL_LINE", 319, 358], ["low-AFP-producing cells", "CELL_TYPE", 371, 394], ["human", "SPECIES", 237, 242], ["human", "SPECIES", 338, 343], ["human", "SPECIES", 237, 242], ["human", "SPECIES", 338, 343], ["the TK/GCV suicide system", "TREATMENT", 35, 60], ["dexamethasone", "TREATMENT", 98, 111], ["a HepG2 cell line", "TREATMENT", 115, 132], ["Thymidine Kinase GeneA retrovirus vector (LNAF0.3TK)", "TREATMENT", 139, 191], ["the HSV", "TEST", 201, 208], ["a human AFP promoter", "TREATMENT", 235, 255], ["GCV", "TEST", 290, 293], ["mediated cytotoxicity", "PROBLEM", 294, 315], ["high-AFP", "PROBLEM", 319, 327], ["human hepatoma cells", "PROBLEM", 338, 358], ["hepatoma cells", "OBSERVATION", 344, 358]]], ["The retrovirus has been further improved so that the HSV-TK gene expression is under the control of a human AFP enhancer directly linked to its promoter [LNAF0.3(E+)TK].", [["retrovirus", "ORGANISM", 4, 14], ["HSV-TK", "ORGANISM", 53, 59], ["human", "ORGANISM", 102, 107], ["AFP", "GENE_OR_GENE_PRODUCT", 108, 111], ["E+)TK", "GENE_OR_GENE_PRODUCT", 162, 167], ["HSV-TK gene", "DNA", 53, 64], ["human AFP enhancer", "DNA", 102, 120], ["promoter", "DNA", 144, 152], ["LNAF0", "DNA", 154, 159], ["human", "SPECIES", 102, 107], ["HSV", "SPECIES", 53, 56], ["human", "SPECIES", 102, 107], ["The retrovirus", "PROBLEM", 0, 14], ["the HSV", "TEST", 49, 56], ["TK gene expression", "PROBLEM", 57, 75], ["a human AFP enhancer", "PROBLEM", 100, 120], ["retrovirus", "OBSERVATION", 4, 14], ["improved", "OBSERVATION_MODIFIER", 32, 40]]], ["The vector also sensitized both low-and intermediate-AFP-producing hepatoma cells to GCV treatment, and did not affect cell growth in nonhepatoma cells (20) .", [["hepatoma cells", "ANATOMY", 67, 81], ["cell", "ANATOMY", 119, 123], ["nonhepatoma cells", "ANATOMY", 134, 151], ["GCV", "CHEMICAL", 85, 88], ["GCV", "CHEMICAL", 85, 88], ["AFP", "GENE_OR_GENE_PRODUCT", 53, 56], ["hepatoma cells", "CELL", 67, 81], ["GCV", "SIMPLE_CHEMICAL", 85, 88], ["cell", "CELL", 119, 123], ["nonhepatoma cells", "CELL", 134, 151], ["low-and intermediate-AFP-producing hepatoma cells", "CELL_LINE", 32, 81], ["nonhepatoma cells", "CELL_TYPE", 134, 151], ["hepatoma cells", "PROBLEM", 67, 81], ["GCV treatment", "TREATMENT", 85, 98], ["cell growth in nonhepatoma cells", "PROBLEM", 119, 151], ["AFP", "ANATOMY", 53, 56], ["hepatoma", "ANATOMY", 67, 75], ["nonhepatoma cells", "OBSERVATION", 134, 151]]], ["In animal models, GCV treatment has led to more pronounced growth inhibition in the LNAF0.3(E+)TK infected cells than in the LNAF0.3TK infected cells (20) .", [["cells", "ANATOMY", 107, 112], ["cells", "ANATOMY", 144, 149], ["GCV", "CHEMICAL", 18, 21], ["GCV", "CHEMICAL", 18, 21], ["GCV", "SIMPLE_CHEMICAL", 18, 21], ["LNAF0", "GENE_OR_GENE_PRODUCT", 84, 89], ["E+)TK", "GENE_OR_GENE_PRODUCT", 92, 97], ["cells", "CELL", 107, 112], ["cells", "CELL", 144, 149], ["LNAF0", "DNA", 84, 89], ["LNAF0.3TK infected cells", "CELL_LINE", 125, 149], ["GCV treatment", "TREATMENT", 18, 31], ["TK infected cells", "PROBLEM", 95, 112], ["more pronounced", "OBSERVATION_MODIFIER", 43, 58], ["growth inhibition", "OBSERVATION", 59, 76], ["TK", "ANATOMY", 95, 97], ["infected cells", "OBSERVATION", 98, 112], ["infected cells", "OBSERVATION", 135, 149]]], ["These results indicate that an AFP enhancer directly linked to its promoter can further enhance tumoricidal activity in gene therapy for hepatocellular carcinoma.Thymidine Kinase GeneMost in vivo studies have used subcutaneously grown human HCC tumor xenografts in mice followed by transfection with an AFP-HSV-TK gene in an adenoviral vector.", [["hepatocellular carcinoma", "ANATOMY", 137, 161], ["HCC tumor xenografts", "ANATOMY", 241, 261], ["hepatocellular carcinoma", "DISEASE", 137, 161], ["Thymidine", "CHEMICAL", 162, 171], ["HCC tumor", "DISEASE", 241, 250], ["Thymidine", "CHEMICAL", 162, 171], ["AFP", "GENE_OR_GENE_PRODUCT", 31, 34], ["hepatocellular carcinoma", "CANCER", 137, 161], ["Thymidine Kinase", "GENE_OR_GENE_PRODUCT", 162, 178], ["human", "ORGANISM", 235, 240], ["HCC tumor xenografts", "CANCER", 241, 261], ["mice", "ORGANISM", 265, 269], ["AFP", "GENE_OR_GENE_PRODUCT", 303, 306], ["HSV", "ORGANISM", 307, 310], ["adenoviral", "ORGANISM", 325, 335], ["AFP enhancer", "DNA", 31, 43], ["subcutaneously grown human HCC tumor xenografts", "CELL_LINE", 214, 261], ["AFP-HSV-TK gene", "DNA", 303, 318], ["human", "SPECIES", 235, 240], ["mice", "SPECIES", 265, 269], ["human", "SPECIES", 235, 240], ["mice", "SPECIES", 265, 269], ["an AFP enhancer", "PROBLEM", 28, 43], ["gene therapy", "TREATMENT", 120, 132], ["hepatocellular carcinoma", "PROBLEM", 137, 161], ["Thymidine Kinase", "TREATMENT", 162, 178], ["vivo studies", "TEST", 191, 203], ["human HCC tumor xenografts", "TREATMENT", 235, 261], ["transfection", "TEST", 282, 294], ["an AFP", "TEST", 300, 306], ["HSV", "PROBLEM", 307, 310], ["an adenoviral vector", "TREATMENT", 322, 342], ["hepatocellular", "ANATOMY", 137, 151], ["carcinoma", "OBSERVATION", 152, 161]]], ["Tumor selectivity was confirmed by the regression of HuH-7 established tumors in athymic mice, whereas normal tissues remained unaffected (7).", [["Tumor", "ANATOMY", 0, 5], ["tumors", "ANATOMY", 71, 77], ["tissues", "ANATOMY", 110, 117], ["tumors", "DISEASE", 71, 77], ["Tumor", "CANCER", 0, 5], ["HuH-7", "CELL", 53, 58], ["tumors", "CANCER", 71, 77], ["mice", "ORGANISM", 89, 93], ["normal tissues", "TISSUE", 103, 117], ["mice", "SPECIES", 89, 93], ["mice", "SPECIES", 89, 93], ["Tumor selectivity", "TEST", 0, 17], ["HuH", "TEST", 53, 56], ["tumors", "OBSERVATION", 71, 77], ["athymic mice", "OBSERVATION", 81, 93], ["tissues", "OBSERVATION_MODIFIER", 110, 117]]], ["The bystander effect enabled tumor regression even when only 10% of the tumor mass expressed HSV-TK (17).", [["tumor", "ANATOMY", 29, 34], ["tumor mass", "ANATOMY", 72, 82], ["tumor", "DISEASE", 29, 34], ["tumor", "DISEASE", 72, 77], ["tumor", "CANCER", 29, 34], ["tumor", "CANCER", 72, 77], ["HSV", "ORGANISM", 93, 96], ["tumor regression", "PROBLEM", 29, 45], ["the tumor mass", "PROBLEM", 68, 82], ["HSV", "TEST", 93, 96], ["tumor", "OBSERVATION", 29, 34], ["tumor", "OBSERVATION_MODIFIER", 72, 77], ["mass", "OBSERVATION", 78, 82]]], ["A similar therapeutic response has been seen in rats with colorectal liver metastases, where following direct intratumoral injections of HSV-TK-producing packaging cells, a 60-fold reduction in tumor mass was noted following GCV treatment when compared with controls (21).", [["colorectal liver metastases", "ANATOMY", 58, 85], ["intratumoral", "ANATOMY", 110, 122], ["cells", "ANATOMY", 164, 169], ["tumor mass", "ANATOMY", 194, 204], ["colorectal liver metastases", "DISEASE", 58, 85], ["tumor", "DISEASE", 194, 199], ["GCV", "CHEMICAL", 225, 228], ["GCV", "CHEMICAL", 225, 228], ["rats", "ORGANISM", 48, 52], ["colorectal", "CANCER", 58, 68], ["liver", "ORGAN", 69, 74], ["intratumoral", "IMMATERIAL_ANATOMICAL_ENTITY", 110, 122], ["HSV-TK", "ORGANISM", 137, 143], ["cells", "CELL", 164, 169], ["tumor", "CANCER", 194, 199], ["GCV", "SIMPLE_CHEMICAL", 225, 228], ["HSV-TK-producing packaging cells", "CELL_LINE", 137, 169], ["rats", "SPECIES", 48, 52], ["HSV", "SPECIES", 137, 140], ["colorectal liver metastases", "PROBLEM", 58, 85], ["direct intratumoral injections", "TREATMENT", 103, 133], ["HSV", "TEST", 137, 140], ["TK", "TEST", 141, 143], ["packaging cells", "TREATMENT", 154, 169], ["a 60-fold reduction", "TREATMENT", 171, 190], ["tumor mass", "PROBLEM", 194, 204], ["GCV treatment", "TREATMENT", 225, 238], ["therapeutic response", "OBSERVATION", 10, 30], ["colorectal", "OBSERVATION_MODIFIER", 58, 68], ["liver", "ANATOMY", 69, 74], ["metastases", "OBSERVATION", 75, 85], ["packaging cells", "OBSERVATION", 154, 169], ["60-fold", "OBSERVATION_MODIFIER", 173, 180], ["reduction", "OBSERVATION_MODIFIER", 181, 190], ["tumor", "OBSERVATION_MODIFIER", 194, 199], ["mass", "OBSERVATION", 200, 204]]], ["Kuriyama et al. described cancer gene therapy with the GCV-HSV-TK system that induced efficient antitumor effects and protective immunity in immunocompetent mice, but not in nude mice.", [["cancer", "ANATOMY", 26, 32], ["antitumor", "ANATOMY", 96, 105], ["cancer", "DISEASE", 26, 32], ["GCV", "CHEMICAL", 55, 58], ["cancer", "CANCER", 26, 32], ["GCV-HSV", "ORGANISM", 55, 62], ["-TK", "ORGANISM", 62, 65], ["antitumor", "CANCER", 96, 105], ["mice", "ORGANISM", 157, 161], ["nude mice", "ORGANISM", 174, 183], ["mice", "SPECIES", 157, 161], ["mice", "SPECIES", 179, 183], ["mice", "SPECIES", 157, 161], ["mice", "SPECIES", 179, 183], ["cancer gene therapy", "TREATMENT", 26, 45], ["the GCV", "TEST", 51, 58], ["HSV", "PROBLEM", 59, 62], ["TK system", "PROBLEM", 63, 72], ["cancer", "OBSERVATION", 26, 32], ["antitumor", "OBSERVATION", 96, 105]]], ["This indicates that a T-cell-mediated immune response may be a critical factor for HSV-TK gene therapy to be successful (22) .Thymidine Kinase GeneUnfortunately, severe hepatic dysfunction has been described following adenovirus-mediated transfer of the HSV-TK gene and GCV administration in a rat model of colorectal liver metastases (23).", [["T-cell", "ANATOMY", 22, 28], ["hepatic", "ANATOMY", 169, 176], ["colorectal liver metastases", "ANATOMY", 307, 334], ["Thymidine", "CHEMICAL", 126, 135], ["hepatic dysfunction", "DISEASE", 169, 188], ["GCV", "CHEMICAL", 270, 273], ["colorectal liver metastases", "DISEASE", 307, 334], ["Thymidine", "CHEMICAL", 126, 135], ["GCV", "CHEMICAL", 270, 273], ["T-cell", "CELL", 22, 28], ["HSV", "ORGANISM", 83, 86], ["-TK", "ORGANISM", 86, 89], ["Thymidine Kinase", "GENE_OR_GENE_PRODUCT", 126, 142], ["hepatic", "ORGAN", 169, 176], ["adenovirus", "ORGANISM", 218, 228], ["HSV", "ORGANISM", 254, 257], ["-TK", "ORGANISM", 257, 260], ["GCV", "SIMPLE_CHEMICAL", 270, 273], ["rat", "ORGANISM", 294, 297], ["colorectal", "CANCER", 307, 317], ["liver", "ORGAN", 318, 323], ["HSV-TK gene", "DNA", 254, 265], ["rat", "SPECIES", 294, 297], ["HSV", "SPECIES", 83, 86], ["rat", "SPECIES", 294, 297], ["HSV-TK gene therapy", "TREATMENT", 83, 102], ["Thymidine Kinase", "TEST", 126, 142], ["severe hepatic dysfunction", "PROBLEM", 162, 188], ["adenovirus", "TREATMENT", 218, 228], ["the HSV-TK gene", "TREATMENT", 250, 265], ["GCV administration", "TREATMENT", 270, 288], ["colorectal liver metastases", "PROBLEM", 307, 334], ["severe", "OBSERVATION_MODIFIER", 162, 168], ["hepatic", "ANATOMY", 169, 176], ["dysfunction", "OBSERVATION", 177, 188], ["colorectal", "OBSERVATION_MODIFIER", 307, 317], ["liver", "ANATOMY", 318, 323], ["metastases", "OBSERVATION", 324, 334]]], ["Hepatic expression of HSV-TK was demonstrated, both in tumor-bearing and in tumor-free liver tissue.", [["Hepatic", "ANATOMY", 0, 7], ["tumor", "ANATOMY", 55, 60], ["tumor", "ANATOMY", 76, 81], ["liver tissue", "ANATOMY", 87, 99], ["tumor", "DISEASE", 55, 60], ["tumor", "DISEASE", 76, 81], ["Hepatic", "MULTI-TISSUE_STRUCTURE", 0, 7], ["HSV", "ORGANISM", 22, 25], ["-TK", "ORGANISM", 25, 28], ["tumor", "CANCER", 55, 60], ["tumor-free", "TISSUE", 76, 86], ["liver tissue", "TISSUE", 87, 99], ["HSV", "SPECIES", 22, 25], ["HSV", "PROBLEM", 22, 25], ["HSV", "OBSERVATION", 22, 25], ["TK", "ANATOMY", 26, 28], ["both", "OBSERVATION_MODIFIER", 47, 51], ["tumor", "OBSERVATION", 55, 60], ["bearing", "OBSERVATION_MODIFIER", 61, 68], ["tumor", "OBSERVATION", 76, 81], ["free", "OBSERVATION_MODIFIER", 82, 86], ["liver", "ANATOMY", 87, 92], ["tissue", "OBSERVATION", 93, 99]]], ["The hepatic HSV-TK expression provoked severe liver dysfunction and mortality upon GCV administration, and, in addition, normal, nonmitotic tissues were affected by the adenovirus-mediated HSV-TK transfer and subsequent GCV administration (23).Cytosine Deaminase GeneCytosine deaminase is a nontoxic gene present in some fungi and bacteria.", [["hepatic", "ANATOMY", 4, 11], ["liver", "ANATOMY", 46, 51], ["nonmitotic tissues", "ANATOMY", 129, 147], ["liver dysfunction", "DISEASE", 46, 63], ["GCV", "CHEMICAL", 83, 86], ["GCV", "CHEMICAL", 220, 223], ["Cytosine", "CHEMICAL", 244, 252], ["GeneCytosine", "CHEMICAL", 263, 275], ["GCV", "CHEMICAL", 83, 86], ["GCV", "CHEMICAL", 220, 223], ["Cytosine", "CHEMICAL", 244, 252], ["GeneCytosine", "CHEMICAL", 263, 275], ["HSV", "ORGANISM", 12, 15], ["liver", "ORGAN", 46, 51], ["GCV", "SIMPLE_CHEMICAL", 83, 86], ["nonmitotic tissues", "TISSUE", 129, 147], ["adenovirus", "ORGANISM", 169, 179], ["HSV", "ORGANISM", 189, 192], ["GCV", "SIMPLE_CHEMICAL", 220, 223], ["Cytosine Deaminase GeneCytosine deaminase", "GENE_OR_GENE_PRODUCT", 244, 285], ["Cytosine Deaminase GeneCytosine deaminase", "PROTEIN", 244, 285], ["The hepatic HSV", "TEST", 0, 15], ["severe liver dysfunction", "PROBLEM", 39, 63], ["GCV administration", "TREATMENT", 83, 101], ["the adenovirus", "TEST", 165, 179], ["subsequent GCV administration", "TREATMENT", 209, 238], ["Cytosine Deaminase GeneCytosine deaminase", "TREATMENT", 244, 285], ["a nontoxic gene", "PROBLEM", 289, 304], ["some fungi", "PROBLEM", 316, 326], ["bacteria", "PROBLEM", 331, 339], ["hepatic", "ANATOMY", 4, 11], ["HSV", "OBSERVATION", 12, 15], ["severe", "OBSERVATION_MODIFIER", 39, 45], ["liver", "ANATOMY", 46, 51], ["dysfunction", "OBSERVATION", 52, 63], ["normal", "OBSERVATION", 121, 127], ["bacteria", "OBSERVATION", 331, 339]]], ["The gene plays a role in the conversion of cytosine to uracil.", [["cytosine", "CHEMICAL", 43, 51], ["uracil", "CHEMICAL", 55, 61], ["cytosine", "CHEMICAL", 43, 51], ["uracil", "CHEMICAL", 55, 61], ["cytosine", "SIMPLE_CHEMICAL", 43, 51], ["uracil", "SIMPLE_CHEMICAL", 55, 61], ["cytosine to uracil", "TREATMENT", 43, 61]]], ["Cells containing this gene can convert 5-fluorocytosine (5-FC) into the cytotoxic chemotherapeutic reagent 5-fluorouracil (5-FU).", [["Cells", "ANATOMY", 0, 5], ["5-fluorocytosine", "CHEMICAL", 39, 55], ["5-FC", "CHEMICAL", 57, 61], ["5-fluorouracil", "CHEMICAL", 107, 121], ["5-FU", "CHEMICAL", 123, 127], ["5-fluorocytosine", "CHEMICAL", 39, 55], ["5-FC", "CHEMICAL", 57, 61], ["5-fluorouracil", "CHEMICAL", 107, 121], ["5-FU", "CHEMICAL", 123, 127], ["Cells", "CELL", 0, 5], ["5-fluorocytosine", "SIMPLE_CHEMICAL", 39, 55], ["5-FC", "SIMPLE_CHEMICAL", 57, 61], ["5-fluorouracil", "SIMPLE_CHEMICAL", 107, 121], ["5-FU", "SIMPLE_CHEMICAL", 123, 127], ["fluorocytosine", "TREATMENT", 41, 55], ["the cytotoxic chemotherapeutic reagent", "TREATMENT", 68, 106], ["fluorouracil", "TREATMENT", 109, 121]]], ["The Escherichia coli CD gene is currently being used as a suicide gene so that genetically modified cells \"commit suicide\" in the presence of 5-FC.Cytosine Deaminase GeneThe CD gene has been used with an AFP promoter to kill AFP-positive HCC cell lines in the presence of 5-FC (6).", [["cells", "ANATOMY", 100, 105], ["AFP-positive HCC cell lines", "ANATOMY", 225, 252], ["5-FC", "CHEMICAL", 142, 146], ["Cytosine", "CHEMICAL", 147, 155], ["HCC", "DISEASE", 238, 241], ["5-FC", "CHEMICAL", 272, 276], ["Cytosine", "CHEMICAL", 147, 155], ["5-FC", "CHEMICAL", 272, 276], ["Escherichia coli", "ORGANISM", 4, 20], ["CD", "GENE_OR_GENE_PRODUCT", 21, 23], ["cells", "CELL", 100, 105], ["Cytosine Deaminase", "GENE_OR_GENE_PRODUCT", 147, 165], ["CD", "GENE_OR_GENE_PRODUCT", 174, 176], ["AFP", "GENE_OR_GENE_PRODUCT", 204, 207], ["AFP", "GENE_OR_GENE_PRODUCT", 225, 228], ["HCC cell lines", "CELL", 238, 252], ["Escherichia coli CD gene", "DNA", 4, 28], ["suicide gene", "DNA", 58, 70], ["genetically modified cells", "CELL_LINE", 79, 105], ["Cytosine Deaminase Gene", "DNA", 147, 170], ["CD gene", "DNA", 174, 181], ["AFP promoter", "DNA", 204, 216], ["AFP-positive HCC cell lines", "CELL_LINE", 225, 252], ["Escherichia coli", "SPECIES", 4, 20], ["Escherichia coli", "SPECIES", 4, 20], ["The Escherichia coli CD gene", "TREATMENT", 0, 28], ["a suicide gene", "TREATMENT", 56, 70], ["Cytosine Deaminase GeneThe CD gene", "TREATMENT", 147, 181], ["an AFP promoter", "TREATMENT", 201, 216], ["AFP", "TEST", 225, 228], ["positive HCC cell lines", "PROBLEM", 229, 252], ["Escherichia coli CD", "OBSERVATION", 4, 23], ["HCC cell lines", "OBSERVATION", 238, 252]]], ["A bystander effect occurred irrespective of cell-tocell contact with transduced cells.", [["cell", "ANATOMY", 44, 48], ["tocell", "ANATOMY", 49, 55], ["cells", "ANATOMY", 80, 85], ["cell", "CELL", 44, 48], ["cells", "CELL", 80, 85], ["transduced cells", "CELL_LINE", 69, 85], ["A bystander effect", "PROBLEM", 0, 18], ["transduced cells", "TREATMENT", 69, 85], ["transduced cells", "OBSERVATION", 69, 85]]], ["On cell lysis, 5-FU is released into the medium and is thus likely to be responsible for the bystander effect, and, indeed, the 5-FU levels in the medium correlated well with the degree of cytotoxicity (24).", [["cell", "ANATOMY", 3, 7], ["5-FU", "CHEMICAL", 15, 19], ["5-FU", "CHEMICAL", 128, 132], ["5-FU", "CHEMICAL", 15, 19], ["5-FU", "CHEMICAL", 128, 132], ["cell", "CELL", 3, 7], ["5-FU", "SIMPLE_CHEMICAL", 15, 19], ["5-FU", "SIMPLE_CHEMICAL", 128, 132], ["cell lysis", "TREATMENT", 3, 13], ["FU levels", "TEST", 130, 139], ["cytotoxicity", "PROBLEM", 189, 201], ["cell lysis", "OBSERVATION", 3, 13], ["thus likely to be responsible", "UNCERTAINTY", 55, 84], ["cytotoxicity", "OBSERVATION", 189, 201]]], ["AFP-positive HCC tumors that have been established subcutaneously in vivo have been shown to regress significantly after adenoviral-mediated insertion of the CD gene (with an AFP promoter) and subsequent 5-FC administration, and in one study, nontumor tissue was unaffected (6).", [["HCC tumors", "ANATOMY", 13, 23], ["subcutaneously", "ANATOMY", 51, 65], ["nontumor tissue", "ANATOMY", 243, 258], ["HCC tumors", "DISEASE", 13, 23], ["5-FC", "CHEMICAL", 204, 208], ["5-FC", "CHEMICAL", 204, 208], ["AFP", "GENE_OR_GENE_PRODUCT", 0, 3], ["HCC tumors", "CANCER", 13, 23], ["adenoviral", "ORGANISM", 121, 131], ["CD", "GENE_OR_GENE_PRODUCT", 158, 160], ["AFP", "GENE_OR_GENE_PRODUCT", 175, 178], ["5-FC", "SIMPLE_CHEMICAL", 204, 208], ["nontumor tissue", "TISSUE", 243, 258], ["AFP", "PROTEIN", 0, 3], ["CD gene", "DNA", 158, 165], ["AFP promoter", "DNA", 175, 187], ["AFP", "TEST", 0, 3], ["positive HCC tumors", "PROBLEM", 4, 23], ["adenoviral-mediated insertion of the CD gene", "TREATMENT", 121, 165], ["an AFP promoter", "TREATMENT", 172, 187], ["subsequent 5-FC administration", "TREATMENT", 193, 223], ["one study", "TEST", 232, 241], ["positive", "OBSERVATION_MODIFIER", 4, 12], ["HCC", "OBSERVATION_MODIFIER", 13, 16], ["tumors", "OBSERVATION", 17, 23], ["nontumor tissue", "OBSERVATION", 243, 258]]], ["Block Sung et al. have recently published the result of a phase I clinical trial using intratumoral injection of escalating doses of adenovirus-mediated suicide gene followed by intravenous GCV at a fixed dose in patients with colorectal liver metastases (13).", [["intravenous", "ANATOMY", 178, 189], ["colorectal liver metastases", "ANATOMY", 227, 254], ["GCV", "CHEMICAL", 190, 193], ["colorectal liver metastases", "DISEASE", 227, 254], ["GCV", "CHEMICAL", 190, 193], ["adenovirus", "ORGANISM", 133, 143], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 178, 189], ["GCV", "SIMPLE_CHEMICAL", 190, 193], ["patients", "ORGANISM", 213, 221], ["colorectal liver", "CANCER", 227, 243], ["adenovirus-mediated suicide gene", "DNA", 133, 165], ["patients", "SPECIES", 213, 221], ["intratumoral injection", "TREATMENT", 87, 109], ["adenovirus-mediated suicide gene", "TREATMENT", 133, 165], ["intravenous GCV", "TREATMENT", 178, 193], ["a fixed dose", "TREATMENT", 197, 209], ["colorectal liver metastases", "PROBLEM", 227, 254], ["liver", "ANATOMY", 238, 243], ["metastases", "OBSERVATION", 244, 254]]], ["The aim was to assess the safety and maximal tolerated dosage of Adv.RSV-TK. The vector was infected into a metastatic tumor in the liver under local anaethesia and ultrasound guidance.", [["metastatic tumor", "ANATOMY", 108, 124], ["liver", "ANATOMY", 132, 137], ["Adv", "CHEMICAL", 65, 68], ["tumor", "DISEASE", 119, 124], ["Adv", "SIMPLE_CHEMICAL", 65, 68], ["RSV", "ORGANISM", 69, 72], ["tumor", "CANCER", 119, 124], ["liver", "ORGAN", 132, 137], ["RSV", "SPECIES", 69, 72], ["RSV", "TEST", 69, 72], ["The vector", "TREATMENT", 77, 87], ["a metastatic tumor in the liver", "PROBLEM", 106, 137], ["local anaethesia", "TREATMENT", 144, 160], ["ultrasound guidance", "TEST", 165, 184], ["TK", "ANATOMY", 73, 75], ["metastatic", "OBSERVATION_MODIFIER", 108, 118], ["tumor", "OBSERVATION", 119, 124], ["liver", "ANATOMY", 132, 137]]], ["A total of 16 patients were entered into the trial who received five dose-level cohorts of Adv.RSV-TK, from 1.0 \u00d7 10 10 to 1.0 \u00d7 10 13 virus particles per patient.", [["patients", "ORGANISM", 14, 22], ["RSV", "ORGANISM", 95, 98], ["patient", "ORGANISM", 155, 162], ["patients", "SPECIES", 14, 22], ["patient", "SPECIES", 155, 162], ["RSV", "SPECIES", 95, 98], ["RSV", "TEST", 95, 98], ["TK", "TEST", 99, 101], ["TK", "ANATOMY", 99, 101]]], ["The response rate was assessed by World Health Organization (WHO) criteria with follow-up imaging studies.", [["The response rate", "TEST", 0, 17], ["follow-up imaging studies", "TEST", 80, 105]]], ["The assessment of toxicity was carried out according to Common Toxicity Criteria v. 2.0 from the National Cancer Institute (Bethesda, MD).", [["toxicity", "DISEASE", 18, 26], ["Toxicity", "DISEASE", 63, 71], ["Cancer", "DISEASE", 106, 112], ["The assessment", "TEST", 0, 14], ["toxicity", "PROBLEM", 18, 26]]], ["One patient was withdrawn from the study because of clinical deterioration from disease and died.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["the study", "TEST", 31, 40], ["clinical deterioration", "PROBLEM", 52, 74], ["disease", "PROBLEM", 80, 87]]], ["Stable disease (defined as < 25% change in the size of the tumor measured on computed tomography [CT] or magnetic resonance imaging [MRI]) was seen in 11 patients.", [["tumor", "ANATOMY", 59, 64], ["tumor", "DISEASE", 59, 64], ["tumor", "CANCER", 59, 64], ["patients", "ORGANISM", 154, 162], ["patients", "SPECIES", 154, 162], ["Stable disease", "PROBLEM", 0, 14], ["the tumor", "PROBLEM", 55, 64], ["computed tomography", "TEST", 77, 96], ["CT", "TEST", 98, 100], ["magnetic resonance imaging", "TEST", 105, 131], ["MRI", "TEST", 133, 136], ["disease", "OBSERVATION", 7, 14], ["size", "OBSERVATION_MODIFIER", 47, 51], ["tumor", "OBSERVATION", 59, 64]]], ["One patient had a biopsy of the injected tumor at 11 wk following treatment that revealed extensive necrosis of the tumor on histology, whereas five others had a biopsy taken at the later date but showed no evidence of necrosis.", [["tumor", "ANATOMY", 41, 46], ["tumor", "ANATOMY", 116, 121], ["tumor", "DISEASE", 41, 46], ["necrosis", "DISEASE", 100, 108], ["tumor", "DISEASE", 116, 121], ["necrosis", "DISEASE", 219, 227], ["patient", "ORGANISM", 4, 11], ["tumor", "CANCER", 41, 46], ["tumor", "CANCER", 116, 121], ["patient", "SPECIES", 4, 11], ["a biopsy", "TEST", 16, 24], ["the injected tumor", "PROBLEM", 28, 46], ["treatment", "TREATMENT", 66, 75], ["extensive necrosis of the tumor", "PROBLEM", 90, 121], ["histology", "TEST", 125, 134], ["a biopsy", "TEST", 160, 168], ["necrosis", "PROBLEM", 219, 227], ["tumor", "OBSERVATION", 41, 46], ["extensive", "OBSERVATION_MODIFIER", 90, 99], ["necrosis", "OBSERVATION", 100, 108], ["tumor", "OBSERVATION", 116, 121], ["no evidence of", "UNCERTAINTY", 204, 218], ["necrosis", "OBSERVATION", 219, 227]]], ["Adv.RSV-TK DNA was not detected in any of these six biopsed specimen.", [["specimen", "ANATOMY", 60, 68], ["Adv", "GENE_OR_GENE_PRODUCT", 0, 3], ["RSV", "ORGANISM", 4, 7], ["DNA", "CELLULAR_COMPONENT", 11, 14], ["Adv", "DNA", 0, 3], ["RSV-TK DNA", "DNA", 4, 14], ["RSV", "SPECIES", 4, 7], ["RSV-TK DNA", "TEST", 4, 14], ["these six biopsed specimen", "TEST", 42, 68], ["TK", "ANATOMY", 8, 10]]], ["Low transient toxicities were present in patients including grade 1 elevations in serum aminotransferase in three patients, grade 2-3 fevers in five patients, grade 3 thrombocytopenia in one patient, and grade 2 leucopenia in three patients.", [["serum", "ANATOMY", 82, 87], ["toxicities", "DISEASE", 14, 24], ["fevers", "DISEASE", 134, 140], ["thrombocytopenia", "DISEASE", 167, 183], ["leucopenia", "DISEASE", 212, 222], ["patients", "ORGANISM", 41, 49], ["serum", "ORGANISM_SUBSTANCE", 82, 87], ["aminotransferase", "SIMPLE_CHEMICAL", 88, 104], ["patients", "ORGANISM", 114, 122], ["patients", "ORGANISM", 149, 157], ["patient", "ORGANISM", 191, 198], ["patients", "ORGANISM", 232, 240], ["serum aminotransferase", "PROTEIN", 82, 104], ["patients", "SPECIES", 41, 49], ["patients", "SPECIES", 114, 122], ["patients", "SPECIES", 149, 157], ["patient", "SPECIES", 191, 198], ["patients", "SPECIES", 232, 240], ["Low transient toxicities", "PROBLEM", 0, 24], ["grade 1 elevations", "PROBLEM", 60, 78], ["serum aminotransferase", "TEST", 82, 104], ["grade 2-3 fevers", "PROBLEM", 124, 140], ["grade 3 thrombocytopenia", "PROBLEM", 159, 183], ["grade 2 leucopenia", "PROBLEM", 204, 222], ["transient", "OBSERVATION_MODIFIER", 4, 13], ["toxicities", "OBSERVATION", 14, 24], ["elevations", "OBSERVATION_MODIFIER", 68, 78], ["fevers", "OBSERVATION", 134, 140], ["grade 3", "OBSERVATION_MODIFIER", 159, 166], ["thrombocytopenia", "OBSERVATION", 167, 183], ["grade 2", "OBSERVATION_MODIFIER", 204, 211], ["leucopenia", "OBSERVATION", 212, 222]]], ["One patient is alive at 40.5 mo, but the remaining 15 died between 0.2 and 36.5 mo (median: 11.3 mo).", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11]]], ["The authors concluded that adv.RSV-TK could be safely administered by percutaneous intratumoral injection in patients with hepatic metastases at doses up to 1.0 \u00d7 10 13 virus particles per patient and could provide the basis for future clinical trials.", [["percutaneous", "ANATOMY", 70, 82], ["hepatic metastases", "ANATOMY", 123, 141], ["hepatic metastases", "DISEASE", 123, 141], ["RSV", "ORGANISM", 31, 34], ["intratumoral", "IMMATERIAL_ANATOMICAL_ENTITY", 83, 95], ["patients", "ORGANISM", 109, 117], ["hepatic", "ORGAN", 123, 130], ["patient", "ORGANISM", 189, 196], ["adv", "DNA", 27, 30], ["patients", "SPECIES", 109, 117], ["patient", "SPECIES", 189, 196], ["RSV", "SPECIES", 31, 34], ["RSV", "PROBLEM", 31, 34], ["percutaneous intratumoral injection", "TREATMENT", 70, 105], ["hepatic metastases", "PROBLEM", 123, 141], ["hepatic", "ANATOMY", 123, 130], ["metastases", "OBSERVATION", 131, 141]]], ["However, the trial did not demonstrate any tumor reponse following intratumoural injection of adv.RSV-TK.Cytosine Deaminase GeneA phase I clinical trial using a replication-deficient adenovirus to deliver the CD gene to metastatic colonic cancer of the liver has been initiated (12).", [["tumor", "ANATOMY", 43, 48], ["intratumoural", "ANATOMY", 67, 80], ["metastatic colonic cancer", "ANATOMY", 220, 245], ["liver", "ANATOMY", 253, 258], ["tumor", "DISEASE", 43, 48], ["Cytosine", "CHEMICAL", 105, 113], ["colonic cancer of the liver", "DISEASE", 231, 258], ["Cytosine", "CHEMICAL", 105, 113], ["tumor", "CANCER", 43, 48], ["RSV", "ORGANISM", 98, 101], ["adenovirus", "ORGANISM", 183, 193], ["CD", "GENE_OR_GENE_PRODUCT", 209, 211], ["colonic cancer", "CANCER", 231, 245], ["liver", "ORGAN", 253, 258], ["adv", "PROTEIN", 94, 97], ["CD gene", "DNA", 209, 216], ["RSV", "SPECIES", 98, 101], ["adenovirus", "SPECIES", 183, 193], ["any tumor reponse", "PROBLEM", 39, 56], ["intratumoural injection of adv", "TREATMENT", 67, 97], ["RSV", "TEST", 98, 101], ["Cytosine Deaminase GeneA phase", "TREATMENT", 105, 135], ["a replication-deficient adenovirus", "TREATMENT", 159, 193], ["the CD gene", "TREATMENT", 205, 216], ["metastatic colonic cancer of the liver", "PROBLEM", 220, 258], ["tumor", "OBSERVATION", 43, 48], ["TK", "ANATOMY", 102, 104], ["metastatic", "OBSERVATION_MODIFIER", 220, 230], ["colonic", "ANATOMY", 231, 238], ["cancer", "OBSERVATION", 239, 245], ["liver", "ANATOMY", 253, 258]]], ["The patients are being treated with a direct intratumoral injection of the CD vector in combination with oral 5-FU.Protocol 3.1.", [["intratumoral", "ANATOMY", 45, 57], ["oral", "ANATOMY", 105, 109], ["5-FU", "CHEMICAL", 110, 114], ["5-FU", "CHEMICAL", 110, 114], ["patients", "ORGANISM", 4, 12], ["oral", "ORGANISM_SUBDIVISION", 105, 109], ["5-FU", "SIMPLE_CHEMICAL", 110, 114], ["patients", "SPECIES", 4, 12], ["a direct intratumoral injection", "TREATMENT", 36, 67], ["the CD vector", "TREATMENT", 71, 84], ["oral 5-FU", "TREATMENT", 105, 114], ["Protocol", "TEST", 115, 123]]], ["IntroductionTo safeguard the development of human gene therapy for clinical application, various countries have now established regulatory bodies for gene therapy to ensure safety and benefit for humankind.", [["human", "ORGANISM", 44, 49], ["human", "SPECIES", 44, 49], ["human", "SPECIES", 44, 49], ["human gene therapy", "TREATMENT", 44, 62], ["clinical application", "TREATMENT", 67, 87], ["gene therapy", "TREATMENT", 150, 162]]], ["In the United States, federal guidelines for research involving recombinant DNA molecules were issued in 1976.", [["DNA", "CELLULAR_COMPONENT", 76, 79], ["recombinant DNA molecules", "PROTEIN", 64, 89], ["federal guidelines", "TREATMENT", 22, 40], ["research involving recombinant DNA molecules", "PROBLEM", 45, 89]]], ["The guidelines require that institutions establish an institutional biosafety committee to monitor the use of recombinant DNA in the laboratory, in micro-organisms, in animals, and in humans.", [["DNA", "CELLULAR_COMPONENT", 122, 125], ["humans", "ORGANISM", 184, 190], ["humans", "SPECIES", 184, 190], ["humans", "SPECIES", 184, 190], ["recombinant DNA", "TREATMENT", 110, 125]]], ["There are a number of approvals that are required for a proposed human clinical gene therapy trial to be approved and allow patient accrual.", [["human", "ORGANISM", 65, 70], ["patient", "ORGANISM", 124, 131], ["human", "SPECIES", 65, 70], ["patient", "SPECIES", 124, 131], ["human", "SPECIES", 65, 70], ["a proposed human clinical gene therapy trial", "TREATMENT", 54, 98]]], ["In the United Kingdom, the Gene Therapy Advisory Committee (GTAC) together with the Medicines Control Agency (MCA) are established to evaluate proposals for human gene therapy.", [["human", "ORGANISM", 157, 162], ["human", "SPECIES", 157, 162], ["human", "SPECIES", 157, 162], ["the Gene Therapy Advisory Committee (GTAC)", "TREATMENT", 23, 65], ["the Medicines", "TREATMENT", 80, 93], ["human gene therapy", "TREATMENT", 157, 175]]], ["The creation of the European Medicines Evaluation Agency (EMEA) has standardized approaches across European countires.", [["the European Medicines", "TREATMENT", 16, 38]]], ["In the United States, guidelines have been drawn up by the Recombinant DNA Advisory Committee (RAC) of the National Institutes of Health to facilitate documentation, review, and discussion on human gene therapy.", [["human", "ORGANISM", 192, 197], ["human", "SPECIES", 192, 197], ["human", "SPECIES", 192, 197], ["human gene therapy", "TREATMENT", 192, 210]]], ["In addition, each of the vector delivery systems used in human gene transfer trials is considered a biologic and requires the filing of an investigation new drug application for each specific vector.Aims1.", [["human", "ORGANISM", 57, 62], ["Aims1", "DNA", 199, 204], ["human", "SPECIES", 57, 62], ["human", "SPECIES", 57, 62], ["the vector delivery systems", "TREATMENT", 21, 48], ["human gene transfer trials", "TREATMENT", 57, 83], ["an investigation new drug application", "TREATMENT", 136, 173]]], ["To assess the safety of direct intratumoural injection of Ad-TK followed by GCV administration 2.", [["intratumoural", "ANATOMY", 31, 44], ["Ad-TK", "CHEMICAL", 58, 63], ["GCV", "CHEMICAL", 76, 79], ["GCV", "CHEMICAL", 76, 79], ["Ad", "ORGANISM", 58, 60], ["GCV", "SIMPLE_CHEMICAL", 76, 79], ["direct intratumoural injection", "TREATMENT", 24, 54], ["Ad-TK", "TREATMENT", 58, 63], ["GCV administration", "TREATMENT", 76, 94]]], ["To assess the efficacy of intratumoral injection of Ad-TK followed by GCV administration, and to compare this treatment with standard treatment of percutaneous ethanol injection alone in groups of patients with irresectable hepatocellular carcinoma.", [["intratumoral", "ANATOMY", 26, 38], ["percutaneous", "ANATOMY", 147, 159], ["hepatocellular carcinoma", "ANATOMY", 224, 248], ["Ad-TK", "CHEMICAL", 52, 57], ["GCV", "CHEMICAL", 70, 73], ["ethanol", "CHEMICAL", 160, 167], ["hepatocellular carcinoma", "DISEASE", 224, 248], ["GCV", "CHEMICAL", 70, 73], ["ethanol", "CHEMICAL", 160, 167], ["Ad", "ORGANISM", 52, 54], ["GCV", "SIMPLE_CHEMICAL", 70, 73], ["ethanol", "SIMPLE_CHEMICAL", 160, 167], ["patients", "ORGANISM", 197, 205], ["hepatocellular carcinoma", "CANCER", 224, 248], ["patients", "SPECIES", 197, 205], ["intratumoral injection", "TREATMENT", 26, 48], ["Ad-TK", "TREATMENT", 52, 57], ["GCV administration", "TREATMENT", 70, 88], ["this treatment", "TREATMENT", 105, 119], ["standard treatment of percutaneous ethanol injection", "TREATMENT", 125, 177], ["irresectable hepatocellular carcinoma", "PROBLEM", 211, 248], ["irresectable", "OBSERVATION_MODIFIER", 211, 223], ["hepatocellular carcinoma", "OBSERVATION", 224, 248]]], ["To study the biological efficacy, including the efficiency and stability of gene transfer by analysis of tumor tissue following therapy.", [["tumor tissue", "ANATOMY", 105, 117], ["tumor", "DISEASE", 105, 110], ["tumor tissue", "TISSUE", 105, 117], ["tumor tissue", "PROBLEM", 105, 117], ["therapy", "TREATMENT", 128, 135], ["tumor", "OBSERVATION", 105, 110]]], ["The clinical evidence of antitumor efficacy will also be noted.", [["antitumor", "ANATOMY", 25, 34], ["antitumor", "CANCER", 25, 34], ["antitumor efficacy", "PROBLEM", 25, 43], ["antitumor efficacy", "OBSERVATION", 25, 43]]], ["To seek to identify dose level by injecting Ad-TK at differing dose levels in successive cohorts of patients.BackgroundLive, wild-type (nonrecombinant) adenoviruses have been used clinically as vaccines for the prophylaxis of adenoviral upper respiratory infections, a disease of low morbidity but high incidence.", [["respiratory", "ANATOMY", 243, 254], ["upper respiratory infections", "DISEASE", 237, 265], ["Ad", "ORGANISM", 44, 46], ["patients", "ORGANISM", 100, 108], ["adenoviruses", "ORGANISM", 152, 164], ["adenoviral", "ORGANISM", 226, 236], ["patients", "SPECIES", 100, 108], ["adenoviral", "SPECIES", 226, 236], ["wild-type (nonrecombinant) adenoviruses", "PROBLEM", 125, 164], ["vaccines", "TREATMENT", 194, 202], ["adenoviral upper respiratory infections", "PROBLEM", 226, 265], ["a disease of low morbidity", "PROBLEM", 267, 293], ["upper", "ANATOMY_MODIFIER", 237, 242], ["respiratory", "ANATOMY", 243, 254], ["infections", "OBSERVATION", 255, 265], ["low morbidity", "OBSERVATION_MODIFIER", 280, 293]]], ["These vaccines, which were at one time given routinely to military recruits, are well tolerated and are considered nononcogenic.", [["These vaccines", "TREATMENT", 0, 14], ["nononcogenic", "PROBLEM", 115, 127]]], ["Recombinant versions of the adenovirus have entered clinical trials both as injections and as oral vaccines (26).", [["oral", "ANATOMY", 94, 98], ["adenovirus", "ORGANISM", 28, 38], ["oral", "ORGANISM_SUBDIVISION", 94, 98], ["the adenovirus", "TREATMENT", 24, 38], ["clinical trials", "TREATMENT", 52, 67], ["oral vaccines", "TREATMENT", 94, 107]]], ["Thus far, they appear to be without significant toxicity.", [["toxicity", "DISEASE", 48, 56], ["significant toxicity", "PROBLEM", 36, 56], ["appear to be without", "UNCERTAINTY", 15, 35], ["significant", "OBSERVATION_MODIFIER", 36, 47], ["toxicity", "OBSERVATION", 48, 56]]], ["Recently, clinical trials using recombinant, replication-defective adenoviral vectors for gene therapy have been initiated.", [["adenoviral", "ORGANISM", 67, 77], ["replication-defective adenoviral vectors", "TREATMENT", 45, 85], ["gene therapy", "TREATMENT", 90, 102]]], ["In these studies, recombinant adenoviral vectors carrying the gene for cystic fibrosis transmembrane conductance regulator (CFTR) are given via intraairway administration to patients with cystic fibrosis.BackgroundTursz at the Gustave Roussy Institut, Paris, initiated a phase I study to evaluate the feasibility, safety, and clinical effects of the intratumor administration of a recombinant-deficient adenovirus containing the marker gene encoding the E. coli enzyme \u03b2galactosidase (Ad-\u03b2-Gal) in untreated patients with advanced lung cancer (27).", [["cystic", "ANATOMY", 188, 194], ["intratumor", "ANATOMY", 350, 360], ["lung cancer", "ANATOMY", 531, 542], ["fibrosis", "DISEASE", 78, 86], ["cystic fibrosis", "DISEASE", 188, 203], ["BackgroundTursz", "CHEMICAL", 204, 219], ["Ad-\u03b2-Gal", "CHEMICAL", 485, 493], ["lung cancer", "DISEASE", 531, 542], ["adenoviral", "ORGANISM", 30, 40], ["cystic fibrosis transmembrane conductance regulator", "GENE_OR_GENE_PRODUCT", 71, 122], ["CFTR", "GENE_OR_GENE_PRODUCT", 124, 128], ["patients", "ORGANISM", 174, 182], ["intratumor", "CANCER", 350, 360], ["adenovirus", "ORGANISM", 403, 413], ["E. coli", "ORGANISM", 454, 461], ["Ad-\u03b2-Gal", "GENE_OR_GENE_PRODUCT", 485, 493], ["patients", "ORGANISM", 508, 516], ["lung cancer", "CANCER", 531, 542], ["cystic fibrosis transmembrane conductance regulator", "PROTEIN", 71, 122], ["CFTR", "PROTEIN", 124, 128], ["marker gene", "DNA", 429, 440], ["E. coli enzyme \u03b2galactosidase", "PROTEIN", 454, 483], ["Ad-\u03b2-Gal", "PROTEIN", 485, 493], ["patients", "SPECIES", 174, 182], ["E. coli", "SPECIES", 454, 461], ["patients", "SPECIES", 508, 516], ["E. coli", "SPECIES", 454, 461], ["these studies", "TEST", 3, 16], ["recombinant adenoviral vectors", "TREATMENT", 18, 48], ["cystic fibrosis transmembrane conductance regulator", "PROBLEM", 71, 122], ["intraairway administration", "TREATMENT", 144, 170], ["cystic fibrosis", "PROBLEM", 188, 203], ["a phase I study", "TEST", 269, 284], ["the intratumor administration", "TREATMENT", 346, 375], ["a recombinant-deficient adenovirus", "TREATMENT", 379, 413], ["the E. coli enzyme \u03b2galactosidase", "TEST", 450, 483], ["advanced lung cancer", "PROBLEM", 522, 542], ["cystic", "OBSERVATION_MODIFIER", 71, 77], ["fibrosis", "OBSERVATION", 78, 86], ["cystic", "OBSERVATION_MODIFIER", 188, 194], ["fibrosis", "OBSERVATION", 195, 203], ["advanced", "OBSERVATION_MODIFIER", 522, 530], ["lung", "ANATOMY", 531, 535], ["cancer", "OBSERVATION", 536, 542]]], ["The first dose level was 10 7 , the second was 10 8 , and the third was 10 9 pfu (plaque-forming units) (three patients per dose level).", [["plaque", "ANATOMY", 82, 88], ["patients", "ORGANISM", 111, 119], ["patients", "SPECIES", 111, 119], ["The first dose level", "TEST", 0, 20], ["plaque", "TEST", 82, 88]]], ["All patients received concomitant chemotherapy. \u03b2-Gal express (X-Gal) staining was observed in three out of six tumor biopsies.", [["tumor biopsies", "ANATOMY", 112, 126], ["tumor", "DISEASE", 112, 117], ["patients", "ORGANISM", 4, 12], ["\u03b2-Gal", "GENE_OR_GENE_PRODUCT", 48, 53], ["X-Gal", "GENE_OR_GENE_PRODUCT", 63, 68], ["tumor biopsies", "CANCER", 112, 126], ["patients", "SPECIES", 4, 12], ["concomitant chemotherapy", "TREATMENT", 22, 46], ["tumor biopsies", "TEST", 112, 126], ["chemotherapy", "OBSERVATION", 34, 46], ["tumor", "OBSERVATION", 112, 117]]], ["The microbiological and immunological follow-up of patients who were carriers of wildtype adenovirus before injection.", [["patients", "ORGANISM", 51, 59], ["wildtype adenovirus", "ORGANISM", 81, 100], ["patients", "SPECIES", 51, 59], ["wildtype adenovirus", "TREATMENT", 81, 100]]], ["Only viral cultures of bronchoalveolar (BAL) specimens taken immediately after Ad-\u03b2-Gal injection were positive in all patients.", [["bronchoalveolar", "ANATOMY", 23, 38], ["BAL", "ANATOMY", 40, 43], ["specimens", "ANATOMY", 45, 54], ["bronchoalveolar", "MULTI-TISSUE_STRUCTURE", 23, 38], ["Ad", "ORGANISM", 79, 81], ["-\u03b2-Gal", "GENE_OR_GENE_PRODUCT", 81, 87], ["patients", "ORGANISM", 119, 127], ["patients", "SPECIES", 119, 127], ["Ad", "SPECIES", 79, 81], ["viral cultures", "TEST", 5, 19], ["bronchoalveolar (BAL) specimens", "TEST", 23, 54], ["Ad-\u03b2-Gal injection", "TREATMENT", 79, 97], ["bronchoalveolar", "ANATOMY", 23, 38]]], ["All body-fluid specimens were positive at polymerase chain reaction (PCR) analysis within the first 10 d after injection, as were blood samples drawn 30 min after injection in three patients at the second dose level.", [["body-fluid specimens", "ANATOMY", 4, 24], ["blood samples", "ANATOMY", 130, 143], ["body-fluid specimens", "ORGANISM_SUBSTANCE", 4, 24], ["blood samples", "ORGANISM_SUBSTANCE", 130, 143], ["patients", "ORGANISM", 182, 190], ["patients", "SPECIES", 182, 190], ["All body-fluid specimens", "TEST", 0, 24], ["polymerase chain reaction", "TEST", 42, 67], ["PCR) analysis", "TEST", 69, 82], ["blood samples", "TEST", 130, 143], ["body", "ANATOMY", 4, 8], ["fluid specimens", "OBSERVATION", 9, 24]]], ["BAL samples remained positive at 1 mo in two patients and at 3 mo in one patient after Ad-\u03b2-Gal injection.", [["BAL samples", "ANATOMY", 0, 11], ["Ad-\u03b2-Gal", "CHEMICAL", 87, 95], ["BAL samples", "CANCER", 0, 11], ["patients", "ORGANISM", 45, 53], ["patient", "ORGANISM", 73, 80], ["Ad", "ORGANISM", 87, 89], ["-\u03b2-Gal", "GENE_OR_GENE_PRODUCT", 89, 95], ["patients", "SPECIES", 45, 53], ["patient", "SPECIES", 73, 80], ["Ad", "SPECIES", 87, 89], ["BAL samples", "TEST", 0, 11], ["Ad-\u03b2-Gal injection", "TREATMENT", 87, 105]]], ["No antibody (Ab) response to \u03b2-Gal was noted in patients, but four had a significant rise in their antiadenovirus Ab titers.", [["\u03b2-Gal", "GENE_OR_GENE_PRODUCT", 29, 34], ["patients", "ORGANISM", 48, 56], ["Ab", "GENE_OR_GENE_PRODUCT", 114, 116], ["antibody (Ab)", "PROTEIN", 3, 16], ["\u03b2-Gal", "PROTEIN", 29, 34], ["antiadenovirus Ab", "PROTEIN", 99, 116], ["patients", "SPECIES", 48, 56], ["antibody (Ab)", "TEST", 3, 16], ["\u03b2-Gal", "TEST", 29, 34], ["a significant rise", "PROBLEM", 71, 89], ["their antiadenovirus Ab titers", "TEST", 93, 123], ["antibody", "OBSERVATION", 3, 11], ["significant", "OBSERVATION_MODIFIER", 73, 84], ["rise", "OBSERVATION_MODIFIER", 85, 89]]], ["All 363 samples (throat and stools) taken by the 54 medical staff before and after injection of patients were negative for wild-type adenovirus and Ad-\u03b2-Gal.", [["samples", "ANATOMY", 8, 15], ["throat", "ANATOMY", 17, 23], ["stools", "ANATOMY", 28, 34], ["throat", "ORGANISM_SUBDIVISION", 17, 23], ["stools", "ORGANISM_SUBDIVISION", 28, 34], ["patients", "ORGANISM", 96, 104], ["adenovirus", "ORGANISM", 133, 143], ["Ad", "ORGANISM", 148, 150], ["-\u03b2-Gal", "GENE_OR_GENE_PRODUCT", 150, 156], ["patients", "SPECIES", 96, 104], ["wild-type adenovirus", "PROBLEM", 123, 143], ["throat", "ANATOMY", 17, 23]]], ["Sera tests (CF) in 202 staff were also negative for antiadenovirus Ab titers.", [["Sera", "ORGANISM_SUBSTANCE", 0, 4], ["antiadenovirus Ab", "GENE_OR_GENE_PRODUCT", 52, 69], ["antiadenovirus Ab", "PROTEIN", 52, 69], ["Sera tests", "TEST", 0, 10], ["antiadenovirus Ab titers", "TEST", 52, 76]]], ["This study shows that a marker gene can be safely transferred into human tumor cells with a recombinant adenoviral vector.STUDY DESIGNThe study seeks to determine the safety, biological efficacy, and effect of the Ad-TK-GCV dose in the locoregional gene therapy of primary malignant tumors of the liver.", [["tumor cells", "ANATOMY", 73, 84], ["primary malignant tumors", "ANATOMY", 265, 289], ["liver", "ANATOMY", 297, 302], ["tumor", "DISEASE", 73, 78], ["GCV", "CHEMICAL", 220, 223], ["malignant tumors of the liver", "DISEASE", 273, 302], ["GCV", "CHEMICAL", 220, 223], ["human", "ORGANISM", 67, 72], ["tumor cells", "CELL", 73, 84], ["adenoviral", "ORGANISM", 104, 114], ["Ad", "ORGANISM", 214, 216], ["GCV", "SIMPLE_CHEMICAL", 220, 223], ["malignant tumors", "CANCER", 273, 289], ["liver", "ORGAN", 297, 302], ["marker gene", "DNA", 24, 35], ["human tumor cells", "CELL_TYPE", 67, 84], ["human", "SPECIES", 67, 72], ["human", "SPECIES", 67, 72], ["This study", "TEST", 0, 10], ["human tumor cells", "TREATMENT", 67, 84], ["a recombinant adenoviral vector", "TREATMENT", 90, 121], ["The study", "TEST", 134, 143], ["the Ad-TK-GCV dose", "TREATMENT", 210, 228], ["the locoregional gene therapy", "TREATMENT", 232, 261], ["primary malignant tumors of the liver", "PROBLEM", 265, 302], ["primary", "OBSERVATION_MODIFIER", 265, 272], ["malignant", "OBSERVATION_MODIFIER", 273, 282], ["tumors", "OBSERVATION", 283, 289], ["liver", "ANATOMY", 297, 302]]], ["The study design consists of an open-label, nonrandomized, dose-escalation phase I/II trial.", [["The study", "TEST", 0, 9], ["dose-escalation phase I/II trial", "TREATMENT", 59, 91]]], ["The Ad-TK will be administered by direct intratumoral injection under CT scan or ultrasound control.", [["intratumoral", "ANATOMY", 41, 53], ["Ad", "ORGANISM", 4, 6], ["The Ad-TK", "TREATMENT", 0, 9], ["direct intratumoral injection", "TREATMENT", 34, 63], ["CT scan", "TEST", 70, 77], ["ultrasound control", "TEST", 81, 99]]], ["The study will include sampling on one occasion of normal and malignant tissue from the livers of patients following Ad-TK-GCV treatment.", [["malignant tissue", "ANATOMY", 62, 78], ["livers", "ANATOMY", 88, 94], ["Ad-TK-", "CHEMICAL", 117, 123], ["GCV", "CHEMICAL", 123, 126], ["GCV", "CHEMICAL", 123, 126], ["malignant tissue", "TISSUE", 62, 78], ["livers", "ORGAN", 88, 94], ["patients", "ORGANISM", 98, 106], ["Ad", "ORGANISM", 117, 119], ["patients", "SPECIES", 98, 106], ["The study", "TEST", 0, 9], ["sampling", "TEST", 23, 31], ["Ad-TK-GCV treatment", "TREATMENT", 117, 136], ["normal", "OBSERVATION", 51, 57], ["malignant tissue", "OBSERVATION", 62, 78], ["livers", "ANATOMY", 88, 94]]], ["This will greatly facilitate assessments of clinical safety and biological efficacy, including efficiency and stability of gene transfer.", [["assessments", "TEST", 29, 40]]], ["Furthermore, sampling of treated tissues will require minimal additional morbidity for study patients.ROUTEThe replication-deficient adenovirus encoding for HSV-TK (Ad-TK) will be administered in 10 cm 3 of normal (0.9%) saline directly into the tumor under ultrasound or CT guidance.", [["tissues", "ANATOMY", 33, 40], ["tumor", "ANATOMY", 246, 251], ["tumor", "DISEASE", 246, 251], ["tissues", "TISSUE", 33, 40], ["patients", "ORGANISM", 93, 101], ["adenovirus", "ORGANISM", 133, 143], ["HSV-TK", "ORGANISM", 157, 163], ["Ad", "ORGANISM", 165, 167], ["-TK", "ORGANISM", 167, 170], ["saline", "SIMPLE_CHEMICAL", 221, 227], ["tumor", "CANCER", 246, 251], ["patients", "SPECIES", 93, 101], ["HSV-TK", "SPECIES", 157, 163], ["treated tissues", "PROBLEM", 25, 40], ["study patients", "TEST", 87, 101], ["ROUTEThe replication", "TREATMENT", 102, 122], ["deficient adenovirus", "TREATMENT", 123, 143], ["HSV", "PROBLEM", 157, 160], ["TK (Ad-TK)", "TREATMENT", 161, 171], ["normal (0.9%) saline", "TREATMENT", 207, 227], ["ultrasound", "TEST", 258, 268], ["CT guidance", "TEST", 272, 283], ["tumor", "OBSERVATION", 246, 251]]], ["Dose escalation will occur until the maximum tolerated level or dose level 1 \u00d7 10 11 pfu is achieved.", [["Dose escalation", "TREATMENT", 0, 15], ["dose level", "TEST", 64, 74]]], ["Thereafter, a further 10 patients will receive the maximum tolerated level.", [["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33]]], ["The GCV will be administered intravenously at 5 mg/kg/d, twice a day for 14 d.", [["intravenously", "ANATOMY", 29, 42], ["GCV", "CHEMICAL", 4, 7], ["GCV", "CHEMICAL", 4, 7], ["GCV", "SIMPLE_CHEMICAL", 4, 7], ["The GCV", "TREATMENT", 0, 7]]], ["The first dose will be given 7 d after Ad-TK administration.RISK ASSESSMENTThis procedure will be used only in patients over the age of 35 yr in whom conventional treatments have failed or are inapplicable.", [["Ad", "ORGANISM", 39, 41], ["patients", "ORGANISM", 111, 119], ["patients", "SPECIES", 111, 119], ["Ad-TK administration", "TREATMENT", 39, 59], ["RISK ASSESSMENTThis procedure", "TREATMENT", 60, 89], ["conventional treatments", "TREATMENT", 150, 173]]], ["The risks to the patients are the nforeseen effects of expression of the vector within the tumor, the transmission of other biologically active products with the vector construct, and the clinical risks associated with the percutaneous biopsy of a tumor.", [["tumor", "ANATOMY", 91, 96], ["percutaneous", "ANATOMY", 223, 235], ["tumor", "ANATOMY", 248, 253], ["tumor", "DISEASE", 91, 96], ["tumor", "DISEASE", 248, 253], ["patients", "ORGANISM", 17, 25], ["tumor", "CANCER", 91, 96], ["tumor", "CANCER", 248, 253], ["patients", "SPECIES", 17, 25], ["the tumor", "PROBLEM", 87, 96], ["the vector construct", "TREATMENT", 158, 178], ["the percutaneous biopsy", "TEST", 219, 242], ["a tumor", "PROBLEM", 246, 253], ["tumor", "OBSERVATION", 91, 96], ["tumor", "OBSERVATION", 248, 253]]], ["The risks seem to be negligible, as 27 patients were treated in the United States with 10 13 -pfu doses (100 times more than the maximum proposed dose in this study) and showed no serious side effects.", [["patients", "ORGANISM", 39, 47], ["patients", "SPECIES", 39, 47], ["this study", "TEST", 154, 164], ["serious side effects", "PROBLEM", 180, 200]]], ["The only abnormalities observed at the 10 13 -pfu dose level were low-grade fevers and transient elevation in liver function tests.", [["liver", "ANATOMY", 110, 115], ["fevers", "DISEASE", 76, 82], ["liver", "ORGAN", 110, 115], ["The only abnormalities", "PROBLEM", 0, 22], ["pfu dose level", "TEST", 46, 60], ["low-grade fevers", "PROBLEM", 66, 82], ["transient elevation in liver function tests", "PROBLEM", 87, 130], ["abnormalities", "OBSERVATION", 9, 22], ["fevers", "OBSERVATION", 76, 82], ["transient", "OBSERVATION_MODIFIER", 87, 96], ["elevation", "OBSERVATION_MODIFIER", 97, 106], ["liver", "ANATOMY", 110, 115]]], ["Recently, however, a death was reported in a 17-yrold man in Pennsylvania (USA), following the administration of 10 13 pfu adenovirus.", [["death", "DISEASE", 21, 26], ["man", "ORGANISM", 54, 57], ["adenovirus", "ORGANISM", 123, 133], ["man", "SPECIES", 54, 57]]], ["The cause of death was reported to be the result of acute respiratory distress syndrome (ARDS).", [["respiratory", "ANATOMY", 58, 69], ["death", "DISEASE", 13, 18], ["acute respiratory distress syndrome", "DISEASE", 52, 87], ["ARDS", "DISEASE", 89, 93], ["death", "PROBLEM", 13, 18], ["acute respiratory distress syndrome", "PROBLEM", 52, 87], ["ARDS", "PROBLEM", 89, 93], ["acute", "OBSERVATION_MODIFIER", 52, 57], ["respiratory distress", "OBSERVATION", 58, 78], ["ARDS", "OBSERVATION", 89, 93]]], ["To the best of our knowledge, the risk appears to be negligible for doses of adenovirus up to 10 11 pfu.RISK ASSESSMENTThe risk of bleeding after percutaneous biopsy of the tumor is less than 1%.", [["percutaneous", "ANATOMY", 146, 158], ["tumor", "ANATOMY", 173, 178], ["bleeding", "DISEASE", 131, 139], ["tumor", "DISEASE", 173, 178], ["adenovirus", "ORGANISM", 77, 87], ["tumor", "CANCER", 173, 178], ["adenovirus", "TREATMENT", 77, 87], ["RISK ASSESSMENT", "TEST", 104, 119], ["bleeding", "PROBLEM", 131, 139], ["percutaneous biopsy", "TEST", 146, 165], ["the tumor", "PROBLEM", 169, 178], ["bleeding", "OBSERVATION", 131, 139], ["tumor", "OBSERVATION", 173, 178]]], ["A generally accepted mortality rate in standard textbooks is between 0.1% and 0 .01% (28,29) .INCLUSION CRITERIAPatients must fulfill all of the following criteria in order to be eligible for study admission: histological diagnosis of primary liver tumor; at least 35 yr and less than 75 yr of age( women of childbearing potential may be included, but must use a reliable and appropriate contraceptive method, not including abstinence, for at least 1 mo before study start, for the duration of the study, and for three mo afterward.", [["primary liver tumor", "ANATOMY", 235, 254], ["primary liver tumor", "DISEASE", 235, 254], ["liver tumor", "CANCER", 243, 254], ["women", "ORGANISM", 299, 304], ["women", "SPECIES", 299, 304], ["primary liver tumor", "PROBLEM", 235, 254], ["appropriate contraceptive method", "TREATMENT", 376, 408], ["the study", "TEST", 494, 503], ["liver", "ANATOMY", 243, 248], ["tumor", "OBSERVATION", 249, 254]]], ["Results of a negative pregnancy test at study start must be available.", [["a negative pregnancy test", "TEST", 11, 36]]], ["Postmenopausal women must be amenorrheal for at least 12 mo before the study start.", [["women", "ORGANISM", 15, 20], ["women", "SPECIES", 15, 20], ["Postmenopausal women", "PROBLEM", 0, 20], ["the study", "TEST", 67, 76]]], ["Men of childbearing potential should practice a barrier method of contraception for the duration of the study, have a life expectancy of at least 3 mo, and have adequate performance status (Karnofsky score \u2265 70%).", [["Men", "SPECIES", 0, 3], ["a barrier method of contraception", "TREATMENT", 46, 79], ["the study", "TEST", 100, 109], ["Karnofsky score", "TEST", 190, 205]]], ["The required values for initial laboratory data are as follows:EXCLUSION CRITERIAPatients with any of the following will be excluded from study admission: pregnant or lactating women; women with either a positive pregnancy test at screen or baseline, or who have not had a pregnancy test; women of childbearing potential who are not using a reliable and appropriate contraceptive method; postmenopausal women who have been amenorrheal for less than 12 mo; uncontrolled serious bacterial, viral, fungal, or parasitic infection; patients who are human immunodeficiency virus (HIV) positive; systemic corticosteroid therapy or other immunosuppressive therapy administered within the last 3 mo; Karnofsky score less than 70%; participation in another investigation therapy study within the last 6 wk; any underlying medical condition that in the Principal Investigators' opinion, will make participation in the study hazardous or obscure the interpretation of adverse events.PRESTUDY EVALUATION AND REQUIREMENTSThe following must be performed within 2 wk prior to study admission: complete medical history; physical examination; toxicity evaluation; performance status; height and weight and body surface area; laboratory screening (, serum electrolytes (sodium, potassium, chloride, bicarbonate), urea, creatinine), alanine transaminase (ALT, alkaline phosphatase, lactate dehydrogenase (LDH), PT); urinalysis; \u03b1-fetoprotein; electrocardiogram (12-lead); chest X-ray (PA and lateral views); abdomen and pelvis CT or MRI scan.Patient Information LeafletThis should contain a title like \"Gene Therapy of Tumors of the Liver Using Ad-TK Intratumourally Followed by Ganciclovir Administration: A Phase I/II Study. \"", [["body surface area", "ANATOMY", 1188, 1205], ["serum", "ANATOMY", 1231, 1236], ["abdomen", "ANATOMY", 1488, 1495], ["pelvis", "ANATOMY", 1500, 1506], ["Tumors", "ANATOMY", 1599, 1605], ["Liver", "ANATOMY", 1613, 1618], ["bacterial, viral, fungal, or parasitic infection", "DISEASE", 477, 525], ["human immunodeficiency virus (HIV) positive", "DISEASE", 544, 587], ["toxicity", "DISEASE", 1125, 1133], ["sodium", "CHEMICAL", 1251, 1257], ["potassium", "CHEMICAL", 1259, 1268], ["chloride", "CHEMICAL", 1270, 1278], ["bicarbonate", "CHEMICAL", 1280, 1291], ["urea", "CHEMICAL", 1294, 1298], ["creatinine", "CHEMICAL", 1300, 1310], ["alanine", "CHEMICAL", 1313, 1320], ["lactate", "CHEMICAL", 1362, 1369], ["sodium", "CHEMICAL", 1251, 1257], ["potassium", "CHEMICAL", 1259, 1268], ["chloride", "CHEMICAL", 1270, 1278], ["bicarbonate", "CHEMICAL", 1280, 1291], ["urea", "CHEMICAL", 1294, 1298], ["creatinine", "CHEMICAL", 1300, 1310], ["alanine", "CHEMICAL", 1313, 1320], ["lactate", "CHEMICAL", 1362, 1369], ["women", "ORGANISM", 177, 182], ["women", "ORGANISM", 184, 189], ["women", "ORGANISM", 289, 294], ["women", "ORGANISM", 403, 408], ["patients", "ORGANISM", 527, 535], ["human immunodeficiency virus", "ORGANISM", 544, 572], ["HIV", "ORGANISM", 574, 577], ["body", "ORGANISM_SUBDIVISION", 1188, 1192], ["serum", "ORGANISM_SUBSTANCE", 1231, 1236], ["sodium", "SIMPLE_CHEMICAL", 1251, 1257], ["potassium", "SIMPLE_CHEMICAL", 1259, 1268], ["chloride", "SIMPLE_CHEMICAL", 1270, 1278], ["bicarbonate", "SIMPLE_CHEMICAL", 1280, 1291], ["urea", "SIMPLE_CHEMICAL", 1294, 1298], ["creatinine", "SIMPLE_CHEMICAL", 1300, 1310], ["alanine", "AMINO_ACID", 1313, 1320], ["transaminase", "SIMPLE_CHEMICAL", 1321, 1333], ["ALT", "SIMPLE_CHEMICAL", 1335, 1338], ["alkaline phosphatase", "GENE_OR_GENE_PRODUCT", 1340, 1360], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 1362, 1383], ["LDH", "SIMPLE_CHEMICAL", 1385, 1388], ["\u03b1-fetoprotein", "SIMPLE_CHEMICAL", 1408, 1421], ["abdomen", "ORGAN", 1488, 1495], ["pelvis", "ORGAN", 1500, 1506], ["Tumors", "CANCER", 1599, 1605], ["Liver", "ORGAN", 1613, 1618], ["Ad", "ORGANISM", 1625, 1627], ["alanine transaminase", "PROTEIN", 1313, 1333], ["ALT", "PROTEIN", 1335, 1338], ["alkaline phosphatase", "PROTEIN", 1340, 1360], ["lactate dehydrogenase", "PROTEIN", 1362, 1383], ["LDH", "PROTEIN", 1385, 1388], ["women", "SPECIES", 177, 182], ["women", "SPECIES", 184, 189], ["women", "SPECIES", 289, 294], ["women", "SPECIES", 403, 408], ["patients", "SPECIES", 527, 535], ["human", "SPECIES", 544, 549], ["immunodeficiency virus", "SPECIES", 550, 572], ["Patient", "SPECIES", 1522, 1529], ["human immunodeficiency virus", "SPECIES", 544, 572], ["HIV", "SPECIES", 574, 577], ["a positive pregnancy test", "PROBLEM", 202, 227], ["a pregnancy test", "PROBLEM", 271, 287], ["uncontrolled serious bacterial, viral, fungal, or parasitic infection", "PROBLEM", 456, 525], ["human immunodeficiency virus", "PROBLEM", 544, 572], ["HIV) positive", "PROBLEM", 574, 587], ["systemic corticosteroid therapy", "TREATMENT", 589, 620], ["other immunosuppressive therapy", "TREATMENT", 624, 655], ["Karnofsky score", "TEST", 691, 706], ["another investigation therapy study", "TEST", 739, 774], ["any underlying medical condition", "PROBLEM", 797, 829], ["the study", "TEST", 903, 912], ["adverse events", "PROBLEM", 956, 970], ["PRESTUDY EVALUATION", "TEST", 971, 990], ["physical examination", "TEST", 1103, 1123], ["toxicity evaluation", "TEST", 1125, 1144], ["performance status", "TEST", 1146, 1164], ["height", "TEST", 1166, 1172], ["weight", "TEST", 1177, 1183], ["body surface area", "TEST", 1188, 1205], ["laboratory screening", "TEST", 1207, 1227], ["serum electrolytes", "TEST", 1231, 1249], ["sodium", "TEST", 1251, 1257], ["potassium", "TEST", 1259, 1268], ["chloride", "TEST", 1270, 1278], ["bicarbonate", "TEST", 1280, 1291], ["urea", "TEST", 1294, 1298], ["creatinine", "TEST", 1300, 1310], ["alanine transaminase", "TEST", 1313, 1333], ["ALT", "TEST", 1335, 1338], ["alkaline phosphatase", "TEST", 1340, 1360], ["lactate dehydrogenase", "TEST", 1362, 1383], ["LDH)", "TEST", 1385, 1389], ["PT", "TEST", 1391, 1393], ["urinalysis", "TEST", 1396, 1406], ["\u03b1-fetoprotein", "TEST", 1408, 1421], ["electrocardiogram", "TEST", 1423, 1440], ["chest X-ray (PA and lateral views", "TEST", 1452, 1485], ["abdomen and pelvis CT", "TEST", 1488, 1509], ["MRI scan", "TEST", 1513, 1521], ["a title like \"Gene Therapy", "TREATMENT", 1569, 1595], ["Tumors of the Liver", "PROBLEM", 1599, 1618], ["Ad-TK", "TREATMENT", 1625, 1630], ["Ganciclovir Administration", "TREATMENT", 1659, 1685], ["fungal", "OBSERVATION_MODIFIER", 495, 501], ["parasitic", "OBSERVATION_MODIFIER", 506, 515], ["infection", "OBSERVATION", 516, 525], ["chest", "ANATOMY", 1452, 1457], ["abdomen", "ANATOMY", 1488, 1495], ["pelvis", "ANATOMY", 1500, 1506], ["Tumors", "OBSERVATION", 1599, 1605], ["Liver", "ANATOMY", 1613, 1618]]], ["Include the following sections and text in the leaflet.PURPOSE AND BACKGROUNDYou are being invited to take part in a research study because the cancer in your liver, unfortunately, cannot be removed surgically or treated in any other way.PURPOSE AND BACKGROUNDThe purpose of the study is to find out which of two treatments may be better for treating your type of liver cancer.", [["sections", "ANATOMY", 22, 30], ["cancer", "ANATOMY", 144, 150], ["liver", "ANATOMY", 159, 164], ["liver cancer", "ANATOMY", 364, 376], ["cancer", "DISEASE", 144, 150], ["liver cancer", "DISEASE", 364, 376], ["leaflet", "CELLULAR_COMPONENT", 47, 54], ["cancer", "CANCER", 144, 150], ["liver", "ORGAN", 159, 164], ["liver cancer", "CANCER", 364, 376], ["a research study", "TEST", 115, 131], ["the cancer in your liver", "PROBLEM", 140, 164], ["the study", "TEST", 275, 284], ["liver cancer", "PROBLEM", 364, 376], ["leaflet", "ANATOMY_MODIFIER", 47, 54], ["cancer", "OBSERVATION", 144, 150], ["liver", "ANATOMY", 159, 164], ["liver", "ANATOMY", 364, 369], ["cancer", "OBSERVATION", 370, 376]]], ["The first is a gene therapy treatment that comprises two different drugs, Ad-TK (a gene therapy product) that will be given by direct injection into the tumor and ganciclovir (a drug that kills certain types of viruses) that will be injected into a vein in your arm.", [["tumor", "ANATOMY", 153, 158], ["vein", "ANATOMY", 249, 253], ["Ad-TK", "CHEMICAL", 74, 79], ["tumor", "DISEASE", 153, 158], ["ganciclovir", "CHEMICAL", 163, 174], ["ganciclovir", "CHEMICAL", 163, 174], ["Ad", "ORGANISM", 74, 76], ["tumor", "CANCER", 153, 158], ["ganciclovir", "SIMPLE_CHEMICAL", 163, 174], ["vein", "MULTI-TISSUE_STRUCTURE", 249, 253], ["arm", "ORGANISM_SUBDIVISION", 262, 265], ["a gene therapy treatment", "TREATMENT", 13, 37], ["two different drugs", "TREATMENT", 53, 72], ["Ad-TK", "TREATMENT", 74, 79], ["a gene therapy product", "TREATMENT", 81, 103], ["the tumor", "PROBLEM", 149, 158], ["ganciclovir", "TREATMENT", 163, 174], ["a drug", "TREATMENT", 176, 182], ["viruses", "PROBLEM", 211, 218], ["tumor", "OBSERVATION", 153, 158], ["vein", "ANATOMY", 249, 253], ["arm", "ANATOMY", 262, 265]]], ["The second treatment is a treatment that is used commonly for liver cancer, which is the injection of ethanol (a type of alcohol) directly into the tumor.", [["liver cancer", "ANATOMY", 62, 74], ["tumor", "ANATOMY", 148, 153], ["liver cancer", "DISEASE", 62, 74], ["ethanol", "CHEMICAL", 102, 109], ["alcohol", "CHEMICAL", 121, 128], ["tumor", "DISEASE", 148, 153], ["ethanol", "CHEMICAL", 102, 109], ["alcohol", "CHEMICAL", 121, 128], ["liver cancer", "CANCER", 62, 74], ["ethanol", "SIMPLE_CHEMICAL", 102, 109], ["alcohol", "SIMPLE_CHEMICAL", 121, 128], ["tumor", "CANCER", 148, 153], ["The second treatment", "TREATMENT", 0, 20], ["a treatment", "TREATMENT", 24, 35], ["liver cancer", "PROBLEM", 62, 74], ["the tumor", "PROBLEM", 144, 153], ["liver", "ANATOMY", 62, 67], ["cancer", "OBSERVATION", 68, 74], ["tumor", "OBSERVATION", 148, 153]]], ["This is a randomized study and so you will only receive one of the treatments described above.", [["a randomized study", "TEST", 8, 26], ["the treatments", "TREATMENT", 63, 77]]], ["Before you decide whether or not to take part in this study it is important for you to understand why the research is being done and what it will involve.", [["this study", "TEST", 49, 59]]], ["Take time to decide whether or not you wish to take part.PURPOSE AND BACKGROUNDThank you for reading this.STUDY PROCEDURESTwo weeks before you have one of the treatments, the following procedures will need to be undertaken:STUDY PROCEDURES1.", [["the treatments", "TREATMENT", 155, 169]]], ["You will have various blood samples taken from a vein in your arm.", [["blood samples", "ANATOMY", 22, 35], ["vein", "ANATOMY", 49, 53], ["blood samples", "ORGANISM_SUBSTANCE", 22, 35], ["vein", "MULTI-TISSUE_STRUCTURE", 49, 53], ["arm", "ORGANISM_SUBDIVISION", 62, 65], ["various blood samples", "TEST", 14, 35], ["vein", "ANATOMY", 49, 53], ["arm", "ANATOMY", 62, 65]]], ["You will have a physical examination.", [["a physical examination", "TEST", 14, 36]]], ["You will have a chest X-ray and an electrocardiogram (ECG) of your heart.", [["heart", "ANATOMY", 67, 72], ["heart", "ORGAN", 67, 72], ["a chest X-ray", "TEST", 14, 27], ["an electrocardiogram", "TEST", 32, 52], ["ECG", "TEST", 54, 57], ["chest", "ANATOMY", 16, 21], ["heart", "ANATOMY", 67, 72]]], ["You will have a special scan of your liver to show the doctors where the tumor is in your liver and so they can measure its size.STUDY PROCEDURESIf you agree to take part in the study, you will be allocated to one of two treatment groups:STUDY PROCEDURESGroup 1: Treatment of your liver tumor with gene therapy (Ad-TK) followed by a 2-wk course of ganciclovir Group 2: Treatment of your liver tumor with ethanol injectionAD-TK-GANCICLOVIRAd-TK will be given by injecting it directly into the tumor under ultrasound or CT scan control in the X-ray department.", [["liver", "ANATOMY", 37, 42], ["tumor", "ANATOMY", 73, 78], ["liver", "ANATOMY", 90, 95], ["liver tumor", "ANATOMY", 281, 292], ["liver tumor", "ANATOMY", 387, 398], ["tumor", "ANATOMY", 492, 497], ["tumor", "DISEASE", 73, 78], ["liver tumor", "DISEASE", 281, 292], ["ganciclovir", "CHEMICAL", 348, 359], ["liver tumor", "DISEASE", 387, 398], ["ethanol", "CHEMICAL", 404, 411], ["tumor", "DISEASE", 492, 497], ["ganciclovir", "CHEMICAL", 348, 359], ["ethanol", "CHEMICAL", 404, 411], ["liver", "ORGAN", 37, 42], ["tumor", "CANCER", 73, 78], ["liver", "ORGAN", 90, 95], ["liver tumor", "CANCER", 281, 292], ["Ad", "ORGANISM", 312, 314], ["ganciclovir", "SIMPLE_CHEMICAL", 348, 359], ["liver tumor", "CANCER", 387, 398], ["ethanol", "SIMPLE_CHEMICAL", 404, 411], ["tumor", "CANCER", 492, 497], ["a special scan", "TEST", 14, 28], ["the tumor", "PROBLEM", 69, 78], ["your liver tumor", "PROBLEM", 276, 292], ["gene therapy", "TREATMENT", 298, 310], ["Ad-TK)", "TREATMENT", 312, 318], ["ganciclovir Group 2", "TREATMENT", 348, 367], ["your liver tumor", "PROBLEM", 382, 398], ["ethanol injectionAD-TK-GANCICLOVIRAd-TK", "TREATMENT", 404, 443], ["ultrasound", "TEST", 504, 514], ["CT scan control", "TEST", 518, 533], ["liver", "ANATOMY", 37, 42], ["tumor", "OBSERVATION", 73, 78], ["liver", "ANATOMY", 90, 95], ["size", "OBSERVATION_MODIFIER", 124, 128], ["liver", "ANATOMY", 281, 286], ["tumor", "OBSERVATION", 287, 292], ["liver", "ANATOMY", 387, 392], ["tumor", "OBSERVATION", 393, 398], ["tumor", "OBSERVATION", 492, 497]]], ["One week after the Ad-TK injection, you will be given ganciclovir into a vein in our arm, twice a day, for 2 wk.", [["vein", "ANATOMY", 73, 77], ["ganciclovir", "CHEMICAL", 54, 65], ["ganciclovir", "CHEMICAL", 54, 65], ["Ad", "ORGANISM", 19, 21], ["ganciclovir", "SIMPLE_CHEMICAL", 54, 65], ["vein", "MULTI-TISSUE_STRUCTURE", 73, 77], ["the Ad-TK injection", "TREATMENT", 15, 34], ["ganciclovir", "TREATMENT", 54, 65], ["a vein in our arm", "TREATMENT", 71, 88], ["vein", "ANATOMY", 73, 77], ["arm", "ANATOMY", 85, 88]]], ["Afterward, you will have to rest for a few hours before going home.AD-TK-GANCICLOVIRYou will also have one liver biopsy performed during the period of the study to see if the drugs have affected the cancer.", [["liver", "ANATOMY", 107, 112], ["cancer", "ANATOMY", 199, 205], ["cancer", "DISEASE", 199, 205], ["liver", "ORGAN", 107, 112], ["cancer", "CANCER", 199, 205], ["one liver biopsy", "TEST", 103, 119], ["the study", "TEST", 151, 160], ["the cancer", "PROBLEM", 195, 205], ["liver", "ANATOMY", 107, 112], ["biopsy", "OBSERVATION", 113, 119], ["cancer", "OBSERVATION", 199, 205]]], ["Blood samples will be taken on each occasion you come to the clinic.AD-TK-GANCICLOVIROn Day 60 (month 2) of your treatment schedule, you will undergo a CT scan or a MRI scan to measure the size of your tumor.", [["Blood samples", "ANATOMY", 0, 13], ["tumor", "ANATOMY", 202, 207], ["AD", "DISEASE", 68, 70], ["tumor", "DISEASE", 202, 207], ["Blood samples", "ORGANISM_SUBSTANCE", 0, 13], ["tumor", "CANCER", 202, 207], ["Blood samples", "TEST", 0, 13], ["your treatment schedule", "TREATMENT", 108, 131], ["a CT scan", "TEST", 150, 159], ["a MRI scan", "TEST", 163, 173], ["your tumor", "PROBLEM", 197, 207], ["size", "OBSERVATION_MODIFIER", 189, 193], ["tumor", "OBSERVATION", 202, 207]]], ["This will help to tell us whether the treatment has been effective.ETHANOL INJECTIONYou will be given an injection of ethanol directly into the tumor in the liver under ultrasound or CT guidance in the x Ray department.", [["tumor", "ANATOMY", 144, 149], ["liver", "ANATOMY", 157, 162], ["ethanol", "CHEMICAL", 118, 125], ["tumor", "DISEASE", 144, 149], ["ethanol", "CHEMICAL", 118, 125], ["ethanol", "SIMPLE_CHEMICAL", 118, 125], ["tumor", "CANCER", 144, 149], ["liver", "ORGAN", 157, 162], ["the treatment", "TREATMENT", 34, 47], ["ETHANOL INJECTIONYou", "TREATMENT", 67, 87], ["an injection of ethanol", "TREATMENT", 102, 125], ["CT guidance", "TEST", 183, 194], ["tumor", "OBSERVATION", 144, 149], ["liver", "ANATOMY", 157, 162]]], ["Afterwards you will have to rest for a few hours before going home.ETHANOL INJECTIONBlood samples will be taken on each occasion you come to the clinic.", [["samples", "ANATOMY", 90, 97], ["ETHANOL INJECTIONBlood samples", "TREATMENT", 67, 97]]], ["On Day 60 (month 2) of your treatment schedule you will undergo a CT scan or a MRI scan to measure the size of your tumour.", [["tumour", "ANATOMY", 116, 122], ["tumour", "DISEASE", 116, 122], ["tumour", "CANCER", 116, 122], ["your treatment schedule", "TREATMENT", 23, 46], ["a CT scan", "TEST", 64, 73], ["a MRI scan", "TEST", 77, 87], ["your tumour", "PROBLEM", 111, 122], ["size", "OBSERVATION_MODIFIER", 103, 107], ["tumour", "OBSERVATION", 116, 122]]], ["This will help to tell us whether the treatment has been effective.FOLLOW-UP PROCEDURESIf you decide to take part in this study, your doctor would like to see you every 3 months in the clinic to follow your progress.FOLLOW-UP PROCEDURESYour doctor would like to track your progress after the study has finished and would also like to keep you informed of any new treatment information about the drugs you had while participating in this study.", [["the treatment", "TREATMENT", 34, 47], ["the study", "TEST", 288, 297], ["the drugs", "TREATMENT", 391, 400], ["this study", "TEST", 432, 442]]], ["In order for this to happen, you must tell your doctor if you move.FOLLOW-UP PROCEDURESIf the treatment has made a difference to the tumor, you will be invited to participate in a further study to receive a further course of treatment.STUDY DURATIONThis study will last for about 60 days (2 months), but the doctors would like to continue to see you every 3 months thereafter.POSSIBLE RISKS AND DISCOMFORTSThere is a small risk of bleeding from the injection site in the liver after treatment with either the gene therapy drug or the ethanol.", [["tumor", "ANATOMY", 133, 138], ["liver", "ANATOMY", 471, 476], ["tumor", "DISEASE", 133, 138], ["bleeding", "DISEASE", 431, 439], ["ethanol", "CHEMICAL", 534, 541], ["ethanol", "CHEMICAL", 534, 541], ["tumor", "CANCER", 133, 138], ["liver", "ORGAN", 471, 476], ["ethanol", "SIMPLE_CHEMICAL", 534, 541], ["a further study", "TEST", 178, 193], ["treatment", "TREATMENT", 225, 234], ["bleeding from the injection site", "PROBLEM", 431, 463], ["treatment", "TREATMENT", 483, 492], ["the gene therapy drug", "TREATMENT", 505, 526], ["tumor", "OBSERVATION", 133, 138], ["small", "OBSERVATION_MODIFIER", 417, 422], ["bleeding", "OBSERVATION", 431, 439], ["liver", "ANATOMY", 471, 476]]], ["Also, a small bruise and some sore-ness may be left for a short time at the spot where the doctors inject the drug through the skin.POSSIBLE RISKS AND DISCOMFORTSThere is a small chance that the liver may bleed after the liver biopsy.", [["skin", "ANATOMY", 127, 131], ["liver", "ANATOMY", 195, 200], ["liver", "ANATOMY", 221, 226], ["skin", "ORGAN", 127, 131], ["liver", "ORGAN", 195, 200], ["liver biopsy", "MULTI-TISSUE_STRUCTURE", 221, 233], ["a small bruise", "PROBLEM", 6, 20], ["some sore-ness", "PROBLEM", 25, 39], ["the liver biopsy", "TEST", 217, 233], ["small", "OBSERVATION_MODIFIER", 8, 13], ["bruise", "OBSERVATION", 14, 20], ["some", "OBSERVATION_MODIFIER", 25, 29], ["sore", "OBSERVATION", 30, 34], ["skin", "ANATOMY", 127, 131], ["small", "OBSERVATION_MODIFIER", 173, 178], ["liver", "ANATOMY", 195, 200], ["bleed", "OBSERVATION", 205, 210], ["liver", "ANATOMY", 221, 226], ["biopsy", "OBSERVATION", 227, 233]]], ["If this happens, you will have to stay in hospital until the bleeding settles.POSSIBLE RISKS AND DISCOMFORTSNormally, there may be slight pain in your arm when blood is taken.", [["blood", "ANATOMY", 160, 165], ["bleeding", "DISEASE", 61, 69], ["pain", "DISEASE", 138, 142], ["blood", "ORGANISM_SUBSTANCE", 160, 165], ["the bleeding", "PROBLEM", 57, 69], ["slight pain in your arm", "PROBLEM", 131, 154], ["bleeding", "OBSERVATION", 61, 69], ["slight", "OBSERVATION_MODIFIER", 131, 137], ["pain", "OBSERVATION", 138, 142], ["arm", "ANATOMY", 151, 154]]], ["A small bruise may be left for a short time at the spot where the blood was taken.POSSIBLE RISKS AND DISCOMFORTSAs this is a new treatment, the risks associated with it are largely unknown.", [["blood", "ANATOMY", 66, 71], ["blood", "ORGANISM_SUBSTANCE", 66, 71], ["A small bruise", "PROBLEM", 0, 14], ["the blood", "TEST", 62, 71], ["a new treatment", "TREATMENT", 123, 138], ["small", "OBSERVATION_MODIFIER", 2, 7], ["bruise", "OBSERVATION", 8, 14], ["left", "ANATOMY_MODIFIER", 22, 26]]], ["However, experiments suggest that the likelihood of serious side effect is extremely small.", [["serious side effect", "PROBLEM", 52, 71], ["serious", "OBSERVATION_MODIFIER", 52, 59], ["side effect", "OBSERVATION_MODIFIER", 60, 71], ["extremely", "OBSERVATION_MODIFIER", 75, 84], ["small", "OBSERVATION_MODIFIER", 85, 90]]], ["If you decide to participate and you experience a reaction to the drug, the doctors will provide you with every medical support.POSSIBLE RISKS AND DISCOMFORTSWe do ask that you or your partner take reliable and appropriate contraceptive precautions for 1 month prior to the treatment and for 3 months afterward to prevent a pregnancy.", [["a reaction", "PROBLEM", 48, 58], ["every medical support", "TREATMENT", 106, 127], ["appropriate contraceptive precautions", "TREATMENT", 211, 248], ["the treatment", "TREATMENT", 270, 283], ["a pregnancy", "PROBLEM", 322, 333]]], ["This is because we do not know the effect the drug might have on an unborn child.POSSIBLE RISKS AND DISCOMFORTSIt is important for you to know that recently a death occurred in the United States following an adenovirus injection given in the same way in which you will receive it.", [["death", "DISEASE", 159, 164], ["adenovirus", "ORGANISM", 208, 218], ["a death", "PROBLEM", 157, 164], ["an adenovirus injection", "TREATMENT", 205, 228]]], ["The patient was suffering from metabolic liver disease and was given a dose far higher than any that you will receive in this study.REASONS WHY YOU MAY BE TAKEN OUT OF THE STUDYYour doctor may take you out of the study if your disease becomes worse, if new relevant scientific developments occur, for administrative reasons, or if your doctor feels that taking part in this study is no longer in your best interest.", [["liver", "ANATOMY", 41, 46], ["metabolic liver disease", "DISEASE", 31, 54], ["patient", "ORGANISM", 4, 11], ["liver", "ORGAN", 41, 46], ["patient", "SPECIES", 4, 11], ["metabolic liver disease", "PROBLEM", 31, 54], ["this study", "TEST", 121, 131], ["the study", "TEST", 209, 218], ["your disease", "PROBLEM", 222, 234], ["metabolic", "OBSERVATION", 31, 40], ["liver", "ANATOMY", 41, 46], ["disease", "OBSERVATION", 47, 54]]], ["You may, of course, wish to withdraw yourself from the study.POSSIBLE BENEFITSIt is not possible to tell if there will be any personal benefit from taking part in this study.", [["the study", "TEST", 51, 60], ["this study", "TEST", 163, 173]]], ["If this happens, your doctor will tell you or your legally accepted representative about it and discuss with you whether you want to continue in the study.", [["the study", "TEST", 145, 154]]], ["If you decide to continue, you may be asked to sign an updated consent form.NEW FINDINGSAlso, on receiving new information, your doctor might consider it to be in your best interests to withdraw you from the study.", [["the study", "TEST", 204, 213]]], ["Any information that leaves the hospital will have your name and address removed so that you cannot be recognized from it.CONFIDENTIALITYYou will not be identified in any report or publication that arises from this study.ALTERNATIVE TREATMENTYou may choose not to take part in this study.", [["this study", "TEST", 210, 220], ["this study", "TEST", 277, 287]]], ["You may choose to have no further tests and receive supportive care only.", [["further tests", "TEST", 26, 39], ["supportive care", "TREATMENT", 52, 67]]], ["Thank you for considering helping us with this important trial.Consent Form\"Gene Therapy of Tumours of the Liver Using Ad-TK Intratumourally Followed by Ganciclovir Administration: A Phase I/II Study\" Name of Researcher: Please initial box I confirm that I have read and understand the information sheet \u1b80 for the above study and have had the opportunity to ask questions.", [["Tumours", "ANATOMY", 92, 99], ["Liver", "ANATOMY", 107, 112], ["Tumours", "CANCER", 92, 99], ["Liver", "ORGAN", 107, 112], ["Gene Therapy", "TREATMENT", 76, 88], ["Tumours of the Liver", "TREATMENT", 92, 112], ["Ad-TK", "TREATMENT", 119, 124], ["the above study", "TEST", 310, 325], ["Liver", "ANATOMY", 107, 112]]], ["I understand that my participation is voluntary and that I am free to withdraw at any time without giving any reason without my medical care or legal rights being affected.", [["my medical care", "TREATMENT", 125, 140]]], ["I understand that sections of any of my medical notes may be \u1b80 looked at by responsible individuals or by individuals from regulatory authorities where it is relevant.", [["sections", "ANATOMY", 18, 26]]], ["I agree to take part in the above study.", [["the above study", "TEST", 24, 39]]], ["The Ad-TK will be given intratumorally under ultrasound or CT scan guidance.", [["intratumorally", "ANATOMY", 24, 38], ["Ad", "ORGANISM", 4, 6], ["intratumorally", "CANCER", 24, 38], ["The Ad-TK", "TREATMENT", 0, 9], ["ultrasound", "TEST", 45, 55], ["CT scan guidance", "TEST", 59, 75]]], ["GCV will be then administered intravenously twice per day for 14 d, starting at d 7 after Ad-TK injection.DOSEDosages will be calculated based on functional units of Ad-TK.", [["intravenously", "ANATOMY", 30, 43], ["GCV", "CHEMICAL", 0, 3], ["GCV", "CHEMICAL", 0, 3], ["GCV", "SIMPLE_CHEMICAL", 0, 3], ["Ad", "ORGANISM", 90, 92], ["Ad", "ORGANISM", 166, 168], ["GCV", "TREATMENT", 0, 3], ["Ad-TK injection", "TREATMENT", 90, 105], ["DOSEDosages", "TREATMENT", 106, 117]]], ["The dose of ganciclovir will be 5 mg/kg/d.", [["ganciclovir", "CHEMICAL", 12, 23], ["ganciclovir", "CHEMICAL", 12, 23], ["ganciclovir", "SIMPLE_CHEMICAL", 12, 23], ["ganciclovir", "TREATMENT", 12, 23]]], ["The first three patients enrolled in the study will receive Ad-TK at Dose Level 1.", [["patients", "ORGANISM", 16, 24], ["Ad", "ORGANISM", 60, 62], ["patients", "SPECIES", 16, 24], ["the study", "TEST", 37, 46], ["Ad-TK", "TREATMENT", 60, 65]]], ["If no dose-limiting toxicity (DLT) is observed after a period of at least 7 d of posttreatment monitoring, the next three patients will receive Ad-TK at Dose Level 2, and so on.", [["toxicity", "DISEASE", 20, 28], ["DLT", "DISEASE", 30, 33], ["patients", "ORGANISM", 122, 130], ["Ad", "ORGANISM", 144, 146], ["patients", "SPECIES", 122, 130], ["limiting toxicity", "PROBLEM", 11, 28], ["posttreatment monitoring", "TEST", 81, 105], ["Ad-TK", "TREATMENT", 144, 149]]], ["If DLT is observed, the appropriate dose escalation decision rule will be followed.DOSE ESCALATIONThe dose level will be escalated to the next level according to the following rules.# of Patients With DLT at Current Dose LevelDose Escalation Decision Rule 0 out of 3 Enter next three patients at the next dose level.", [["Patients", "ORGANISM", 187, 195], ["patients", "ORGANISM", 284, 292], ["Patients", "SPECIES", 187, 195], ["patients", "SPECIES", 284, 292], ["the appropriate dose escalation", "TREATMENT", 20, 51], ["The dose level", "TEST", 98, 112], ["DLT", "TREATMENT", 201, 204], ["Current Dose LevelDose Escalation", "TREATMENT", 208, 241]]], ["1 out of 3# of Patients With DLT at Current Dose LevelEnter up to three additional patients at current dose level.", [["Patients", "ORGANISM", 15, 23], ["patients", "ORGANISM", 83, 91], ["Patients", "SPECIES", 15, 23], ["patients", "SPECIES", 83, 91], ["DLT", "TREATMENT", 29, 32], ["Current Dose LevelEnter", "TREATMENT", 36, 59]]], ["If none or one out of the three of the second group experiences DLT, then enter three patients at the next dose level.", [["DLT", "DISEASE", 64, 67], ["patients", "ORGANISM", 86, 94], ["patients", "SPECIES", 86, 94], ["DLT", "TREATMENT", 64, 67]]], ["As soon as two of the second group experience DLT, then the MTD has been reached at the previous (lower) level and dose escalation will stop.", [["DLT", "DISEASE", 46, 49], ["MTD", "CHEMICAL", 60, 63], ["dose escalation", "TREATMENT", 115, 130]]], ["2 out of 3 Enter up to three additional patients at current dose level.", [["patients", "ORGANISM", 40, 48], ["patients", "SPECIES", 40, 48]]], ["If none experience DLT, then enter three patients at the next dose level.", [["patients", "ORGANISM", 41, 49], ["patients", "SPECIES", 41, 49], ["DLT", "TEST", 19, 22]]], ["As soon as any patient of the second group experi ences DLT, the MTD has been reached at the previous (lower) level and dose escalation will stop.", [["DLT", "DISEASE", 56, 59], ["MTD", "CHEMICAL", 65, 68], ["patient", "ORGANISM", 15, 22], ["patient", "SPECIES", 15, 22], ["dose escalation", "TREATMENT", 120, 135]]], ["3 out of 3 The MTD has been reached at the previous (lower) level and dose escalation will stop.ETHANOL INJECTION GROUPPatients randomized for ethanol injection will be given 50 cm 3 of ethanol intratumorally under an ultrasound or CT scan guidance.SchemaOnce a patient has been enrolled in the study she/he will be randomized to receive either Ad-TK-GCV or ethanol.", [["intratumorally", "ANATOMY", 194, 208], ["MTD", "CHEMICAL", 15, 18], ["ethanol", "CHEMICAL", 143, 150], ["ethanol", "CHEMICAL", 186, 193], ["Ad-TK-GCV", "CHEMICAL", 345, 354], ["ethanol", "CHEMICAL", 358, 365], ["ethanol", "CHEMICAL", 143, 150], ["ethanol", "CHEMICAL", 186, 193], ["GCV", "CHEMICAL", 351, 354], ["ethanol", "CHEMICAL", 358, 365], ["MTD", "CANCER", 15, 18], ["ethanol", "SIMPLE_CHEMICAL", 143, 150], ["ethanol", "SIMPLE_CHEMICAL", 186, 193], ["intratumorally", "CANCER", 194, 208], ["patient", "ORGANISM", 262, 269], ["Ad-TK-GCV", "SIMPLE_CHEMICAL", 345, 354], ["ethanol", "SIMPLE_CHEMICAL", 358, 365], ["patient", "SPECIES", 262, 269], ["dose escalation", "TREATMENT", 70, 85], ["ETHANOL INJECTION GROUPPatients", "TREATMENT", 96, 127], ["ethanol injection", "TREATMENT", 143, 160], ["ethanol intratumorally", "TREATMENT", 186, 208], ["an ultrasound", "TEST", 215, 228], ["CT scan guidance", "TEST", 232, 248], ["the study", "TEST", 291, 300], ["ethanol", "TREATMENT", 358, 365]]], ["Patients will be treated in the radiology department or the clinic on an outpatient basis.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["Immediately following Ad-TK application, vital signs (body temperature, respiratory rate, heart rate, blood pressure) will be performed every 15 min during the first hour after the injection.", [["body", "ANATOMY", 54, 58], ["heart", "ANATOMY", 90, 95], ["blood", "ANATOMY", 102, 107], ["Ad", "ORGANISM", 22, 24], ["body", "ORGANISM_SUBDIVISION", 54, 58], ["heart", "ORGAN", 90, 95], ["blood", "ORGANISM_SUBSTANCE", 102, 107], ["Ad-TK application", "TREATMENT", 22, 39], ["vital signs", "TEST", 41, 52], ["body temperature", "TEST", 54, 70], ["respiratory rate", "TEST", 72, 88], ["heart rate", "TEST", 90, 100], ["blood pressure", "TEST", 102, 116], ["the injection", "TREATMENT", 177, 190], ["heart", "ANATOMY", 90, 95]]], ["These evaluations will be performed on d 1, 15, 30, and 60 and will include clinical evaluations (complete history, physical examination, toxicity evaluation, performance status, height and weight, body surface area), as well as blood tests (CBC with differential, platelet count, serum electrolytes [sodium, potassium, chloride, bicarbonate], BUN, creatinine, glucose, uric acid, albumin, total protein, calcium, phosphorus, and magnesium, AST, ALT, total bilirubin, alkaline phosphatase, LDH, PT, PTT), and urinalysis.", [["body surface area", "ANATOMY", 198, 215], ["blood", "ANATOMY", 229, 234], ["platelet", "ANATOMY", 265, 273], ["serum", "ANATOMY", 281, 286], ["toxicity", "DISEASE", 138, 146], ["sodium", "CHEMICAL", 301, 307], ["potassium", "CHEMICAL", 309, 318], ["bicarbonate", "CHEMICAL", 330, 341], ["creatinine", "CHEMICAL", 349, 359], ["glucose", "CHEMICAL", 361, 368], ["uric acid", "CHEMICAL", 370, 379], ["calcium", "CHEMICAL", 405, 412], ["phosphorus", "CHEMICAL", 414, 424], ["magnesium", "CHEMICAL", 430, 439], ["bilirubin", "CHEMICAL", 457, 466], ["sodium", "CHEMICAL", 301, 307], ["potassium", "CHEMICAL", 309, 318], ["chloride", "CHEMICAL", 320, 328], ["bicarbonate", "CHEMICAL", 330, 341], ["creatinine", "CHEMICAL", 349, 359], ["glucose", "CHEMICAL", 361, 368], ["uric acid", "CHEMICAL", 370, 379], ["calcium", "CHEMICAL", 405, 412], ["phosphorus", "CHEMICAL", 414, 424], ["magnesium", "CHEMICAL", 430, 439], ["bilirubin", "CHEMICAL", 457, 466], ["body", "ORGANISM_SUBDIVISION", 198, 202], ["blood", "ORGANISM_SUBSTANCE", 229, 234], ["platelet", "CELL", 265, 273], ["serum", "ORGANISM_SUBSTANCE", 281, 286], ["electrolytes", "SIMPLE_CHEMICAL", 287, 299], ["sodium", "SIMPLE_CHEMICAL", 301, 307], ["potassium", "SIMPLE_CHEMICAL", 309, 318], ["chloride", "SIMPLE_CHEMICAL", 320, 328], ["bicarbonate", "SIMPLE_CHEMICAL", 330, 341], ["BUN", "SIMPLE_CHEMICAL", 344, 347], ["creatinine", "SIMPLE_CHEMICAL", 349, 359], ["glucose", "SIMPLE_CHEMICAL", 361, 368], ["uric acid", "SIMPLE_CHEMICAL", 370, 379], ["albumin", "SIMPLE_CHEMICAL", 381, 388], ["calcium", "SIMPLE_CHEMICAL", 405, 412], ["phosphorus", "SIMPLE_CHEMICAL", 414, 424], ["magnesium", "SIMPLE_CHEMICAL", 430, 439], ["AST", "SIMPLE_CHEMICAL", 441, 444], ["ALT", "SIMPLE_CHEMICAL", 446, 449], ["bilirubin", "SIMPLE_CHEMICAL", 457, 466], ["alkaline phosphatase", "GENE_OR_GENE_PRODUCT", 468, 488], ["LDH", "SIMPLE_CHEMICAL", 490, 493], ["PT", "SIMPLE_CHEMICAL", 495, 497], ["albumin", "PROTEIN", 381, 388], ["AST", "PROTEIN", 441, 444], ["ALT", "PROTEIN", 446, 449], ["alkaline phosphatase", "PROTEIN", 468, 488], ["LDH", "PROTEIN", 490, 493], ["These evaluations", "TEST", 0, 17], ["clinical evaluations", "TEST", 76, 96], ["physical examination", "TEST", 116, 136], ["toxicity evaluation", "TEST", 138, 157], ["height", "TEST", 179, 185], ["weight", "TEST", 190, 196], ["blood tests", "TEST", 229, 240], ["CBC", "TEST", 242, 245], ["differential", "TEST", 251, 263], ["platelet count", "TEST", 265, 279], ["serum electrolytes", "TEST", 281, 299], ["sodium", "TEST", 301, 307], ["potassium", "TEST", 309, 318], ["chloride", "TEST", 320, 328], ["bicarbonate", "TEST", 330, 341], ["BUN", "TEST", 344, 347], ["creatinine", "TEST", 349, 359], ["glucose", "TEST", 361, 368], ["uric acid", "TEST", 370, 379], ["albumin", "TEST", 381, 388], ["total protein", "TEST", 390, 403], ["calcium", "TEST", 405, 412], ["phosphorus", "TEST", 414, 424], ["magnesium", "TEST", 430, 439], ["AST", "TEST", 441, 444], ["ALT", "TEST", 446, 449], ["total bilirubin", "TEST", 451, 466], ["alkaline phosphatase", "TEST", 468, 488], ["LDH", "TEST", 490, 493], ["PT", "TEST", 495, 497], ["PTT", "TEST", 499, 502], ["urinalysis", "TEST", 509, 519]]], ["Other studies will also be undertaken that will include pharmacokinetics and immune responses.", [["Other studies", "TEST", 0, 13]]], ["Serum will be stored in case of future investigations.Flow SheetPatients will undergo percutaneous Tru-cut liver biopsy of the liver tumor and normal liver as guided by ultrasound or CT scan.Follow-Up EvaluationPatients will be considered to be actively on study from the time of study admission until poststudy evaluation on d 60.", [["Serum", "ANATOMY", 0, 5], ["percutaneous", "ANATOMY", 86, 98], ["liver", "ANATOMY", 107, 112], ["liver tumor", "ANATOMY", 127, 138], ["liver", "ANATOMY", 150, 155], ["liver tumor", "DISEASE", 127, 138], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["liver biopsy", "MULTI-TISSUE_STRUCTURE", 107, 119], ["liver tumor", "CANCER", 127, 138], ["liver", "ORGAN", 150, 155], ["future investigations", "TEST", 32, 53], ["percutaneous Tru-cut liver biopsy", "TREATMENT", 86, 119], ["the liver tumor", "PROBLEM", 123, 138], ["ultrasound", "TEST", 169, 179], ["CT scan", "TEST", 183, 190], ["poststudy evaluation", "TEST", 302, 322], ["liver", "ANATOMY", 107, 112], ["biopsy", "OBSERVATION", 113, 119], ["liver", "ANATOMY", 127, 132], ["tumor", "OBSERVATION", 133, 138], ["normal", "OBSERVATION", 143, 149], ["liver", "ANATOMY", 150, 155]]], ["Patients will be considered associated with the study after poststudy evaluation and will undergo regular follow-up evaluations thereafter.Follow-Up EvaluationThe following evaluations will be performed on an outpatient basis on day 60 (poststudy evaluation), then every 3 mo for 1 yr, then annually.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["the study", "TEST", 44, 53], ["poststudy evaluation", "TEST", 60, 80], ["regular follow-up evaluations", "TEST", 98, 127], ["Evaluation", "TEST", 149, 159], ["poststudy evaluation", "TEST", 237, 257]]], ["These evaluations will be the same as in Subheading 3.5.1.", [["These evaluations", "TEST", 0, 17]]], ["Abdomen and pelvis CT or MRI scan will be performed on d 60.", [["Abdomen", "ANATOMY", 0, 7], ["pelvis", "ANATOMY", 12, 18], ["Abdomen", "MULTI-TISSUE_STRUCTURE", 0, 7], ["pelvis", "ORGAN", 12, 18], ["Abdomen and pelvis CT", "TEST", 0, 21], ["MRI scan", "TEST", 25, 33], ["pelvis", "ANATOMY", 12, 18]]], ["If tumor response is noted, the abdominal scan will be repeated.Follow-Up EvaluationOne of the main objectives of this study is to assess the biological efficacy of Ad-TK, including efficiency and stability.", [["tumor", "ANATOMY", 3, 8], ["abdominal", "ANATOMY", 32, 41], ["tumor", "DISEASE", 3, 8], ["tumor", "CANCER", 3, 8], ["abdominal", "ORGAN", 32, 41], ["Ad", "ORGANISM", 165, 167], ["tumor response", "PROBLEM", 3, 17], ["the abdominal scan", "TEST", 28, 46], ["this study", "TEST", 114, 124], ["tumor", "OBSERVATION", 3, 8], ["abdominal", "ANATOMY", 32, 41], ["stability", "OBSERVATION_MODIFIER", 197, 206]]], ["The molecular and cellular effects of Ad-TK treatment on malignant tissue will be assayed.", [["cellular", "ANATOMY", 18, 26], ["malignant tissue", "ANATOMY", 57, 73], ["Ad-TK", "CHEMICAL", 38, 43], ["cellular", "CELL", 18, 26], ["Ad", "ORGANISM", 38, 40], ["malignant tissue", "TISSUE", 57, 73], ["Ad-TK treatment", "TREATMENT", 38, 53], ["malignant tissue", "PROBLEM", 57, 73], ["cellular effects", "OBSERVATION", 18, 34], ["malignant tissue", "OBSERVATION", 57, 73]]], ["Malignant tissue from the Ad-TK-treated liver will be obtained with Tru-cut biopsy.Potential Toxicity, Dose Modification, and ManagementToxicity will be assessed using the National Cancer Institute criteria.", [["Malignant tissue", "ANATOMY", 0, 16], ["liver", "ANATOMY", 40, 45], ["Toxicity", "DISEASE", 93, 101], ["Cancer", "DISEASE", 181, 187], ["Malignant tissue", "TISSUE", 0, 16], ["Ad", "ORGANISM", 26, 28], ["liver", "ORGAN", 40, 45], ["Malignant tissue", "PROBLEM", 0, 16], ["biopsy", "TEST", 76, 82], ["Potential Toxicity", "PROBLEM", 83, 101], ["Dose Modification", "TREATMENT", 103, 120], ["ManagementToxicity", "TREATMENT", 126, 144], ["liver", "ANATOMY", 40, 45], ["Toxicity", "OBSERVATION", 93, 101]]], ["Toxicity will be formally evaluated on d 1, 15, 30, 60 and then every 3 mo for 1 yr, then annually.", [["Toxicity", "DISEASE", 0, 8]]], ["All toxic events will be managed with full and optimal supportive care, including transfer to the intensive care unit (ICU) if appropriate.Adverse Drug Reaction (ADR) ReportsThe terms \"adverse event,\" \"adverse experience,\" and \"adverse reaction\" include any adverse event whether or not it is considered to be drug related.", [["All toxic events", "PROBLEM", 0, 16], ["Adverse Drug Reaction", "PROBLEM", 139, 160], ["adverse reaction", "PROBLEM", 228, 244], ["toxic", "OBSERVATION", 4, 9]]], ["This includes any side effect, injury, toxicity, or sensitivity reaction.Adverse Drug Reaction (ADR) ReportsAn adverse event is considered serious if any of the following occur: It is fatal or life-threatening; it is severely or permanently disabling; it requires new or prolonged inpatient hospitalization; it involves the exacerbation of a congenital anomaly or the development of cancer; it results in an overdose.", [["cancer", "ANATOMY", 383, 389], ["toxicity", "DISEASE", 39, 47], ["congenital anomaly", "DISEASE", 342, 360], ["cancer", "DISEASE", 383, 389], ["overdose", "DISEASE", 408, 416], ["cancer", "CANCER", 383, 389], ["any side effect", "PROBLEM", 14, 29], ["injury", "PROBLEM", 31, 37], ["toxicity", "PROBLEM", 39, 47], ["sensitivity reaction", "PROBLEM", 52, 72], ["Adverse Drug Reaction", "PROBLEM", 73, 94], ["permanently disabling", "PROBLEM", 229, 250], ["a congenital anomaly", "PROBLEM", 340, 360], ["cancer", "PROBLEM", 383, 389], ["an overdose", "PROBLEM", 405, 416], ["side effect", "OBSERVATION_MODIFIER", 18, 29], ["injury", "OBSERVATION", 31, 37], ["fatal", "OBSERVATION_MODIFIER", 184, 189], ["new", "OBSERVATION_MODIFIER", 264, 267], ["congenital", "OBSERVATION_MODIFIER", 342, 352], ["anomaly", "OBSERVATION", 353, 360], ["cancer", "OBSERVATION", 383, 389]]], ["An adverse event is considered unexpected if it is not identified in nature, severity, or frequency in the current investigator brochure.Adverse Event Reporting RequirementsPatients will be instructed to report any adverse event to the investigators.", [["Patients", "ORGANISM", 173, 181], ["Patients", "SPECIES", 173, 181], ["An adverse event", "PROBLEM", 0, 16], ["not identified", "UNCERTAINTY", 51, 65]]], ["All adverse events occurring during participation in the study will be documented.", [["All adverse events", "PROBLEM", 0, 18], ["the study", "TEST", 53, 62]]], ["All adverse events will be reported to both the local ethical committee and the GTAC, with a description of the severity, duration, and outcome of the event, and the investigator's opinion regarding the relationship, if any, between the event and the study treatment.Response CriteriaThe tumor response to either treatment regimen is one of the primary objectives of this study.", [["tumor", "ANATOMY", 288, 293], ["tumor", "DISEASE", 288, 293], ["tumor", "CANCER", 288, 293], ["All adverse events", "PROBLEM", 0, 18], ["the study treatment", "TREATMENT", 247, 266], ["treatment regimen", "TREATMENT", 313, 330], ["this study", "TEST", 367, 377], ["tumor", "OBSERVATION", 288, 293]]], ["Observations of antitumor activity will be collected and analyzed.", [["antitumor", "ANATOMY", 16, 25], ["antitumor", "CANCER", 16, 25], ["antitumor activity", "TREATMENT", 16, 34]]], ["Standard criteria will be formally employed to classify the antitumor responses observed in patients with measurable disease in the liver.", [["antitumor", "ANATOMY", 60, 69], ["liver", "ANATOMY", 132, 137], ["antitumor", "CANCER", 60, 69], ["patients", "ORGANISM", 92, 100], ["liver", "ORGAN", 132, 137], ["patients", "SPECIES", 92, 100], ["measurable disease in the liver", "PROBLEM", 106, 137], ["disease", "OBSERVATION", 117, 124], ["liver", "ANATOMY", 132, 137]]], ["Measurable disease will consist of bidimensionally measurable liver lesions with perpendicular diameters of \u2265 1 cm \u00d7 \u2265 1 cm.Removal From StudyPatients may withdraw or be removed from the study for any of the following reasons:Removal From Study\u2022 Patient's request to withdraw \u2022 Patient unwilling or unable to comply with study requirements \u2022 Clinical need for concomitant or ancillary therapy not permitted in the study \u2022 Any unacceptable treatment-related toxicity precluding further participation in the study \u2022 Unrelated intercurrent illness that, in the judgment of the principal investigator, will affect assessments of clinical status to a significant degree A patient removed from the study prior to any of the scheduled response evaluations will not be considered inevaluable for response.Pharmacokinetic AnalysisThe study will explore the relationships among pharmacokinetic parameters, toxicity, and biological efficacy.Analysis of Gene Transfer EfficiencyThe study will explore the relationship between dose of Ad-TK and efficiency of transduction (gene transfer).Analysis of Clinical EfficacyEvaluation of clinical efficacy is one of the primary objectives of this study.", [["liver lesions", "ANATOMY", 62, 75], ["toxicity", "DISEASE", 457, 465], ["intercurrent illness", "DISEASE", 524, 544], ["toxicity", "DISEASE", 896, 904], ["liver lesions", "CANCER", 62, 75], ["patient", "ORGANISM", 667, 674], ["Ad", "ORGANISM", 1022, 1024], ["Patient", "SPECIES", 246, 253], ["Patient", "SPECIES", 278, 285], ["patient", "SPECIES", 667, 674], ["Measurable disease", "PROBLEM", 0, 18], ["bidimensionally measurable liver lesions", "PROBLEM", 35, 75], ["perpendicular diameters", "TEST", 81, 104], ["Removal", "TREATMENT", 124, 131], ["the study", "TEST", 183, 192], ["Removal", "TREATMENT", 226, 233], ["study requirements", "TEST", 321, 339], ["concomitant or ancillary therapy", "TREATMENT", 360, 392], ["the study", "TEST", 410, 419], ["related toxicity", "PROBLEM", 449, 465], ["the study", "TEST", 502, 511], ["Unrelated intercurrent illness", "PROBLEM", 514, 544], ["the study", "TEST", 688, 697], ["the scheduled response evaluations", "TEST", 714, 748], ["Pharmacokinetic Analysis", "TEST", 797, 821], ["The study", "TEST", 821, 830], ["pharmacokinetic parameters", "TEST", 868, 894], ["toxicity", "PROBLEM", 896, 904], ["Gene Transfer Efficiency", "PROBLEM", 942, 966], ["The study", "TEST", 966, 975], ["Ad-TK", "TREATMENT", 1022, 1027], ["transduction (gene transfer)", "TREATMENT", 1046, 1074], ["Clinical Efficacy", "TEST", 1087, 1104], ["this study", "TEST", 1172, 1182], ["disease", "OBSERVATION", 11, 18], ["measurable", "OBSERVATION_MODIFIER", 51, 61], ["liver", "ANATOMY", 62, 67], ["lesions", "OBSERVATION", 68, 75], ["perpendicular", "OBSERVATION_MODIFIER", 81, 94], ["diameters", "OBSERVATION_MODIFIER", 95, 104], ["1 cm", "OBSERVATION_MODIFIER", 110, 114], ["\u2265 1 cm", "OBSERVATION_MODIFIER", 117, 123], ["unacceptable", "OBSERVATION_MODIFIER", 426, 438], ["treatment", "OBSERVATION", 439, 448], ["intercurrent", "OBSERVATION_MODIFIER", 524, 536], ["illness", "OBSERVATION", 537, 544]]], ["Treatment effect will be estimated as the proportion of patients with an objective response (complete or partial) following Ad-TK-GCV as compared with objective response to alcohol therapy.", [["GCV", "CHEMICAL", 130, 133], ["alcohol", "CHEMICAL", 173, 180], ["GCV", "CHEMICAL", 130, 133], ["alcohol", "CHEMICAL", 173, 180], ["patients", "ORGANISM", 56, 64], ["Ad", "ORGANISM", 124, 126], ["alcohol", "SIMPLE_CHEMICAL", 173, 180], ["patients", "SPECIES", 56, 64], ["Ad-TK-GCV", "TREATMENT", 124, 133], ["alcohol therapy", "TREATMENT", 173, 188]]], ["Chi-square tests and logistic regression will be used to analyze which variables are significant predictors of response.Survival AnalysisThe Kaplan-Meier method will be used to estimate progression-free survival.", [["Chi-square tests", "TEST", 0, 16], ["logistic regression", "TEST", 21, 40], ["Survival Analysis", "TEST", 120, 137], ["The Kaplan-Meier method", "TREATMENT", 137, 160]]], ["It is expected that the construct will not spread to other persons.", [["persons", "ORGANISM", 59, 66], ["persons", "SPECIES", 59, 66]]], ["Tursz et al. studied 10 patients treated with recombinant adenoviral vectors in lung cancer patients and found no cross-contamination to the medical and nursing staff (27).", [["lung cancer", "ANATOMY", 80, 91], ["lung cancer", "DISEASE", 80, 91], ["patients", "ORGANISM", 24, 32], ["adenoviral", "ORGANISM", 58, 68], ["lung cancer", "CANCER", 80, 91], ["patients", "ORGANISM", 92, 100], ["patients", "SPECIES", 24, 32], ["patients", "SPECIES", 92, 100], ["recombinant adenoviral vectors", "TREATMENT", 46, 76], ["lung cancer", "PROBLEM", 80, 91], ["lung", "ANATOMY", 80, 84], ["cancer", "OBSERVATION", 85, 91]]], ["In the French study, there was no shedding of the virus beyond the third day, and we intend to keep the patients overnight in separate rooms with barrier nursing.", [["patients", "ORGANISM", 104, 112], ["patients", "SPECIES", 104, 112], ["the French study", "TEST", 3, 19], ["shedding of the virus", "PROBLEM", 34, 55], ["barrier nursing", "TREATMENT", 146, 161], ["no", "UNCERTAINTY", 31, 33], ["virus", "OBSERVATION", 50, 55]]], ["We will analyze the urine and sputum of the medical and nursing staff during this period.Exclusion of Risks to OffspringIn order to minimize the risk of cross-infection to offspring, only patients above the age of 40 will be included.", [["urine", "ANATOMY", 20, 25], ["sputum", "ANATOMY", 30, 36], ["urine", "ORGANISM_SUBSTANCE", 20, 25], ["sputum", "ORGANISM_SUBSTANCE", 30, 36], ["patients", "ORGANISM", 188, 196], ["patients", "SPECIES", 188, 196], ["the urine", "TEST", 16, 25], ["cross-infection", "PROBLEM", 153, 168], ["cross-infection", "OBSERVATION", 153, 168]]], ["It is unlikely that cancer patients above this age will remain reproductively active.", [["cancer", "ANATOMY", 20, 26], ["cancer", "DISEASE", 20, 26], ["cancer", "CANCER", 20, 26], ["patients", "ORGANISM", 27, 35], ["patients", "SPECIES", 27, 35], ["cancer", "PROBLEM", 20, 26], ["unlikely", "UNCERTAINTY", 6, 14], ["cancer", "OBSERVATION", 20, 26]]], ["Nevertheless, patients will be warned of the risk and will be advised to take contraceptive measures.Another System of Gene Therapy in Patients With Liver Tumors: E1B-Deleted Adenovirus Gene TherapyFor this type of anticancer therapy, viruses need to be rigidly tumor-cell-specific. dl1520 originally produced by Barker and Berk in 1987 (30) has the ability to target and destroy tumor cells only and led to it being termed the \"smart bomb\" cancer virus (31).", [["Liver Tumors", "ANATOMY", 149, 161], ["anticancer", "ANATOMY", 215, 225], ["tumor-cell", "ANATOMY", 262, 272], ["tumor cells", "ANATOMY", 380, 391], ["cancer", "ANATOMY", 441, 447], ["Liver Tumors", "DISEASE", 149, 161], ["tumor", "DISEASE", 262, 267], ["dl1520", "CHEMICAL", 283, 289], ["tumor", "DISEASE", 380, 385], ["cancer", "DISEASE", 441, 447], ["patients", "ORGANISM", 14, 22], ["Patients", "ORGANISM", 135, 143], ["Liver Tumors", "CANCER", 149, 161], ["E1B", "GENE_OR_GENE_PRODUCT", 163, 166], ["Adenovirus", "ORGANISM", 175, 185], ["anticancer", "CANCER", 215, 225], ["tumor-cell", "CELL", 262, 272], ["dl1520", "GENE_OR_GENE_PRODUCT", 283, 289], ["tumor cells", "CELL", 380, 391], ["smart bomb\" cancer", "CANCER", 429, 447], ["tumor cells", "CELL_TYPE", 380, 391], ["patients", "SPECIES", 14, 22], ["Patients", "SPECIES", 135, 143], ["contraceptive measures", "TREATMENT", 78, 100], ["Gene Therapy", "TREATMENT", 119, 131], ["Liver Tumors", "PROBLEM", 149, 161], ["E1B-Deleted Adenovirus Gene Therapy", "TREATMENT", 163, 198], ["anticancer therapy", "TREATMENT", 215, 233], ["viruses", "PROBLEM", 235, 242], ["rigidly tumor", "PROBLEM", 254, 267], ["destroy tumor cells", "PROBLEM", 372, 391], ["cancer virus", "PROBLEM", 441, 453], ["Liver", "ANATOMY", 149, 154], ["Tumors", "OBSERVATION", 155, 161], ["anticancer therapy", "OBSERVATION", 215, 233], ["tumor", "OBSERVATION", 262, 267]]], ["After viral internalization, intracellular adenoviral replication augments an administered dose to the level required to kill the tumor host cells only, leaving neighboring normal tissues intact. dl1520 is an adenovirus hybrid of serotypes 2 and 5 with a genome deletion in the E1B region, causing loss of expression of viral 55-kDa protein (E1B 55K).", [["intracellular", "ANATOMY", 29, 42], ["tumor", "ANATOMY", 130, 135], ["cells", "ANATOMY", 141, 146], ["tissues", "ANATOMY", 180, 187], ["tumor", "DISEASE", 130, 135], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 29, 42], ["adenoviral", "ORGANISM", 43, 53], ["tumor host cells", "CELL", 130, 146], ["normal tissues", "TISSUE", 173, 187], ["dl1520", "GENE_OR_GENE_PRODUCT", 196, 202], ["adenovirus", "ORGANISM", 209, 219], ["5", "ORGANISM", 246, 247], ["E1B", "GENE_OR_GENE_PRODUCT", 278, 281], ["E1B 55K", "GENE_OR_GENE_PRODUCT", 342, 349], ["tumor host cells", "CELL_TYPE", 130, 146], ["E1B region", "DNA", 278, 288], ["viral 55-kDa protein", "PROTEIN", 320, 340], ["E1B 55K", "PROTEIN", 342, 349], ["viral internalization", "TREATMENT", 6, 27], ["intracellular adenoviral replication augments", "TREATMENT", 29, 74], ["an adenovirus hybrid of serotypes", "TREATMENT", 206, 239], ["a genome deletion in the E1B region", "TREATMENT", 253, 288], ["adenoviral replication", "OBSERVATION", 43, 65], ["tumor", "OBSERVATION", 130, 135], ["host cells", "OBSERVATION", 136, 146], ["normal tissues", "OBSERVATION", 173, 187], ["adenovirus hybrid", "OBSERVATION", 209, 226]]], ["E1B 55K has been shown to bind to the mammalian tumor cell suppressor protein p53 and block p53-mediated transcriptional activation (32). p53 has many functions including arrest of the G 1 phase of cell proliferation via the cyclindependent kinase inhibitor p21/WAF1/Cip1, or apoptosis through induction of genes such as bax (33) .", [["tumor cell", "ANATOMY", 48, 58], ["cell", "ANATOMY", 198, 202], ["E1B 55K", "CHEMICAL", 0, 7], ["tumor", "DISEASE", 48, 53], ["E1B 55K", "GENE_OR_GENE_PRODUCT", 0, 7], ["tumor cell", "CELL", 48, 58], ["p53", "GENE_OR_GENE_PRODUCT", 78, 81], ["p53", "GENE_OR_GENE_PRODUCT", 92, 95], ["p53", "GENE_OR_GENE_PRODUCT", 138, 141], ["cell", "CELL", 198, 202], ["cyclindependent kinase", "GENE_OR_GENE_PRODUCT", 225, 247], ["p21", "GENE_OR_GENE_PRODUCT", 258, 261], ["WAF1", "GENE_OR_GENE_PRODUCT", 262, 266], ["Cip1", "GENE_OR_GENE_PRODUCT", 267, 271], ["bax (33)", "GENE_OR_GENE_PRODUCT", 321, 329], ["E1B 55K", "PROTEIN", 0, 7], ["mammalian tumor cell suppressor protein", "PROTEIN", 38, 77], ["p53", "PROTEIN", 78, 81], ["p53", "PROTEIN", 92, 95], ["p53", "PROTEIN", 138, 141], ["cyclindependent kinase inhibitor", "PROTEIN", 225, 257], ["p21", "PROTEIN", 258, 261], ["WAF1", "PROTEIN", 262, 266], ["Cip1", "PROTEIN", 267, 271], ["bax (33)", "DNA", 321, 329], ["block p53", "TEST", 86, 95], ["arrest", "PROBLEM", 171, 177], ["cell proliferation", "TREATMENT", 198, 216], ["the cyclindependent kinase inhibitor", "TREATMENT", 221, 257], ["WAF1/Cip1", "TREATMENT", 262, 271], ["apoptosis", "PROBLEM", 276, 285], ["tumor cell suppressor protein p53", "OBSERVATION", 48, 81], ["G 1 phase", "OBSERVATION_MODIFIER", 185, 194], ["cell proliferation", "OBSERVATION", 198, 216]]], ["Studies have shown that dl1520 appears to replicate independently of p53 status in many tumor cell lines (33-36) .Another System of Gene Therapy in Patients With Liver Tumors: E1B-Deleted Adenovirus Gene TherapyPhase I trials of direct intratumoral injection of dl1520 in more than 22 patients with recurrent head and neck cancer with p53 mutations have already shown necrosis in a significant number of tumors, without evidence of damage to normal tissue (37).", [["tumor cell lines", "ANATOMY", 88, 104], ["Liver Tumors", "ANATOMY", 162, 174], ["intratumoral", "ANATOMY", 236, 248], ["head and neck cancer", "ANATOMY", 309, 329], ["tumors", "ANATOMY", 404, 410], ["tissue", "ANATOMY", 449, 455], ["tumor", "DISEASE", 88, 93], ["Liver Tumors", "DISEASE", 162, 174], ["dl1520", "CHEMICAL", 262, 268], ["head and neck cancer", "DISEASE", 309, 329], ["necrosis", "DISEASE", 368, 376], ["tumors", "DISEASE", 404, 410], ["dl1520", "GENE_OR_GENE_PRODUCT", 24, 30], ["p53", "GENE_OR_GENE_PRODUCT", 69, 72], ["tumor cell lines", "CELL", 88, 104], ["Patients", "ORGANISM", 148, 156], ["Liver Tumors", "CANCER", 162, 174], ["E1B", "GENE_OR_GENE_PRODUCT", 176, 179], ["Adenovirus", "ORGANISM", 188, 198], ["intratumoral", "IMMATERIAL_ANATOMICAL_ENTITY", 236, 248], ["patients", "ORGANISM", 285, 293], ["head and neck cancer", "CANCER", 309, 329], ["p53", "GENE_OR_GENE_PRODUCT", 335, 338], ["tumors", "CANCER", 404, 410], ["tissue", "TISSUE", 449, 455], ["dl1520", "PROTEIN", 24, 30], ["p53", "PROTEIN", 69, 72], ["tumor cell lines", "CELL_LINE", 88, 104], ["p53", "PROTEIN", 335, 338], ["Patients", "SPECIES", 148, 156], ["patients", "SPECIES", 285, 293], ["Studies", "TEST", 0, 7], ["many tumor cell lines", "TREATMENT", 83, 104], ["Gene Therapy", "TREATMENT", 132, 144], ["Liver Tumors", "PROBLEM", 162, 174], ["E1B-Deleted Adenovirus Gene Therapy", "TREATMENT", 176, 211], ["direct intratumoral injection", "TREATMENT", 229, 258], ["recurrent head and neck cancer", "PROBLEM", 299, 329], ["p53 mutations", "PROBLEM", 335, 348], ["necrosis", "PROBLEM", 368, 376], ["a significant number of tumors", "PROBLEM", 380, 410], ["damage to normal tissue", "PROBLEM", 432, 455], ["tumor cell lines", "OBSERVATION", 88, 104], ["Liver", "ANATOMY", 162, 167], ["Tumors", "OBSERVATION", 168, 174], ["head", "ANATOMY", 309, 313], ["neck", "ANATOMY", 318, 322], ["cancer", "OBSERVATION", 323, 329], ["necrosis", "OBSERVATION", 368, 376], ["significant", "OBSERVATION_MODIFIER", 382, 393], ["number", "OBSERVATION_MODIFIER", 394, 400], ["tumors", "OBSERVATION", 404, 410], ["without evidence of", "UNCERTAINTY", 412, 431], ["damage", "OBSERVATION", 432, 438], ["normal tissue", "OBSERVATION", 442, 455]]], ["Habib et al. (11) have reported the results of a phase I and a phase II clinical study, in which patients with primary and secondary liver tumors were treated with E1B 55-kDa deleted dl1520.", [["primary", "ANATOMY", 111, 118], ["liver tumors", "ANATOMY", 133, 145], ["primary and secondary liver tumors", "DISEASE", 111, 145], ["patients", "ORGANISM", 97, 105], ["liver tumors", "CANCER", 133, 145], ["E1B", "GENE_OR_GENE_PRODUCT", 164, 167], ["E1B 55-kDa deleted dl1520", "DNA", 164, 189], ["patients", "SPECIES", 97, 105], ["a phase II clinical study", "TEST", 61, 86], ["primary and secondary liver tumors", "PROBLEM", 111, 145], ["E1B", "TREATMENT", 164, 167], ["liver", "ANATOMY", 133, 138], ["tumors", "OBSERVATION", 139, 145]]], ["The adenovirus was given via three different routes: intratumoral, intra-arterial, and intravenous.", [["intratumoral", "ANATOMY", 53, 65], ["intra-arterial", "ANATOMY", 67, 81], ["intravenous", "ANATOMY", 87, 98], ["adenovirus", "ORGANISM", 4, 14], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 87, 98], ["adenovirus", "SPECIES", 4, 14], ["The adenovirus", "TREATMENT", 0, 14], ["intratumoral, intra-arterial", "TREATMENT", 53, 81], ["intravenous", "TREATMENT", 87, 98]]], ["The study has confirmed that dl1520 was well tolerated when given as either monotherapy or in combination with chemotherapy.", [["dl1520", "CHEMICAL", 29, 35], ["dl1520", "CHEMICAL", 29, 35], ["dl1520", "SIMPLE_CHEMICAL", 29, 35], ["The study", "TEST", 0, 9], ["monotherapy", "TREATMENT", 76, 87], ["chemotherapy", "TREATMENT", 111, 123]]], ["Furthermore, ultrastructural examination of tissue showed the presence of adenovirus in cell cytoplasm around the nucleus and revealed two dissimilar end points of cell death after virus infection: a preapoptotic sequence and necrosis (11).", [["tissue", "ANATOMY", 44, 50], ["cell cytoplasm", "ANATOMY", 88, 102], ["nucleus", "ANATOMY", 114, 121], ["cell", "ANATOMY", 164, 168], ["death", "DISEASE", 169, 174], ["infection", "DISEASE", 187, 196], ["necrosis", "DISEASE", 226, 234], ["tissue", "TISSUE", 44, 50], ["adenovirus", "ORGANISM", 74, 84], ["cell cytoplasm", "ORGANISM_SUBSTANCE", 88, 102], ["nucleus", "CELLULAR_COMPONENT", 114, 121], ["cell", "CELL", 164, 168], ["preapoptotic sequence", "DNA", 200, 221], ["ultrastructural examination of tissue", "TEST", 13, 50], ["adenovirus in cell cytoplasm", "PROBLEM", 74, 102], ["cell death", "PROBLEM", 164, 174], ["virus infection", "PROBLEM", 181, 196], ["a preapoptotic sequence", "TEST", 198, 221], ["necrosis", "PROBLEM", 226, 234], ["adenovirus", "OBSERVATION", 74, 84], ["cell cytoplasm", "OBSERVATION", 88, 102], ["nucleus", "ANATOMY", 114, 121], ["two", "OBSERVATION_MODIFIER", 135, 138], ["dissimilar", "OBSERVATION_MODIFIER", 139, 149], ["end", "OBSERVATION_MODIFIER", 150, 153], ["cell death", "OBSERVATION", 164, 174], ["necrosis", "OBSERVATION", 226, 234]]], ["Reid et al. have recently published their results of a phase I study in patients with colorectal liver metastases by using intra-arterial administration of a replication-selective adenovirus (dl1520) (38) .", [["colorectal liver metastases", "ANATOMY", 86, 113], ["intra-arterial", "ANATOMY", 123, 137], ["colorectal liver metastases", "DISEASE", 86, 113], ["dl1520", "CHEMICAL", 192, 198], ["patients", "ORGANISM", 72, 80], ["colorectal", "CANCER", 86, 96], ["liver", "ORGAN", 97, 102], ["intra-arterial", "IMMATERIAL_ANATOMICAL_ENTITY", 123, 137], ["adenovirus", "ORGANISM", 180, 190], ["patients", "SPECIES", 72, 80], ["a phase I study", "TEST", 53, 68], ["colorectal liver metastases", "PROBLEM", 86, 113], ["a replication-selective adenovirus", "TREATMENT", 156, 190], ["liver", "ANATOMY", 97, 102], ["metastases", "OBSERVATION", 103, 113]]], ["In this study, dl1520 was infused into the hepatic artery at doses of 2 \u00d7 10 8 to 2 \u00d7 10 12 particles for two cycles (d 1 and 8) with subsequent cycles of dl1520 administered in combination with intravenous 5-FU and leucovorin.", [["hepatic artery", "ANATOMY", 43, 57], ["intravenous", "ANATOMY", 195, 206], ["dl1520", "CHEMICAL", 15, 21], ["dl1520", "CHEMICAL", 155, 161], ["5-FU", "CHEMICAL", 207, 211], ["leucovorin", "CHEMICAL", 216, 226], ["dl1520", "CHEMICAL", 15, 21], ["dl1520", "CHEMICAL", 155, 161], ["5-FU", "CHEMICAL", 207, 211], ["leucovorin", "CHEMICAL", 216, 226], ["dl1520", "SIMPLE_CHEMICAL", 15, 21], ["hepatic artery", "MULTI-TISSUE_STRUCTURE", 43, 57], ["dl1520", "SIMPLE_CHEMICAL", 155, 161], ["5-FU", "SIMPLE_CHEMICAL", 207, 211], ["leucovorin", "SIMPLE_CHEMICAL", 216, 226], ["this study", "TEST", 3, 13], ["dl1520", "TREATMENT", 15, 21], ["subsequent cycles of dl1520", "TREATMENT", 134, 161], ["intravenous", "TREATMENT", 195, 206], ["leucovorin", "TREATMENT", 216, 226], ["hepatic artery", "ANATOMY", 43, 57]]], ["They have successfully demonstrated intravascular administration of dl1520 virus and have shown that hepatic artery infusion of the attenuated adenovirus dl1520 was well tolerated at doses resulting in infection, replication, and chemotherapy-associated antitumoral activity.", [["intravascular", "ANATOMY", 36, 49], ["hepatic artery", "ANATOMY", 101, 115], ["antitumoral", "ANATOMY", 254, 265], ["dl1520", "CHEMICAL", 154, 160], ["infection", "DISEASE", 202, 211], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 36, 49], ["dl1520 virus", "ORGANISM", 68, 80], ["hepatic artery", "MULTI-TISSUE_STRUCTURE", 101, 115], ["adenovirus", "ORGANISM", 143, 153], ["dl1520", "GENE_OR_GENE_PRODUCT", 154, 160], ["antitumoral", "CANCER", 254, 265], ["adenovirus", "SPECIES", 143, 153], ["intravascular administration of dl1520 virus", "TREATMENT", 36, 80], ["hepatic artery infusion", "TREATMENT", 101, 124], ["the attenuated adenovirus", "TREATMENT", 128, 153], ["infection", "PROBLEM", 202, 211], ["replication", "TREATMENT", 213, 224], ["chemotherapy", "TREATMENT", 230, 242], ["hepatic artery", "ANATOMY", 101, 115], ["infection", "OBSERVATION", 202, 211], ["antitumoral activity", "OBSERVATION", 254, 274]]]], "7d66f2c304295aa1de86551c007c589ae53c632d": [["IntroductionIn the United States (US), 54% of hospitalizations for COVID-19 are among men.", [["men", "ORGANISM", 86, 89], ["men", "SPECIES", 86, 89], ["COVID", "TEST", 67, 72]]], ["1 In Italy, men represent 70% of COVID-19-related deaths.", [["deaths", "DISEASE", 50, 56], ["men", "ORGANISM", 12, 15], ["men", "SPECIES", 12, 15], ["COVID", "TEST", 33, 38]]], ["2 Additionally, there is a relative lack of pre-pubertal infection.", [["pre-pubertal infection", "DISEASE", 44, 66], ["pre-pubertal infection", "PROBLEM", 44, 66], ["pre-pubertal", "OBSERVATION_MODIFIER", 44, 56], ["infection", "OBSERVATION", 57, 66]]], ["3 The reason for these higher rates of infection and mortality in men, and the correspondingly low rates in pre-pubertal children remains unknown.", [["infection", "DISEASE", 39, 48], ["men", "ORGANISM", 66, 69], ["children", "ORGANISM", 121, 129], ["men", "SPECIES", 66, 69], ["children", "SPECIES", 121, 129], ["infection", "PROBLEM", 39, 48], ["infection", "OBSERVATION", 39, 48]]], ["It is possible that an androgen-dependent process may help account for these epidemiological findings, which is a topic of intense focus currently.", [["androgen", "CHEMICAL", 23, 31], ["androgen", "SIMPLE_CHEMICAL", 23, 31], ["an androgen-dependent process", "PROBLEM", 20, 49], ["androgen", "OBSERVATION", 23, 31], ["dependent", "OBSERVATION_MODIFIER", 32, 41], ["process", "OBSERVATION", 42, 49], ["may help account for", "UNCERTAINTY", 50, 70], ["intense", "OBSERVATION_MODIFIER", 123, 130], ["focus", "OBSERVATION", 131, 136]]], ["[4] [5] [6] An androgen-mediated protein (Transmembrane serine protease 2: TMPRSS2) plays a critical role in priming the virus' spike proteins for entry into the host cell as one of the first steps involved in infection.", [["cell", "ANATOMY", 167, 171], ["infection", "DISEASE", 210, 219], ["androgen", "CHEMICAL", 15, 23], ["serine", "CHEMICAL", 56, 62], ["[4] [5] [6", "SIMPLE_CHEMICAL", 0, 10], ["androgen", "SIMPLE_CHEMICAL", 15, 23], ["Transmembrane serine protease 2", "GENE_OR_GENE_PRODUCT", 42, 73], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 75, 82], ["host cell", "CELL", 162, 171], ["androgen-mediated protein", "PROTEIN", 15, 40], ["Transmembrane serine protease 2", "PROTEIN", 42, 73], ["TMPRSS2", "PROTEIN", 75, 82], ["virus' spike proteins", "PROTEIN", 121, 142], ["An androgen-mediated protein (Transmembrane serine protease", "TREATMENT", 12, 71], ["the virus' spike proteins", "PROBLEM", 117, 142], ["infection", "PROBLEM", 210, 219], ["host cell", "OBSERVATION", 162, 171], ["infection", "OBSERVATION", 210, 219]]], ["7 To enter the cell, the SARS-CoV-2 virus uses primed spike proteins to bind cellular angiotensin converting enzyme receptor 2 (ACE2), which leads to cell entry and infection.", [["cell", "ANATOMY", 15, 19], ["cellular", "ANATOMY", 77, 85], ["cell", "ANATOMY", 150, 154], ["angiotensin", "CHEMICAL", 86, 97], ["infection", "DISEASE", 165, 174], ["cell", "CELL", 15, 19], ["SARS-CoV-2 virus", "ORGANISM", 25, 41], ["cellular", "CELL", 77, 85], ["angiotensin converting enzyme receptor 2", "GENE_OR_GENE_PRODUCT", 86, 126], ["ACE2", "GENE_OR_GENE_PRODUCT", 128, 132], ["cell", "CELL", 150, 154], ["primed spike proteins", "PROTEIN", 47, 68], ["cellular angiotensin converting enzyme receptor 2", "PROTEIN", 77, 126], ["ACE2", "PROTEIN", 128, 132], ["SARS-CoV-2 virus", "SPECIES", 25, 41], ["the SARS", "PROBLEM", 21, 29], ["CoV-2 virus", "TREATMENT", 30, 41], ["bind cellular angiotensin", "TREATMENT", 72, 97], ["enzyme receptor", "TREATMENT", 109, 124], ["cell entry", "PROBLEM", 150, 160], ["infection", "PROBLEM", 165, 174], ["cell entry", "OBSERVATION", 150, 160], ["infection", "OBSERVATION", 165, 174]]], ["TMPRSS2 activity is essential for spike priming, and its activation is dependent on androgens.", [["androgens", "CHEMICAL", 84, 93], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 0, 7], ["androgens", "SIMPLE_CHEMICAL", 84, 93], ["TMPRSS2", "PROTEIN", 0, 7], ["TMPRSS2 activity", "TEST", 0, 16], ["spike priming", "PROBLEM", 34, 47], ["dependent", "OBSERVATION_MODIFIER", 71, 80]]], ["8 Additionally, TMPRSS2 may interact directly with ACE2 receptors allowing for augmented viral entry.", [["TMPRSS2", "GENE_OR_GENE_PRODUCT", 16, 23], ["ACE2", "GENE_OR_GENE_PRODUCT", 51, 55], ["TMPRSS2", "PROTEIN", 16, 23], ["ACE2 receptors", "PROTEIN", 51, 65], ["ACE2 receptors", "TREATMENT", 51, 65], ["augmented viral entry", "PROBLEM", 79, 100], ["viral entry", "OBSERVATION", 89, 100]]], ["7 Because of its critical role in the process of viral infectivity, an understanding of TMPRSS2 is essential in explaining the gender disparities associated with COVID-19.IntroductionKnowledge gained from prostate cancer research revealed the androgen dependent nature of TMPRSS2: an activated androgen receptor (AR) upregulates TMPRSS2 mRNA, 9 while androgen deprivation therapy (ADT) suppresses it.", [["prostate cancer", "ANATOMY", 205, 220], ["prostate cancer", "DISEASE", 205, 220], ["androgen", "CHEMICAL", 243, 251], ["androgen", "CHEMICAL", 294, 302], ["androgen", "CHEMICAL", 351, 359], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 88, 95], ["prostate cancer", "CANCER", 205, 220], ["androgen", "SIMPLE_CHEMICAL", 243, 251], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 272, 279], ["androgen receptor", "GENE_OR_GENE_PRODUCT", 294, 311], ["AR", "GENE_OR_GENE_PRODUCT", 313, 315], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 329, 336], ["androgen", "SIMPLE_CHEMICAL", 351, 359], ["TMPRSS2", "DNA", 88, 95], ["TMPRSS2", "PROTEIN", 272, 279], ["androgen receptor", "PROTEIN", 294, 311], ["AR", "PROTEIN", 313, 315], ["TMPRSS2 mRNA", "RNA", 329, 341], ["viral infectivity", "PROBLEM", 49, 66], ["TMPRSS2", "PROBLEM", 88, 95], ["COVID", "TEST", 162, 167], ["prostate cancer", "PROBLEM", 205, 220], ["an activated androgen receptor (AR", "TREATMENT", 281, 315], ["TMPRSS2 mRNA", "TEST", 329, 341], ["androgen deprivation therapy (ADT)", "TREATMENT", 351, 385], ["viral infectivity", "OBSERVATION", 49, 66], ["prostate", "ANATOMY", 205, 213], ["cancer", "OBSERVATION", 214, 220]]], ["10 The androgen-dependent nature is evident outside of the prostate, as administering exogenous testosterone in vitro modestly increases expression of TMPRSS2.", [["prostate", "ANATOMY", 59, 67], ["testosterone", "CHEMICAL", 96, 108], ["androgen", "CHEMICAL", 7, 15], ["testosterone", "CHEMICAL", 96, 108], ["androgen", "SIMPLE_CHEMICAL", 7, 15], ["prostate", "ORGAN", 59, 67], ["testosterone", "SIMPLE_CHEMICAL", 96, 108], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 151, 158], ["TMPRSS2", "PROTEIN", 151, 158], ["exogenous testosterone", "TREATMENT", 86, 108], ["TMPRSS2", "PROBLEM", 151, 158], ["androgen", "OBSERVATION", 7, 15], ["dependent nature", "OBSERVATION_MODIFIER", 16, 32], ["prostate", "ANATOMY", 59, 67]]], ["9 Additional in vitro research has shown that inhibition of TMPRSS2 can prevent SARS-CoV-2 infectivity.", [["TMPRSS2", "CHEMICAL", 60, 67], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 60, 67], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 80, 90], ["TMPRSS2", "PROTEIN", 60, 67], ["TMPRSS2", "PROBLEM", 60, 67], ["SARS", "PROBLEM", 80, 84], ["CoV-2 infectivity", "PROBLEM", 85, 102]]], ["7 This knowledge, in conjunction with the male predilection for infection, has led many to investigate how testosterone levels and androgen manipulation may attenuate the impact of Given the complex relationship between androgens and the impact of COVID-19, there are three specific patient populations that deserve closer study to better understand the pathophysiology of androgens on SARS-CoV-2: Men receiving ADT, men with testosterone deficiency (TD), and men receiving testosterone therapy (TT).Can Androgen Deprivation Therapy prevent COVID-19-related morbidity?AR activity is considered a requirement for the transcription of the TMPRSS2 gene.", [["infection", "DISEASE", 64, 73], ["testosterone", "CHEMICAL", 107, 119], ["testosterone", "CHEMICAL", 426, 438], ["TD", "DISEASE", 451, 453], ["testosterone", "CHEMICAL", 474, 486], ["testosterone", "CHEMICAL", 107, 119], ["androgen", "CHEMICAL", 131, 139], ["androgens", "CHEMICAL", 220, 229], ["COVID-19", "CHEMICAL", 248, 256], ["androgens", "CHEMICAL", 373, 382], ["testosterone", "CHEMICAL", 426, 438], ["testosterone", "CHEMICAL", 474, 486], ["Androgen", "CHEMICAL", 504, 512], ["testosterone", "SIMPLE_CHEMICAL", 107, 119], ["androgen", "SIMPLE_CHEMICAL", 131, 139], ["androgens", "SIMPLE_CHEMICAL", 220, 229], ["patient", "ORGANISM", 283, 290], ["androgens", "SIMPLE_CHEMICAL", 373, 382], ["Men", "ORGANISM", 398, 401], ["men", "ORGANISM", 417, 420], ["testosterone", "SIMPLE_CHEMICAL", 426, 438], ["men", "ORGANISM", 460, 463], ["testosterone", "SIMPLE_CHEMICAL", 474, 486], ["Androgen", "SIMPLE_CHEMICAL", 504, 512], ["AR", "GENE_OR_GENE_PRODUCT", 568, 570], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 637, 644], ["AR", "PROTEIN", 568, 570], ["TMPRSS2 gene", "DNA", 637, 649], ["patient", "SPECIES", 283, 290], ["men", "SPECIES", 417, 420], ["men", "SPECIES", 460, 463], ["infection", "PROBLEM", 64, 73], ["testosterone levels", "TEST", 107, 126], ["androgen manipulation", "TREATMENT", 131, 152], ["COVID", "TEST", 248, 253], ["closer study", "TEST", 316, 328], ["ADT", "TREATMENT", 412, 415], ["testosterone deficiency", "PROBLEM", 426, 449], ["testosterone therapy", "TREATMENT", 474, 494], ["Androgen Deprivation", "TREATMENT", 504, 524], ["Therapy", "TREATMENT", 525, 532], ["COVID", "TEST", 541, 546], ["morbidity", "PROBLEM", 558, 567], ["the TMPRSS2 gene", "TREATMENT", 633, 649], ["infection", "OBSERVATION", 64, 73]]], ["11 Expression of TMPRSS2 decreases when men are subjected to ADT, 10 therefore decreased transcription of the TMPRSS2 gene could lead to reduced viral entry and milder symptoms.", [["TMPRSS2", "GENE_OR_GENE_PRODUCT", 17, 24], ["men", "ORGANISM", 40, 43], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 110, 117], ["TMPRSS2", "PROTEIN", 17, 24], ["TMPRSS2 gene", "DNA", 110, 122], ["men", "SPECIES", 40, 43], ["TMPRSS2 decreases", "PROBLEM", 17, 34], ["ADT", "TEST", 61, 64], ["the TMPRSS2 gene", "TREATMENT", 106, 122], ["reduced viral entry", "PROBLEM", 137, 156], ["milder symptoms", "PROBLEM", 161, 176], ["decreases", "OBSERVATION_MODIFIER", 25, 34], ["reduced", "OBSERVATION_MODIFIER", 137, 144], ["viral entry", "OBSERVATION", 145, 156]]], ["A population based study of 4532 men sought to determine the possible role of ADT in prevention or reduction of SARS-CoV-2 infection in patients affected by prostate cancer (PCa).", [["prostate cancer", "ANATOMY", 157, 172], ["PCa", "ANATOMY", 174, 177], ["ADT", "CHEMICAL", 78, 81], ["SARS-CoV-2 infection", "DISEASE", 112, 132], ["prostate cancer", "DISEASE", 157, 172], ["PCa", "DISEASE", 174, 177], ["men", "ORGANISM", 33, 36], ["SARS-CoV-2", "ORGANISM", 112, 122], ["patients", "ORGANISM", 136, 144], ["prostate cancer", "CANCER", 157, 172], ["PCa", "CANCER", 174, 177], ["men", "SPECIES", 33, 36], ["patients", "SPECIES", 136, 144], ["SARS-CoV-2", "SPECIES", 112, 122], ["A population based study", "TEST", 0, 24], ["ADT in prevention", "TREATMENT", 78, 95], ["SARS", "PROBLEM", 112, 116], ["CoV", "PROBLEM", 117, 120], ["2 infection", "PROBLEM", 121, 132], ["prostate cancer", "PROBLEM", 157, 172], ["SARS", "OBSERVATION", 112, 116], ["infection", "OBSERVATION", 123, 132], ["prostate", "ANATOMY", 157, 165], ["cancer", "OBSERVATION", 166, 172]]], ["12 In this cohort, men with PCa who received ADT had significantly lower rates of infection compared to men with PCa who did not receive ADT (OR 4.05; 95% CI 1.55-10.59).", [["PCa", "ANATOMY", 28, 31], ["PCa", "ANATOMY", 113, 116], ["PCa", "DISEASE", 28, 31], ["infection", "DISEASE", 82, 91], ["PCa", "DISEASE", 113, 116], ["men", "ORGANISM", 19, 22], ["PCa", "CANCER", 28, 31], ["men", "ORGANISM", 104, 107], ["PCa", "CANCER", 113, 116], ["men", "SPECIES", 19, 22], ["men", "SPECIES", 104, 107], ["PCa", "TREATMENT", 28, 31], ["ADT", "TREATMENT", 45, 48], ["significantly lower rates of infection", "PROBLEM", 53, 91], ["PCa", "TREATMENT", 113, 116], ["ADT", "TREATMENT", 137, 140], ["CI", "TEST", 155, 157], ["infection", "OBSERVATION", 82, 91]]], ["Additionally, PCa patients receiving ADT showed a decreased risk of SARS-CoV-2 infection compared to patients affected by other cancers (OR 5.17; 95% CI 2.02-13.40).", [["PCa", "ANATOMY", 14, 17], ["cancers", "ANATOMY", 128, 135], ["PCa", "DISEASE", 14, 17], ["SARS-CoV-2 infection", "DISEASE", 68, 88], ["cancers", "DISEASE", 128, 135], ["PCa", "CANCER", 14, 17], ["patients", "ORGANISM", 18, 26], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 68, 78], ["patients", "ORGANISM", 101, 109], ["cancers", "CANCER", 128, 135], ["patients", "SPECIES", 18, 26], ["patients", "SPECIES", 101, 109], ["SARS-CoV", "SPECIES", 68, 76], ["PCa", "TREATMENT", 14, 17], ["ADT", "TREATMENT", 37, 40], ["SARS", "PROBLEM", 68, 72], ["CoV-2 infection", "PROBLEM", 73, 88], ["other cancers", "PROBLEM", 122, 135], ["CI", "TEST", 150, 152], ["SARS", "OBSERVATION", 68, 72], ["infection", "OBSERVATION", 79, 88], ["cancers", "OBSERVATION", 128, 135]]], ["This paper had several weaknesses, including its observational nature, its use of a tumor registry study as a comparison group, and most notably, the small number of prostate cancer patients without ADT (N=114) and with ADT The potential protective effect of ADT on COVID-19 is particularly interesting considering the use of ADT is associated with major adverse cardiac events (MACE) and venous thromboembolism (VTE).", [["tumor", "ANATOMY", 84, 89], ["prostate cancer", "ANATOMY", 166, 181], ["cardiac", "ANATOMY", 363, 370], ["venous", "ANATOMY", 389, 395], ["tumor", "DISEASE", 84, 89], ["prostate cancer", "DISEASE", 166, 181], ["ADT", "CHEMICAL", 259, 262], ["COVID-19", "CHEMICAL", 266, 274], ["ADT", "CHEMICAL", 326, 329], ["adverse cardiac events", "DISEASE", 355, 377], ["venous thromboembolism", "DISEASE", 389, 411], ["VTE", "DISEASE", 413, 416], ["tumor", "CANCER", 84, 89], ["prostate cancer", "CANCER", 166, 181], ["patients", "ORGANISM", 182, 190], ["ADT", "SIMPLE_CHEMICAL", 259, 262], ["COVID-19", "GENE_OR_GENE_PRODUCT", 266, 274], ["ADT", "SIMPLE_CHEMICAL", 326, 329], ["cardiac", "ORGAN", 363, 370], ["venous", "PATHOLOGICAL_FORMATION", 389, 395], ["patients", "SPECIES", 182, 190], ["several weaknesses", "PROBLEM", 15, 33], ["a tumor registry study", "TEST", 82, 104], ["prostate cancer", "PROBLEM", 166, 181], ["ADT", "TEST", 199, 202], ["ADT", "PROBLEM", 220, 223], ["ADT on COVID", "TREATMENT", 259, 271], ["ADT", "TREATMENT", 326, 329], ["major adverse cardiac events", "PROBLEM", 349, 377], ["venous thromboembolism (VTE", "PROBLEM", 389, 416], ["several", "OBSERVATION_MODIFIER", 15, 22], ["weaknesses", "OBSERVATION", 23, 33], ["small", "OBSERVATION_MODIFIER", 150, 155], ["prostate", "ANATOMY", 166, 174], ["cancer", "OBSERVATION", 175, 181], ["potential", "UNCERTAINTY", 228, 237], ["protective", "OBSERVATION_MODIFIER", 238, 248], ["effect", "OBSERVATION_MODIFIER", 249, 255], ["venous", "ANATOMY", 389, 395], ["thromboembolism", "OBSERVATION", 396, 411]]], ["13 Given that COVID-19 carries a worse prognosis in comorbid men, 1 and the high rate of VTE seen in patients with COVID-19, 14 it will be important to see how these competing factors balance out in future clinical trials.How does Testosterone Deficiency (TD) affect SARS-CoV-2 infection?Similar to men receiving ADT, we can posit that men with TD may experience milder effects of SARS-CoV-2 infection due to lack of TMPRSS2 transcription.", [["VTE", "DISEASE", 89, 92], ["Testosterone", "CHEMICAL", 231, 243], ["TD", "DISEASE", 256, 258], ["SARS", "DISEASE", 267, 271], ["infection", "DISEASE", 278, 287], ["TD", "DISEASE", 345, 347], ["SARS", "DISEASE", 381, 385], ["infection", "DISEASE", 392, 401], ["Testosterone", "CHEMICAL", 231, 243], ["men", "ORGANISM", 61, 64], ["patients", "ORGANISM", 101, 109], ["Testosterone", "SIMPLE_CHEMICAL", 231, 243], ["SARS-CoV-2", "ORGANISM", 267, 277], ["men", "ORGANISM", 299, 302], ["men", "ORGANISM", 336, 339], ["SARS-CoV-2", "ORGANISM", 381, 391], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 417, 424], ["COVID-19", "DNA", 14, 22], ["TMPRSS2", "PROTEIN", 417, 424], ["men", "SPECIES", 61, 64], ["patients", "SPECIES", 101, 109], ["men", "SPECIES", 299, 302], ["men", "SPECIES", 336, 339], ["SARS-CoV", "SPECIES", 381, 389], ["VTE", "PROBLEM", 89, 92], ["COVID", "TEST", 115, 120], ["Testosterone Deficiency (TD) affect SARS", "PROBLEM", 231, 271], ["CoV-2 infection", "PROBLEM", 272, 287], ["ADT", "TREATMENT", 313, 316], ["SARS", "PROBLEM", 381, 385], ["CoV", "PROBLEM", 386, 389], ["2 infection", "PROBLEM", 390, 401], ["TMPRSS2 transcription", "PROBLEM", 417, 438], ["infection", "OBSERVATION", 278, 287]]], ["However, the observational data collected thus far supports the opposite conclusion: that men with TD appear to have a worse prognosis with COVID-19.How does Testosterone Deficiency (TD) affect SARS-CoV-2 infection?One study from Italy measured reproductive hormones in men on admission to a respiratory ICU.", [["TD", "DISEASE", 99, 101], ["Testosterone", "CHEMICAL", 158, 170], ["TD", "DISEASE", 183, 185], ["SARS", "DISEASE", 194, 198], ["infection", "DISEASE", 205, 214], ["Testosterone", "CHEMICAL", 158, 170], ["men", "ORGANISM", 90, 93], ["Testosterone", "SIMPLE_CHEMICAL", 158, 170], ["SARS-CoV-2", "ORGANISM", 194, 204], ["men", "ORGANISM", 270, 273], ["men", "SPECIES", 90, 93], ["men", "SPECIES", 270, 273], ["the observational data", "TEST", 9, 31], ["COVID", "TEST", 140, 145], ["Testosterone Deficiency (TD) affect SARS", "PROBLEM", 158, 198], ["CoV-2 infection", "PROBLEM", 199, 214], ["One study", "TEST", 215, 224], ["infection", "OBSERVATION", 205, 214]]], ["Lower testosterone on admission was associated with a higher likelihood of mortality or escalation of care.", [["testosterone", "CHEMICAL", 6, 18], ["testosterone", "CHEMICAL", 6, 18], ["testosterone", "SIMPLE_CHEMICAL", 6, 18], ["Lower testosterone", "PROBLEM", 0, 18], ["escalation of care", "TREATMENT", 88, 106]]], ["5 Similarly, a cohort from Germany identified low testosterone and dihydrotestosterone (DHT) levels in 67% and 49% of SARS-CoV-2 infected men on admission to the ICU, respectively.", [["testosterone", "CHEMICAL", 50, 62], ["dihydrotestosterone", "CHEMICAL", 67, 86], ["DHT", "CHEMICAL", 88, 91], ["SARS-CoV-2 infected", "DISEASE", 118, 137], ["testosterone", "CHEMICAL", 50, 62], ["dihydrotestosterone", "CHEMICAL", 67, 86], ["DHT", "CHEMICAL", 88, 91], ["testosterone", "SIMPLE_CHEMICAL", 50, 62], ["dihydrotestosterone", "SIMPLE_CHEMICAL", 67, 86], ["DHT", "SIMPLE_CHEMICAL", 88, 91], ["SARS-CoV-2", "ORGANISM", 118, 128], ["men", "ORGANISM", 138, 141], ["CoV-", "SPECIES", 123, 127], ["men", "SPECIES", 138, 141], ["SARS-CoV", "SPECIES", 118, 126], ["low testosterone", "TREATMENT", 46, 62], ["dihydrotestosterone (DHT) levels", "TEST", 67, 99], ["SARS", "TEST", 118, 122], ["CoV", "TEST", 123, 126], ["low testosterone", "OBSERVATION", 46, 62]]], ["15 These studies suggest a relationship between testosterone and SARS-CoV-2 infection, however these observational data must be interpreted with caution for several reasons.How does Testosterone Deficiency (TD) affect SARS-CoV-2 infection?Without baseline androgen levels pre-infection, it is challenging to explain the directionality of this relationship seen in the prior studies.", [["testosterone", "CHEMICAL", 48, 60], ["SARS", "DISEASE", 65, 69], ["infection", "DISEASE", 76, 85], ["Testosterone", "CHEMICAL", 182, 194], ["TD", "DISEASE", 207, 209], ["SARS", "DISEASE", 218, 222], ["infection", "DISEASE", 229, 238], ["testosterone", "CHEMICAL", 48, 60], ["Testosterone", "CHEMICAL", 182, 194], ["androgen", "CHEMICAL", 256, 264], ["testosterone", "SIMPLE_CHEMICAL", 48, 60], ["SARS-CoV-2", "ORGANISM", 65, 75], ["Testosterone", "SIMPLE_CHEMICAL", 182, 194], ["SARS-CoV-2", "ORGANISM", 218, 228], ["androgen", "GENE_OR_GENE_PRODUCT", 256, 264], ["SARS-CoV", "SPECIES", 65, 73], ["These studies", "TEST", 3, 16], ["testosterone", "TREATMENT", 48, 60], ["SARS", "PROBLEM", 65, 69], ["CoV-2 infection", "PROBLEM", 70, 85], ["these observational data", "TEST", 95, 119], ["Testosterone Deficiency (TD) affect SARS", "PROBLEM", 182, 222], ["CoV-2 infection", "PROBLEM", 223, 238], ["baseline androgen levels pre-infection", "PROBLEM", 247, 285], ["the prior studies", "TEST", 364, 381], ["infection", "OBSERVATION", 76, 85], ["infection", "OBSERVATION", 229, 238], ["androgen levels", "OBSERVATION", 256, 271]]], ["Not only does testosterone decline with age, but the decline is also accelerated in men with comorbidities, and in the presence of acute illness.", [["testosterone", "CHEMICAL", 14, 26], ["acute illness", "DISEASE", 131, 144], ["testosterone", "CHEMICAL", 14, 26], ["testosterone", "SIMPLE_CHEMICAL", 14, 26], ["men", "ORGANISM", 84, 87], ["men", "SPECIES", 84, 87], ["testosterone decline", "PROBLEM", 14, 34], ["comorbidities", "PROBLEM", 93, 106], ["acute illness", "PROBLEM", 131, 144], ["acute", "OBSERVATION_MODIFIER", 131, 136], ["illness", "OBSERVATION", 137, 144]]], ["16 Low testosterone in the older male appears to be a robust marker of poor health, and possible mortality, rather than a causal factor.", [["testosterone", "CHEMICAL", 7, 19], ["testosterone", "CHEMICAL", 7, 19], ["testosterone", "SIMPLE_CHEMICAL", 7, 19], ["Low testosterone", "OBSERVATION_MODIFIER", 3, 19], ["possible", "UNCERTAINTY", 88, 96]]], ["17 Without a baseline testosterone level, it is difficult to know whether or not these prior studies simply represent a continuum of testosterone suppression that follows increasing severity of SARS-CoV-2 infection and acute illness, rather than a true cause-effect relationship.How does Testosterone Deficiency (TD) affect SARS-CoV-2 infection?Finally, TD may play a role in SARS-CoV-2 infection due to their shared effect on inflammation.How does Testosterone Deficiency (TD) affect SARS-CoV-2 infection?The clinical deterioration seen with COVID-19 is in large part due to overwhelming inflammation.", [["testosterone", "CHEMICAL", 22, 34], ["testosterone", "CHEMICAL", 133, 145], ["SARS", "DISEASE", 194, 198], ["infection", "DISEASE", 205, 214], ["acute illness", "DISEASE", 219, 232], ["Testosterone", "CHEMICAL", 288, 300], ["TD", "DISEASE", 313, 315], ["SARS", "DISEASE", 324, 328], ["infection", "DISEASE", 335, 344], ["TD", "DISEASE", 354, 356], ["infection", "DISEASE", 387, 396], ["inflammation", "DISEASE", 427, 439], ["Testosterone", "CHEMICAL", 449, 461], ["TD", "DISEASE", 474, 476], ["SARS", "DISEASE", 485, 489], ["infection", "DISEASE", 496, 505], ["COVID-19", "CHEMICAL", 543, 551], ["inflammation", "DISEASE", 589, 601], ["testosterone", "CHEMICAL", 22, 34], ["testosterone", "CHEMICAL", 133, 145], ["Testosterone", "CHEMICAL", 288, 300], ["Testosterone", "CHEMICAL", 449, 461], ["COVID-19", "CHEMICAL", 543, 551], ["testosterone", "SIMPLE_CHEMICAL", 22, 34], ["testosterone", "SIMPLE_CHEMICAL", 133, 145], ["SARS-CoV-2", "ORGANISM", 194, 204], ["Testosterone", "SIMPLE_CHEMICAL", 288, 300], ["SARS-CoV-2", "ORGANISM", 324, 334], ["SARS-CoV-2", "ORGANISM", 376, 386], ["Testosterone", "SIMPLE_CHEMICAL", 449, 461], ["SARS-CoV-2", "ORGANISM", 485, 495], ["SARS-CoV", "SPECIES", 194, 202], ["SARS-CoV-2", "SPECIES", 376, 386], ["a baseline testosterone level", "TEST", 11, 40], ["these prior studies", "TEST", 81, 100], ["testosterone suppression", "TREATMENT", 133, 157], ["SARS", "PROBLEM", 194, 198], ["CoV-2 infection", "PROBLEM", 199, 214], ["acute illness", "PROBLEM", 219, 232], ["Testosterone Deficiency (TD) affect SARS", "PROBLEM", 288, 328], ["CoV-2 infection", "PROBLEM", 329, 344], ["SARS", "PROBLEM", 376, 380], ["CoV", "PROBLEM", 381, 384], ["2 infection", "PROBLEM", 385, 396], ["inflammation", "PROBLEM", 427, 439], ["Testosterone Deficiency (TD) affect SARS", "PROBLEM", 449, 489], ["CoV-2 infection", "PROBLEM", 490, 505], ["The clinical deterioration", "PROBLEM", 506, 532], ["COVID", "TEST", 543, 548], ["overwhelming inflammation", "PROBLEM", 576, 601], ["infection", "OBSERVATION", 205, 214], ["acute", "OBSERVATION_MODIFIER", 219, 224], ["illness", "OBSERVATION", 225, 232], ["infection", "OBSERVATION", 335, 344], ["inflammation", "OBSERVATION", 427, 439], ["infection", "OBSERVATION", 496, 505], ["overwhelming", "OBSERVATION_MODIFIER", 576, 588], ["inflammation", "OBSERVATION", 589, 601]]], ["18 Meanwhile, sex hormones in healthy men exert key functions on immune cell targets that express AR such as monocytes, macrophages, and neutrophils.", [["immune cell", "ANATOMY", 65, 76], ["monocytes", "ANATOMY", 109, 118], ["macrophages", "ANATOMY", 120, 131], ["neutrophils", "ANATOMY", 137, 148], ["men", "ORGANISM", 38, 41], ["immune cell", "CELL", 65, 76], ["AR", "GENE_OR_GENE_PRODUCT", 98, 100], ["monocytes", "CELL", 109, 118], ["macrophages", "CELL", 120, 131], ["neutrophils", "CELL", 137, 148], ["AR", "PROTEIN", 98, 100], ["monocytes", "CELL_TYPE", 109, 118], ["macrophages", "CELL_TYPE", 120, 131], ["neutrophils", "CELL_TYPE", 137, 148], ["men", "SPECIES", 38, 41], ["immune cell targets", "TEST", 65, 84], ["AR", "PROBLEM", 98, 100], ["monocytes", "TEST", 109, 118], ["macrophages", "TEST", 120, 131], ["neutrophils", "TEST", 137, 148], ["immune cell", "OBSERVATION", 65, 76], ["neutrophils", "ANATOMY", 137, 148]]], ["6 In general, this action tends to be immunosuppressive; higher levels of inflammatory cytokines are seen in men with low testosterone, and these levels normalize with testosterone replacement.", [["testosterone", "CHEMICAL", 122, 134], ["testosterone", "CHEMICAL", 168, 180], ["testosterone", "CHEMICAL", 122, 134], ["testosterone", "CHEMICAL", 168, 180], ["men", "ORGANISM", 109, 112], ["testosterone", "SIMPLE_CHEMICAL", 122, 134], ["testosterone", "SIMPLE_CHEMICAL", 168, 180], ["inflammatory cytokines", "PROTEIN", 74, 96], ["men", "SPECIES", 109, 112], ["immunosuppressive", "TREATMENT", 38, 55], ["inflammatory cytokines", "PROBLEM", 74, 96], ["low testosterone", "TREATMENT", 118, 134], ["these levels", "TEST", 140, 152], ["testosterone replacement", "TREATMENT", 168, 192], ["inflammatory cytokines", "OBSERVATION", 74, 96]]], ["6 Because of this, some have hypothesized that men with TD are more susceptible to the inflammatory sequelae that come with COVID-19.", [["TD", "DISEASE", 56, 58], ["COVID-19", "CHEMICAL", 124, 132], ["men", "ORGANISM", 47, 50], ["men", "SPECIES", 47, 50], ["TD", "PROBLEM", 56, 58], ["the inflammatory sequelae", "PROBLEM", 83, 108], ["COVID", "TEST", 124, 129], ["inflammatory", "OBSERVATION", 87, 99]]], ["6 Data on baseline androgen levels in men prior to SARS-CoV-2 infection would be a useful first step to understanding this relationship.How does Testosterone Deficiency (TD) affect SARS-CoV-2 infection?Are SARS-CoV-2 positive men who receive testosterone therapy at higher risk of MACE?How does Testosterone Deficiency (TD) affect SARS-CoV-2 infection?SARS-CoV-2 infection leads to a hypercoagulable state due to a combination of hypoxemia and a systemic inflammatory response syndrome, characterized by high fibrinogen and demonstrated by progressive D-dimer elevation.", [["SARS", "DISEASE", 51, 55], ["infection", "DISEASE", 62, 71], ["Testosterone", "CHEMICAL", 145, 157], ["TD", "DISEASE", 170, 172], ["SARS", "DISEASE", 181, 185], ["infection", "DISEASE", 192, 201], ["testosterone", "CHEMICAL", 242, 254], ["Testosterone", "CHEMICAL", 295, 307], ["TD", "DISEASE", 320, 322], ["SARS", "DISEASE", 331, 335], ["infection", "DISEASE", 342, 351], ["SARS", "DISEASE", 352, 356], ["infection", "DISEASE", 363, 372], ["hypercoagulable state", "DISEASE", 384, 405], ["hypoxemia", "DISEASE", 430, 439], ["systemic inflammatory response syndrome", "DISEASE", 446, 485], ["androgen", "CHEMICAL", 19, 27], ["Testosterone", "CHEMICAL", 145, 157], ["testosterone", "CHEMICAL", 242, 254], ["Testosterone", "CHEMICAL", 295, 307], ["androgen", "GENE_OR_GENE_PRODUCT", 19, 27], ["men", "ORGANISM", 38, 41], ["SARS-CoV-2", "ORGANISM", 51, 61], ["Testosterone", "SIMPLE_CHEMICAL", 145, 157], ["SARS-CoV-2", "ORGANISM", 181, 191], ["SARS-CoV-2", "ORGANISM", 206, 216], ["men", "ORGANISM", 226, 229], ["testosterone", "SIMPLE_CHEMICAL", 242, 254], ["Testosterone", "SIMPLE_CHEMICAL", 295, 307], ["SARS-CoV-2", "ORGANISM", 331, 341], ["SARS-CoV-2", "ORGANISM", 352, 362], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 509, 519], ["D-dimer", "SIMPLE_CHEMICAL", 552, 559], ["fibrinogen", "PROTEIN", 509, 519], ["men", "SPECIES", 38, 41], ["men", "SPECIES", 226, 229], ["SARS-CoV", "SPECIES", 51, 59], ["SARS-CoV-2", "SPECIES", 352, 362], ["baseline androgen levels", "TEST", 10, 34], ["SARS", "PROBLEM", 51, 55], ["CoV-2 infection", "PROBLEM", 56, 71], ["Testosterone Deficiency (TD) affect SARS", "PROBLEM", 145, 185], ["CoV-2 infection", "PROBLEM", 186, 201], ["SARS", "TEST", 206, 210], ["CoV", "TEST", 211, 214], ["testosterone therapy", "TREATMENT", 242, 262], ["Testosterone Deficiency (TD) affect SARS", "PROBLEM", 295, 335], ["CoV-2 infection", "PROBLEM", 336, 351], ["SARS", "PROBLEM", 352, 356], ["CoV", "PROBLEM", 357, 360], ["2 infection", "PROBLEM", 361, 372], ["a hypercoagulable state", "PROBLEM", 382, 405], ["hypoxemia", "PROBLEM", 430, 439], ["a systemic inflammatory response syndrome", "PROBLEM", 444, 485], ["high fibrinogen", "PROBLEM", 504, 519], ["progressive D-dimer elevation", "PROBLEM", 540, 569], ["infection", "OBSERVATION", 62, 71], ["infection", "OBSERVATION", 192, 201], ["infection", "OBSERVATION", 342, 351], ["infection", "OBSERVATION", 363, 372], ["hypercoagulable", "OBSERVATION", 384, 399], ["hypoxemia", "OBSERVATION", 430, 439], ["systemic", "OBSERVATION_MODIFIER", 446, 454], ["inflammatory response syndrome", "OBSERVATION", 455, 485], ["high fibrinogen", "OBSERVATION", 504, 519], ["progressive", "OBSERVATION_MODIFIER", 540, 551], ["dimer elevation", "OBSERVATION", 554, 569]]], ["14 Early on, abnormal coagulation parameters were identified as a poor prognostic factor in those infected with SARS-CoV-2.", [["SARS", "DISEASE", 112, 116], ["SARS-CoV-2", "ORGANISM", 112, 122], ["SARS-CoV", "SPECIES", 112, 120], ["abnormal coagulation parameters", "PROBLEM", 13, 44], ["a poor prognostic factor", "PROBLEM", 64, 88], ["CoV", "TEST", 117, 120]]], ["14 Further study showed that patients in the ICU with COVID-19 were found to suffer from a higher rate of thrombosis than the typical ICU patient despite anticoagulation, up to a rate of 79% in one study of ICU patients in France.", [["thrombosis", "DISEASE", 106, 116], ["patients", "ORGANISM", 29, 37], ["patient", "ORGANISM", 138, 145], ["patients", "ORGANISM", 211, 219], ["patients", "SPECIES", 29, 37], ["patient", "SPECIES", 138, 145], ["patients", "SPECIES", 211, 219], ["Further study", "TEST", 3, 16], ["COVID", "TEST", 54, 59], ["thrombosis", "PROBLEM", 106, 116], ["anticoagulation", "TREATMENT", 154, 169], ["a rate", "TEST", 177, 183], ["thrombosis", "OBSERVATION", 106, 116]]], ["19 These findings have led some centers to place patients on higher prophylactic doses of anticoagulation to try and prevent sequelae of COVID-related coagulopathy, and is the subject of ongoing clinical trials.", [["COVID", "DISEASE", 137, 142], ["coagulopathy", "DISEASE", 151, 163], ["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 49, 57], ["higher prophylactic doses", "TREATMENT", 61, 86], ["anticoagulation", "TREATMENT", 90, 105], ["COVID-related coagulopathy", "PROBLEM", 137, 163], ["coagulopathy", "OBSERVATION", 151, 163]]], ["20 Testosterone therapy (TT), particularly when resulting in supratherapeutic levels of testosterone, can induce a coagulopathic state in men, characterized by polycythemia.", [["Testosterone", "CHEMICAL", 3, 15], ["testosterone", "CHEMICAL", 88, 100], ["polycythemia", "DISEASE", 160, 172], ["Testosterone", "CHEMICAL", 3, 15], ["testosterone", "CHEMICAL", 88, 100], ["Testosterone", "SIMPLE_CHEMICAL", 3, 15], ["testosterone", "SIMPLE_CHEMICAL", 88, 100], ["men", "ORGANISM", 138, 141], ["men", "SPECIES", 138, 141], ["20 Testosterone therapy", "TREATMENT", 0, 23], ["supratherapeutic levels of testosterone", "PROBLEM", 61, 100], ["a coagulopathic state", "PROBLEM", 113, 134], ["polycythemia", "PROBLEM", 160, 172], ["coagulopathic", "OBSERVATION", 115, 128], ["polycythemia", "OBSERVATION", 160, 172]]], ["21 It is not clear whether TT causes venous thromboembolism (VTE), however the risk of secondary polycythemia (Hct \u2265 54%) is well-established, and appears to occur at higher rates in certain modalities of TT.", [["venous", "ANATOMY", 37, 43], ["venous thromboembolism", "DISEASE", 37, 59], ["VTE", "DISEASE", 61, 64], ["polycythemia", "DISEASE", 97, 109], ["venous", "PATHOLOGICAL_FORMATION", 37, 43], ["venous thromboembolism", "PROBLEM", 37, 59], ["VTE", "PROBLEM", 61, 64], ["secondary polycythemia", "PROBLEM", 87, 109], ["Hct", "TEST", 111, 114], ["not clear", "UNCERTAINTY", 9, 18], ["venous", "ANATOMY", 37, 43], ["thromboembolism", "OBSERVATION", 44, 59], ["secondary", "OBSERVATION_MODIFIER", 87, 96], ["polycythemia", "OBSERVATION", 97, 109]]], ["21 Some of the lowest rates have been seen with selective estrogen receptor modulators (SERMs) at 1.7%, 22 or intranasal testosterone, at 2.6%, 23 while longer-acting modalities such as injectable or implantable pellets of testosterone have published rates of polycythemia upwards of 66.7% and 35%, respectively.", [["estrogen", "CHEMICAL", 58, 66], ["testosterone", "CHEMICAL", 121, 133], ["testosterone", "CHEMICAL", 223, 235], ["polycythemia", "DISEASE", 260, 272], ["estrogen", "CHEMICAL", 58, 66], ["testosterone", "CHEMICAL", 121, 133], ["testosterone", "CHEMICAL", 223, 235], ["estrogen receptor modulators", "GENE_OR_GENE_PRODUCT", 58, 86], ["testosterone", "SIMPLE_CHEMICAL", 121, 133], ["testosterone", "SIMPLE_CHEMICAL", 223, 235], ["selective estrogen receptor modulators", "TREATMENT", 48, 86], ["SERMs", "TEST", 88, 93], ["intranasal testosterone", "TREATMENT", 110, 133], ["injectable or implantable pellets of testosterone", "TREATMENT", 186, 235], ["polycythemia upwards", "PROBLEM", 260, 280], ["polycythemia", "OBSERVATION", 260, 272]]], ["24 Multiple studies support a link between polycythemia and increased rate of MACE and VTE.", [["polycythemia", "DISEASE", 43, 55], ["VTE", "DISEASE", 87, 90], ["Multiple studies", "TEST", 3, 19], ["a link between polycythemia", "PROBLEM", 28, 55], ["increased rate of MACE", "PROBLEM", 60, 82], ["VTE", "PROBLEM", 87, 90], ["polycythemia", "OBSERVATION", 43, 55], ["increased", "OBSERVATION_MODIFIER", 60, 69]]], ["21, 25 Whether TT induced polycythemia causes MACE or VTE is still a matter of debate, one which may be addressed by current ongoing clinical trials.How does Testosterone Deficiency (TD) affect SARS-CoV-2 infection?The androgen-susceptible nature of TMPRSS2, as well as the potential for a coagulopathy with TT, may lead some practitioners to question the safety of TT during this pandemic.", [["polycythemia", "DISEASE", 26, 38], ["MACE", "DISEASE", 46, 50], ["VTE", "DISEASE", 54, 57], ["Testosterone", "CHEMICAL", 158, 170], ["TD", "DISEASE", 183, 185], ["SARS", "DISEASE", 194, 198], ["infection", "DISEASE", 205, 214], ["coagulopathy", "DISEASE", 290, 302], ["Testosterone", "CHEMICAL", 158, 170], ["androgen", "CHEMICAL", 219, 227], ["Testosterone", "SIMPLE_CHEMICAL", 158, 170], ["SARS-CoV-2", "ORGANISM", 194, 204], ["androgen", "SIMPLE_CHEMICAL", 219, 227], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 250, 257], ["TMPRSS2", "PROTEIN", 250, 257], ["TT induced polycythemia", "PROBLEM", 15, 38], ["MACE", "PROBLEM", 46, 50], ["VTE", "PROBLEM", 54, 57], ["Testosterone Deficiency (TD) affect SARS", "PROBLEM", 158, 198], ["CoV-2 infection", "PROBLEM", 199, 214], ["TMPRSS2", "PROBLEM", 250, 257], ["a coagulopathy", "PROBLEM", 288, 302], ["TT", "TREATMENT", 308, 310], ["this pandemic", "PROBLEM", 376, 389], ["polycythemia", "OBSERVATION", 26, 38], ["infection", "OBSERVATION", 205, 214], ["coagulopathy", "OBSERVATION", 290, 302]]], ["On the contrary, if TD is a potential poor prognostic factor for COVID-19 due to the changes in the inflammatory milieu, then TT may in fact be beneficial.", [["TD", "DISEASE", 20, 22], ["COVID-19", "GENE_OR_GENE_PRODUCT", 65, 73], ["COVID", "TEST", 65, 70], ["the changes in the inflammatory milieu", "PROBLEM", 81, 119], ["TT", "TREATMENT", 126, 128], ["inflammatory", "OBSERVATION_MODIFIER", 100, 112]]], ["Currently, there are no observational data to help guide practice on this.", [["observational data", "TEST", 24, 42], ["no", "UNCERTAINTY", 21, 23]]], ["Based on a precautionary principle, if testosterone is being prescribed, perhaps it is prudent to use a modality with less risk of polycythemia such as shortacting preparations or off-label drugs such as clomiphene citrate or human chorionic gonadotropin until more robust data becomes available.ConclusionThe association between testosterone and COVID-19 is multifactorial.", [["testosterone", "CHEMICAL", 39, 51], ["polycythemia", "DISEASE", 131, 143], ["clomiphene citrate", "CHEMICAL", 204, 222], ["testosterone", "CHEMICAL", 330, 342], ["testosterone", "CHEMICAL", 39, 51], ["clomiphene citrate", "CHEMICAL", 204, 222], ["testosterone", "CHEMICAL", 330, 342], ["COVID-19", "CHEMICAL", 347, 355], ["testosterone", "SIMPLE_CHEMICAL", 39, 51], ["clomiphene citrate", "SIMPLE_CHEMICAL", 204, 222], ["human", "ORGANISM", 226, 231], ["chorionic gonadotropin", "GENE_OR_GENE_PRODUCT", 232, 254], ["testosterone", "SIMPLE_CHEMICAL", 330, 342], ["COVID-19", "GENE_OR_GENE_PRODUCT", 347, 355], ["human", "SPECIES", 226, 231], ["human", "SPECIES", 226, 231], ["a precautionary principle", "TREATMENT", 9, 34], ["testosterone", "TREATMENT", 39, 51], ["a modality", "TREATMENT", 102, 112], ["polycythemia", "PROBLEM", 131, 143], ["shortacting preparations", "TREATMENT", 152, 176], ["label drugs", "TREATMENT", 184, 195], ["clomiphene citrate", "TREATMENT", 204, 222], ["human chorionic gonadotropin", "TREATMENT", 226, 254], ["testosterone and COVID", "TREATMENT", 330, 352], ["multifactorial", "PROBLEM", 359, 373], ["polycythemia", "OBSERVATION", 131, 143], ["multifactorial", "OBSERVATION_MODIFIER", 359, 373]]], ["Current studies using ADT to suppress activation of TMPRSS2 with the potential to prevent cellular entry of SARS-CoV-2 are underway.", [["cellular", "ANATOMY", 90, 98], ["ADT", "CHEMICAL", 22, 25], ["SARS", "DISEASE", 108, 112], ["ADT", "SIMPLE_CHEMICAL", 22, 25], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 52, 59], ["cellular", "CELL", 90, 98], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 108, 118], ["TMPRSS2", "PROTEIN", 52, 59], ["Current studies", "TEST", 0, 15], ["ADT", "TREATMENT", 22, 25], ["TMPRSS2", "TREATMENT", 52, 59], ["SARS", "PROBLEM", 108, 112]]], ["Whether or not testosterone deficiency worsens prognosis because of TMPRSS2 interaction, increased inflammatory state, or simply because of the associated poor health with low testosterone is unclear.", [["testosterone", "CHEMICAL", 15, 27], ["testosterone", "CHEMICAL", 176, 188], ["testosterone", "CHEMICAL", 15, 27], ["testosterone", "CHEMICAL", 176, 188], ["testosterone", "SIMPLE_CHEMICAL", 15, 27], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 68, 75], ["testosterone", "SIMPLE_CHEMICAL", 176, 188], ["TMPRSS2", "PROTEIN", 68, 75], ["testosterone deficiency", "PROBLEM", 15, 38], ["TMPRSS2 interaction", "PROBLEM", 68, 87], ["increased inflammatory state", "PROBLEM", 89, 117], ["low testosterone", "PROBLEM", 172, 188], ["increased", "OBSERVATION_MODIFIER", 89, 98], ["inflammatory", "OBSERVATION_MODIFIER", 99, 111]]], ["The relationship between TT and COVID-19 remains to be elucidated, as it is not yet clear whether TT worsens or improves outcomes.", [["COVID-19", "GENE_OR_GENE_PRODUCT", 32, 40], ["TT and COVID", "TREATMENT", 25, 37]]], ["Identifying men on TT who go on to contract COVID-19, and establishing baseline androgen levels prior to infection, will be an important first step to answer this question.", [["infection", "DISEASE", 105, 114], ["androgen", "CHEMICAL", 80, 88], ["men", "ORGANISM", 12, 15], ["androgen", "GENE_OR_GENE_PRODUCT", 80, 88], ["men", "SPECIES", 12, 15], ["COVID", "TEST", 44, 49], ["baseline androgen levels", "PROBLEM", 71, 95], ["infection", "PROBLEM", 105, 114], ["infection", "OBSERVATION", 105, 114]]], ["Prior to robust data, any changes to practice need to be made with caution, and after an informed discussion with patients.", [["patients", "ORGANISM", 114, 122], ["patients", "SPECIES", 114, 122]]]], "PMC7284663": [["Allgemeine Orientierungshilfe f\u00fcr die CPR-Ausbildung w\u00e4hrend der Pandemie", [["Allgemeine Orientierungshilfe f\u00fcr die CPR-Ausbildung w\u00e4hrend der Pandemie", "SPECIES", 0, 73]]]]}